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Abstract
Studies on Secretor Status, faecal flora and the
Humoral immune Response in Ankylosing spondylitis.
It has been suggested that ankylosing spondylitis (AS) is a form of reactive
arthritis similar to that observed among patients with genitourinary or
intestinal infections. This hypothesis was supported by several studies in which
some, but not all, found an increased isolation rate of Klebsiella species from the
stools of AS patients. The strongest association known of a human leucocyte
antigen (HLA) with disease is observed with HLA-B27 and AS. One hypothesis
proposed to explain this association is molecular mimicry, in which cross-
reactivity between HLA-B27 and arthritogenic bacteria leads to a cross-reacting
immune response and inflammation. Non-secretion of ABO blood group
substances, an autosomal recessive characteristic, is another factor associated
with susceptibility to disease, particularly to infection of mucosal surfaces. In a
study in 1987, non-secretors were found to be over-represented in patients with
AS, evidence which supported the hypothesis of an infectious aetiology in AS.
The aims of this work were to reassess the association of non-secretion with AS;
to study the faecal flora in a cohort of patients with spondyloarthropathy; to
determine the prevalence of bacteria expressing antigens cross-reactive with the
HLA-B27 antigen; to examine the humoral immune responses of patients and
controls to their own faecal flora; and to correlate these findings with the disease
activity of the patients as assessed clinically and by the erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) as laboratory parameters of
inflammation.
The proportion of non-secretors in this AS population was identical to that in
the control population when determined by haemagglutination inhibition assay
(HAI) and confirmed by enzyme-linked immunosorbent assay (ELISA) for Lewis
antigens. Careful scrutiny of the secretor status in a group of patients examined
in both present and initial studies revealed that 27% of non-secretors in the
previous survey had been wrongly typed and were indeed secretors. Enzymatic
degradation of blood group antigens in some saliva specimens could explain this
discrepancy and might have resulted from inadequate cooling prior to
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processing and storage in the previous study. Although there was a direct
correlation between clinical disease activity and ESR and CRP for all patients
with spondyloarthropathy and for AS patients alone, there was no evidence that
non-secretors experienced more severe disease than secretors by either clinical or
laboratory indices.
Analysis of stool samples from AS patients and controls showed no significant
differences in types of organisms isolated. Klebsiella species were isolated in
8.5% of patients' and 19.4% of controls' stools. The presence of a HLA-B27 cross-
reactive epitope on enteric bacteria from patients' and controls' stools was
sought by immunoassay and flow cytometry; however, none of the bacteria
examined expressed epitopes cross-reactive with that to which the monoclonal
was produced.
Previous work examining the humoral response to enteric bacteria has largely
concentrated on measuring serum antibody levels to laboratory strains of
bacteria which might not be part of the faecal flora of any of the patients under
investigation. In this study an ELISA was developed to measure specific
antibody levels to autologous enteric bacteria harvested from faeces. The
concentration of serum IgM reactive with self gut bacteria was significantly
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Ankylosing spondylitis (AS) is a chronic rheumatic disease primarily affecting
the spine and sacroiliac joints in which early inflammatory changes can be
followed by progressive restriction of spinal movement, loss of normal posture
and the development of a rigid, stooped spine. The name derives from the
Greek words ankylos (bent or crooked) and spondylos (vertebra). The disease
has a preponderance of males and, typically, has an insidious onset in the third
decade presenting with low back pain and morning stiffness. Peripheral joint
involvement affects up to 35% of patients during the course of the disease, is
often asymmetrical and frequently affects the lower limb joints. Inflammation
can also occur at extra-articular sites such as the eye, heart and lungs (Calin,
1989). In most patients the disease is characterised by exacerbations and
remissions, tending towards fewer episodes of acute exacerbations after the age
of 40 years.
l.l Historical Review
A comprehensive examination of Egyptian mummified remains from the
Roman period (200 AD) to the fflrd Dynasty (2980-2900 BC) provides evidence of
AS in the skeletons at that time (Ruffer and Rietti, 1912). The first description of
AS was in 1693 by Bernard Connor who studied the fusion of the ilium, sacrum,
vertebrae and ribs in a skeleton (cited by Bywaters, 1980). Arguably, the best early
clinical description of AS was by Sir Benjamin Brodie in 1850 who described a 31
year old man with a 3 year history of 'pain referred to the spine from the neck
downwards, but especially to the middle dorsal vertebrae' (Brodie, 1850). This
pain was aggravated by sneezing and the patient had occasional pains in the
pelvis and lower extremities. On bending 'he experienced a sense of stiffness of
the spine, and there was scarcely any perceptible flexure of it, the stooping being
apparently confined to the motion of the pelvis on the thigh'. He had lost
weight and had intermittent fevers. He had an effusion of one knee and the
spine was "rigid and inflexible". On subsequent review of this man over a 3 year
period, Brodie noted that although there was no improvement in his spinal
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mobility, he was generally much less symptomatic apart from occasional
'inflammation of the eye'.
In the 1890's, Strumpell in Germany, von Bechterew in Russia and Marie in
France all published papers on the disease. Marie, with his pupil Leri, gave the
characteristic clinical and pathological description as it is known today.
In the first and second world wars, X-ray screening highlighted the presence of
this disease which had often been unrecognised by the individual.
1.2 EpidemiologyofAnkylosing Spondylitis
1.2.1 Ethnic and geographical distribution
Direct comparison of different studies on the prevalence of AS is difficult
because of differences in survey methods, populations studied and diagnostic
criteria employed. The prevalence of AS in the UK is about 1 per 2000
population (0.05%) (West, 1949; Wright and Moll, 1973) with a similar order of
frequency (0.013%) determined from hospital records in the USA (Carter et al.,
1979). Population surveys have given higher prevalence estimates of 0.2% in
north-west England (Lawrence, 1977) and 0.23% in Hungary (Gomor et al., 1977).
Marked differences in the prevalence of AS are recognised in different racial and
ethnic groups. The prevalence in the UK is similar to that in the Japanese (0.02-
0.04%) (Sonozaki et al., 1975), is low in New Zealand Maoris (Rose and Isdale,
1963) and is rare in African blacks. No cases of AS were found in over 600 West
African blacks (Muller et al., 1972) and only 1 case was identified in 1300 South
African blacks (Solomon et al., 1975). Gofton et al. (1966) found no instance of
sacroiliitis in 255 normal Jamaican males. Studies of Caucasians and Afro-
American blacks showed that racial intermixture produced a prevalence of AS
in Afro-Americans to be about one quarter that seen in whites (Baum and Ziff,
1971). In contrast, there is a high prevalence among several North American
Indian populations in which AS affects 6.7% of males of the Haida tribe, 7.6% of
male Bella Bella Indians, 5.9% of male Pima Indians, 3.1% of males of the Bella
Coola tribe (Gofton et al., 1972) and 9% of the male Chippewa Indians (Arnett et
al., 1982).
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The racial differences in AS prevalence clearly relate to the frequency of HLA-
B27 in these populations. The HLA-B27 gene is found mostly in Caucasoid and
Mongoloid racial groups and is particularly common among the North
American Indian tribes mentioned above. The gene is virtually absent in
African negroids of unmixed ancestry and rare in Orientals.
1.2.2 Age and sex distribution
Probably the only true incidence survey of AS has come from Rochester,
Minnesota, USA, in which the overall age-adjusted incidence rate for both sexes
combined was 6.6 per 100,000 population per year (Carter et al., 1979). The age-
specific incidence rates peaked in the 25-34 year old age group, while the
maximum prevalence was in the 55-64 year old age group. This agrees with the
observation several years earlier that the disease usually presents between the
ages of 20-40 years with less than 5% beginning after the age of 50 years
(Wilkinson and Bywaters, 1958).
The male to female ratio is approximately 4:1 in patient series (Wilkinson and
Bywaters, 1958; Wright and Moll, 1973; van der Linden et al., 1984b) and in
population studies (Carter et al., 1979). The higher ratio of 10:1 reported in other
studies (West, 1949) indicates that the disease was previously underdiagnosed in
females. One explanation for this is that chronic low back pain in young women
was often attributed to pelvic pathology and not investigated radiologically to
avoid possible irradiation damage to germ cells (Calin and Fries, 1975). Young
men, however, might have sought medical advice earlier if back pain was
interfering with work.
1.2.3 Morbidity and mortality
In terms of morbidity, AS patients are hospitalised infrequently and retain good
functional capabilities. A 25-year follow-up study of 76 patients showed that 65%
were still able to work full-time; approximately half of these had retained their
original jobs, while the remainder had to change to a less physically demanding
job. 5% of the patients had retired because of age and only 30% were unfit to
work (Lehtinen, 1981).
Most, but not all, surveys have noted an increased mortality in AS patients. A
study of over 14000 AS patients who had received radiotherapy reported a 1.8-
3
fold greater excess mortality than expected compared with national death rates.
The excess deaths were attributed to the spondylitis itself, amyloidosis,
leukaemia, aplastic anaemia, cancers originating in heavily-irradiated tissues
and ulcerative colitis (Court Brown and Doll, 1965). Radford and colleagues
(1977) studied over 800 patients diagnosed during the same period but who did
not receive radiotherapy and found a 1.6-fold increase in mortality compared
with the general population. This was significant for males but not for females.
The excess mortality was attributed to the disease itself and to ulcerative colitis,
peptic ulcer disease, tuberculosis or other respiratory disease and nephritis. A
survey of 151 Canadian World War II veterans with AS showed that there was
an increased mortality only in those who had received radiotherapy (Kaprove et
al., 1980). The causes of this excess mortality were due to lymphatic and
haematological malignancies and an increase in cardiovascular, cerebrovascular,
pulmonary and renal disease. In a study in Minnesota, the mortality in AS
patients was not significantly different from that in the general population
(Carter et al., 1979).
The causes of death in 79 Finnish patients with AS were examined by Lehtinen
(1980). No comparisons were made with the national death rates in age-
matched controls, therefore no conclusions can be drawn regarding mortality
rates of AS patients compared with the general population. Almost every
patient received radiotherapy for pain (albeit a small dose), but only 1 patient
had a lymphoma and another had chronic lymphatic leukaemia. Renal failure
due to amyloidosis was reported considerably more frequently (21.5%) than in
other surveys.
A more recent retrospective appraisal of the effect of single treatment
radiotherapy on survival of AS patients, showed that compared with the general
population of England and Wales, there was a threefold increase in mortality
due to leukaemia, a 30% increase in mortality for cancer of the colon and a 28%
increase in mortality for cancers others than leukaemia or colon (Darby et al.,
1987). In addition, there was a 51% increase in mortality for non-neoplastic
conditions in AS patients.
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1.3 Diagnosis
Criteria for diagnosing AS were first formulated in Rome in 1961 and were based
on 5 clinical features and the presence of radiological sacroiliitis (Table 1.1). AS
could be diagnosed if either 4 clinical findings, or a combination of 1 clinical
feature and radiographic sacroiliitis existed. Criticisms of the Rome criteria are
that limitation of movement is not defined, and reduced chest expansion is a
late event in the course of the disease by which time the diagnosis should be
obvious.
Table 1.1
The Rome criteria (1961)
1. Clinical criteria:
a. Low back pain and stiffness for more than 3 months that is not
relieved by rest;
b. Pain and stiffness in the thoracic region;
c. Limited motion in the lumbar spine;
d. Limited chest expansion;
e. History or evidence of iritis or its sequelae.
2. Radiologic criterion:
a. X-ray showing bilateral sacroiliac changes characteristic of
ankylosing spondylitis. (This would exclude bilateral
osteoarthrosis of the sacroiliac joints).
A revised set of criteria was introduced in New York in 1966 (Table 1.2).
Limitation of spinal mobility in three directions is a requirement as limitation
of forward flexion alone can be seen in several low back conditions. Discomfort
rather than pain might better describe what is experienced. Absent in the New
York criteria is the relationship of pain to rest. Analysis of the New York
criterion of pain in the dorso-lumbar spine was considered to lack specificity
and the chest expansion criterion to lack sensitivity (van der Linden et al.,
1984a). A modification of the New York criteria was proposed by these authors
in an attempt to identify early cases of AS (Table 1.3). Interpretation of
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radiological sacroiliac changes, however, is open to procedural and observer
variability. An anteroposterior view is usually sufficient but special views of the
sacroiliac joints are sometimes required.
Table 1.2
The New York criteria (1966)
A. Diagnosis
1. Limitation of motion of the lumbar spine in all three planes-
anterior flexion, lateral flexion, and extension;
2. History or the presence of pain at the dorsolumbar junction or in
the lumbar spine;
3. Limitation of chest expansion to 2.5cm or less, measured at the
level of the fourth intercostal space.
B. Grading
Definite as:
Grade 3-4 bilateral sacroiliitis with at least one clinical criterion;
or
Grade 3-4 unilateral or Grade 2 bilateral sacroiliitis with clinical criterion
1 (limitation of back movement in all three planes) or with both clinical
criteria 2 and 3 (back pain and limitation of chest expansion).
Probable as:
Grade 3-4 bilateral sacroiliitis with no clinical criteria.
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Table 1.3
The modified New York criteria
Diagnosis
Clinical criteria:
1. Low back pain and stiffness for more than 3 months which
improves with excercise, but not relieved by rest;
2. Limitation of the lumbar spine in both the sagittal and frontal
planes;
3. Limitation of the chest expansion relative to normal values when
corrected for age and sex.
Radiological criterion:
Sacroiliitis grade > 2 bilaterally or sacroiliitis grade 3-4 unilaterally.
Grading
Definite ankylosing spondylitis:
If the radiological criterion is associated with at least one clinical
criterion.
Probable ankylosing spondylitis:
Three clinical criteria are present;
or
The radiological criterion is present without any signs or symptoms
satisfying the clinical criteria (other causes of sacroiliitis should be
considered).
It is now recognised that AS can occur in the absence of sacroiliitis (Calin, 1979)
and spondyloarthropathy without sacroiliitis may be associated with the HLA-
B27 antigen in relatives of those with AS (Khan et al., 1985). Lone sacroiliitis is
uncommon and progression to ascending spinal disease is primarily a function
of disease duration. Sacroiliitis and ascending spinal disease are indeed part of
the same spectrum (Calin and Elswood, 1988).
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HLA-B27 typing is not necessary for the diagnosis of AS which should be made
on the existing clinical and radiological criteria (Calin, 1980).
1.4 The Spondyloarthropathies
Until 30 years ago, AS was known throughout different parts of the world as
rheumatoid spondylitis; psoriatic arthropathy and arthritis associated with
inflammatory bowel disease were thought of as variants of rheumatoid arthritis.
In 1963, the American Rheumatism Association produced a classification in
which rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative
colitis and Crohn's disease appeared as separate entities. This classification was
based not only on clinical features, but also on the finding that rheumatoid
factor, while present in the serum of over 70% of patients with rheumatoid
arthritis, was absent in patients with these 'variant' diseases. The term
'seronegative' was coined to describe the phenomenon. The other finding
common to these diseases is spondylitic involvement and 'spondylarthritis' was
the term applied.
AS is the prototype of this group of inter-related disorders known collectively as
the seronegative spondyloarthropathies. This concept was originally proposed
by Moll and colleagues (Moll et al., 1974) and includes uncomplicated AS,
Reiter's disease, psoriatic arthropathy, ulcerative colitis, Crohn's disease,
juvenile chronic arthritis, Behcet's syndrome, Whipple's disease, reactive
arthritis and acute anterior uveitis. All these conditions are characterised by the
following; radiographic sacroiliitis (with or without ankylosing spondylitis);
peripheral inflammatory arthritis; muco-cutaneous features such as oro-genital
ulceration; inflammatory eye disease; and a tendency to familial clustering.
Other common features are the absence of rheumatoid factor and the absence of
subcutaneous nodules.
AS is considered to be primary if no other rheumatic disease is present, and
secondary if the spondylitis is associated with inflammatory bowel disease,
Reiter's syndrome or psoriasis.
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1.5 PATHOLOGY
The essential pathological feature of the spondarthritides is an enthesopathy-
inflammation occurring at the sites of attachment of tendons, ligaments and
joint capsules to bone. Enthesopathy is not peculiar to AS. The most common
cause for an isolated lesion is trauma and enthesitis has been recorded in
schistosomiasis (Atkin et al., 1986) and leprosy (Atkin et al., 1990).
Inflammatory lesions of particular bone surfaces in AS eg., the tip of vertebral
spinous processes, were first described nearly 40 years ago (Engfeldt et al., 1954).
Further work by Ball (1971) showed that destruction of the chondrified and
calcified parts of the ligament occurs leaving a small erosion or defect in the
cortical bone. This becomes infiltrated by lymphocytes, plasma cells and a few
polymorphonuclear cells which are arranged in a perivascular distribution.
Around this area of erosion an osteitis develops. During the repair process,
these areas of focal osteitis become filled by reactive or cancellous bone which is
laid down in a finely fibrous connective tissue without preceding cartilage
formation. This new bone joins the deeper bone to the eroded end of the
ligament and so lies above the original bone surface forming a new enthesis.
Re-modelling takes place with mature lamellar bone replacing the reactive bone
forming a prominence or spur.
Erosive changes, when they occur at the sites of attachment of the outer fibres of
the annulus fibrosus of the intervertebral disc to the vertebral body, result in
syndesmophyte formation and eventually ankylosis of the spine (Bywaters,
1987). Similar lesions occur in the capsular attachments of the apophyseal and
sacroiliac joints leading to ossification and ankylosis.
Destructive lesions of the vertebral bodies sometimes occur which often present
with a sudden onset of localised back pain and in some there is a history of
trauma (Cawley et al., 1972). These lesions may be localised defects in the
cartilaginous end-plate and are due to discal herniae, or be present in the
vertebral rim and due to focal osteoporotic defects of the subchondral plate.
Enthesopathy of more peripheral ligamentous insertions are common. Plantar
fasciitis occurs particularly in Reiter's syndrome, is less frequent in AS and
psoriatic arthritis and is due to inflammation at the insertion of the plantar
9
aponeurosis and long plantar ligaments into the calcaneum (Niepal and Sit'aj,
1979). Achilles tendon enthesitis and enthesopathies around the pelvis and
upper femora are especially common in AS and are also seen in psoriatic
arthritis and Reiter's syndrome.
The predilection of the disease process for the enthesis remains a mystery. One
hypothesis proposed to explain this site as the disease 'target' is that as the
enthesis is a site of transmission of stress/load forces, it is possible that trauma
initiates the lesions in a genetically predisposed host (Wisnieski, 1984; Moll,
1987). In support of this is the observation that enthesitis is more common in
the pelvis and lower limb than in the upper limb. Patients often associate injury
with the development or flare-up in such lesions, but this has not been
validated statistically. Trauma, by a shearing effect, could expose molecules on
the surface of cells that form part of the enthesis and which were hidden prior to
trauma. Antigens could also appear in the lesion from bleeding due to trauma.
These previously-hidden molecules are now exposed and might associate with
other cell surface antigens, or might have a structure that is similar to antigenic
determinants present on enteric bacteria. In this way these host molecules could
act as a target for an autoimmune response.
The synovial pathology of AS is very similar to that of rheumatoid arthritis
(Cruikshank, 1951; Julkunen, 1966; Revell and Mayston, 1982). Proliferation of
synovium occurs over the surface of the articular cartilage, granulation tissue
destroys the cartilage and penetrates the underlying bone. The histological
similarities originally led to the interpretation that rheumatoid arthritis and AS
were variants of the same disease. It has subsequently been recognised that the
pathological lesions represent a common reaction to different aetiological
factors.
Immunohistological techniques have identified the presence of CD4-positive
cells in the synovium of patients with AS. Monoclonal antibodies, including
one directed to RFT2 antigen, have been used to detect T cell 'activation
markers'. RFT2 is a 40kD molecule preferentially expressed by T cell blasts or
activated T cells. 8% of the synovial membrane T cells from AS patients were
RFT2-positive compared with 25% of those from patients with rheumatoid
arthritis and less than 1% of synovial membrane T cells from normal




The influence of heredity was suggested from von Bechterew's original report in
1893 of first and second generation relatives of probands of AS patients also
being affected (cited by Riecker et al., 1950). There were similar reports in the
early part of the century of a familial occurrence of 'spondylitis rhizomelique'.
The validity of these early reports, however, must be accepted with the
reservations that the history was not typical in some cases, X rays were not
available and the diagnosis of AS in relatives (with a few exceptions) relied on
hearsay evidence. Several reports in the 1930s and 1940s noted a familial
occurrence of the disease but these cases were relatively isolated and could
hardly constitute significant evidence for the operation of genetic factors.
One pedigree described 5 affected individuals in 3 generations (Riecker et al.,
1950) and another family study identified 8 affected individuals in 2 generations
(Graham and Uchida, 1957). These observations supported an autosomal
dominant gene transmission. In the study of Stecher et al. (1957) and that of de
Blecourt et al. (1961) AS was found to be 30 times (Stecher et al., 1957) and 23
times (de Blecourt et al., 1961) more common among relatives of spondylitics
than among relatives of healthy controls with no history of the disease. In a
review of 10 series in which 960 AS patients were examined, 14% had 1 or more
first-degree relatives with AS (Hochberg, 1984). This data was compatible with
an autosomal dominant pattern of inheritance with incomplete penetrance.
The landmark discovery in 1973 of the strong association of the human
leucocyte group A (HLA) antigen B27 with AS was the major development that
allowed progress to be made in understanding the genetics of this disease
(Brewerton et al., 1973b; Schlosstein et al., 1973). HLA-B27 is found in up to 95%
of Caucasians with AS compared with 8% of the general population.
A number of studies compared the prevalence of AS in HLA-B27-positive
relatives of probands with AS with the prevalence of disease in relatives of
healthy HLA-B27-positive individuals. The entry criteria for disease phenotype
varied for each study. This explains the considerable variation in frequencies of
disease between studies; but, in each case, there was a greater frequency of disease
in HLA-B27-positive relatives of AS patients than in HLA-B27-positive relatives
of healthy controls (Lochead et al., 1983; Woodrow et al., 1983; Calin et al., 1983;
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van der Linden et al., 1984b). Earlier studies had suggested that the risk of
disease in relatives was greater for female probands than for males (Stecher et
al., 1957). Calin and colleagues (1983), however, found that the risk was not
significantly different for a female than it was for a male proband.
Data from twin studies suggest that genetic factors alone are not sufficient to
explain the disease. In a review, Moesmann (1960) noted 9 monozygotic twins
of which 3 were discordant for AS. In a later study of 3 monozygotic twins over
45 years of age, 2 were discordant for AS and in the third there was a marked
difference in the severity of the disease (Eastmond and Woodrow, 1977). As the
two discordant pairs were aged 48 and 52 years respectively, it is unlikely that the
unaffected twin would subsequently develop the disease. This leaves room for
the participation of other influences such as environmental factors.
There is no good evidence for an association of non-HLA-B27 B locus antigens
conferring susceptibility to AS. A group of HLA-B locus antigens (B7, Bw22, B40)
which form a cross-reactive group (B7-CREG) was found to be associated with
HLA-B27-negative patients with spondyloarthropathy (Arnett et al., 1977). In
contrast, Khan and colleagues (1983) did not find a significant association with
the B27-CREG antigens in their series of HLA-B27-negative white patients with
AS, Reiter's or in those with secondary AS.
Because of the existence of HLA-B27-negative AS patients and healthy HLA-B27-
positive individuals, studies were done to determine other genetic loci
contributing to susceptibility to AS. A study of haplotypes in HLA-B27
individuals with and without AS did not reveal any significant differences
between the two groups (Lochead et al., 1983). This is evidence in favour of the
HLA-B27 gene being the major HLA-linked susceptibility gene for AS.
HLA-A2 is increased in frequency in AS due to linkage disequilibrium with
HLA-B27. HLA-Bw60 is thought to act in conjunction with HLA-B27 to increase
susceptibility to AS by a factor of approximately 3 (Robinson et al., 1989).
A study to assess the relative importance of genetic and environmental factors
in disease expression concluded that environmental factors play a greater role in
determining the age of onset of AS, whereas genetic factors have more influence
on progression of radiological signs and physical disability (Calin and Elswood,
1989).
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1.7 ENVIRONMENTAL AND OTHER FACTORS PROPOSED TO BE INVOLVED
in theAetiologyofAnkylosing Spondylitis
1.7.1 Trauma
It was proposed by Wehrsig in 1910 that AS was the result of an abnormal
reaction to trauma (cited by Moll, 1980). In recent years, there have been
anecdotal reports of trauma being implicated in the initiation of both AS
(Oliveri et al., 1988; Jacoby et al., 1985) and Reiter's syndrome (Masson et al.,
1985; Wisnieski, 1984). In the case of spinal AS, physical injury tends to bring
the condition to the patients' attention, probably through enforced
immobilisation rather than provoking the disease (Jacoby, 1985). Oliveri et al.
(1988) reported the development of a destructive peripheral arthropathy
immediately after trauma in 2 HLA-B27-positive patients; 1 of these patients had
a 4 year history of sacroiliitis but no peripheral joint symptoms until her injury.
From his observations, Wisnieski (1984) suggested that new antigens might be
exposed through trauma and lead to an abnormal autoimmune reaction in
genetically predisposed individuals.
1.7.2 Metabolic abnormality
An association between hyperparathyroidism (diagnosed on somewhat loose
grounds) and AS was noted (Funsten, 1933); 14/26 AS patients in this series were
treated by parathyroidectomy and all but 1 improved. This vogue for
parathyroidectomy, however, did not last long. Buckley (1945) postulated a
defect in the metabolism of bone alkaline phosphatase causing a mobilisation of
calcium from the bone and its deposition in the adjacent ligaments.
1.7.3 Viruses
In view of the association of AS with a HLA class I molecule (see below), a viral
aetiology has been suggested. High levels of an adenylic acid polymer
considered to be a marker for viral replication, have been found among patients
with AS and psoriatic arthropathy but not in seropositive rheumatoid arthritis,
acute chondrocalcinosis or healthy controls (Luxembourg et al., 1987). Raised
IgG antibodies to measles virus have been detected in the sera of AS patients
without iritis compared with hospitalised controls, but the significance of this is
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not clear (Kalliomaki et al., 1983). So far, no virus has been conclusively shown
to be the trigger for the development of AS.
1.7.4 Bacteria
Following the observation that acute rheumatic complaints and endocarditis can
be preceded by a tonsillar infection (rheumatic fever), focal sepsis became a
common explanation for several illnesses. In the investigation of chronic
arthritis and nephritis it was recommended that a diligent search was made for
septic foci in tonsils, gingiva, sinuses, pulmonary cavities, gall bladder, bowels,
urinary and genital tract and that these foci be removed (Billings, 1912). It was
suggested that as sacroiliitis was the likely result of some chronic infection, then
eradication of this infection should reduce the possibility of ankylosis and
spondylitis (Scott, 1936). Indeed, the sacroiliac joints of 3 patients were curetted;
soft bone and granulation tissue but no pus was found. Attempts to grow
cultures from the debris were abortive due to contamination (Scott, 1936).
In 1926 Marie suggested that AS was the result of gonococcal infection (cited by
Romanus, 1953). In two studies chronic prostatovesiculitis was associated with
AS: 89% of 114 AS patients in one study (Romanus, 1953); 83% of 54 spondylitics
in another (Mason et al., 1958). A later study also supported urogenital infection
as a cause of AS (Julkunen et al., 1966). It has been suggested (Olhagen, 1983) that
the high proportion of prostatic infection in two of these studies (Romanus,
1953; Mason et al., 1958) was probably due to the fact that most of the patients
considered had the onset of their disease before the advent of antibiotics.
Romanus (1953) suggested that the erosive and ankylosing changes of the
sacroiliac joints previously demonstrated in paraplegics (Abramson and
Kamberg, 1949) were due to chronic urinary tract infection (UTI). Subsequent
studies have revealed that sacroiliitis is not more common in paraplegics with
significant UTI, as manifest by persistent hydronephrosis, than in those without
(Liberson et al., 1966).
Several bacteria have been well-documented to be associated with reactive
arthritis. This term, coined by Ahvonen et al. (1969), describes the nonpurulent
inflammatory arthritis which occurs in association with a definite or highly-
suggestive precipitating genito-urinary or gastrointestinal infection. Reiter's
syndrome is the term originally applied to the triad of features of reactive
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arthritis, urethritis and conjunctivitis. This classical definition of Reiter's
syndrome has been replaced by more broadly-based criteria of an episode of
arthritis lasting more than one month in association with urethritis or cervicitis
(Willkens et al., 1981), or as defined by Fox et al. (1979) in Table 1.4. It must be
borne in mind that while many Reiter's syndrome patients do fall into either
the epidemic (or enteric) form or the endemic (or post-veneral) form, some are
not so easily classified. Post-venereal Reiter's syndrome has been considered the
more common form of Reiter's syndrome in Britain and the United States,
whereas in Europe the post-dysenteric form is more common.
Table 1.4
Definition of Reiter's syndrome
Seronegative asymmetric arthropathy (predominantly lower limb)
Plus one or more of the following:
Urethritis/cervicitis
Inflammatory eye disease






Bacteria implicated in the enteric form of reactive arthritis and Reiter's
syndrome include Shigella flexneri (Paronen, 1948; Simon et al., 1981),
Salmonella typhimurium (Vartiainen and Hurri, 1964), Salmonella enteriditis
(Iveson et al., 1975), Yersinia spp (Ahvonen et al, 1969) and Campylobacter
jejuni (Berden et al., 1979; Gumpel et al., 1981). Neither Shigella sonnei (which
causes dysentery) nor enteropathic Escherichia coli have been associated with a
reactive arthropathy or Reiter's syndrome. Noer et al. (1966) found an incidence
of Reiter's syndrome of 1.5% in an epidemic of Shigella dysentery. It was later
calculated that the risk of a HLA-B27-positive individual with shigellosis
developing Reiter's was between 16% and 37% (Calin and Fries, 1976).
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Reiter's syndrome develops in a small proportion of subjects with nonspecific
urethritis (NSU), from 1% (Csonka, 1958) to 3% (Keat et al., 1978). Some of these
cases have been associated with Chlamydia trachomatis. In a follow-up study of
531 men with NSU, arthritis developed in 16 and 5 of these were positive for
chlamydia (Keat et al., 1978). 40% of the patients with arthritis were HLA-B27-
positive compared with 6% in the total series and 20% of the HLA-B27-positive
patients developed reactive arthritis. It was calculated that a HLA-B27-positive
individual with NSU was ten times more likely to develop Reiter's syndrome
than an HLA-B27-negative individual (Keat et al., 1978).
Reiter's syndrome, in common with AS, shares a strong association with HLA-
B27; about 70-80% of Caucasians with Reiter's are HLA-B27-positive (Brewerton
et al., 1973a; Fox et al., 1979). In blacks the link is less strong (Good et al., 1976). It
is possible that HLA-B27-positive individuals might react to different organisms
(or react in a different way to certain organisms) and develop either a reactive
arthritis or Reiter's syndrome depending on other unknown genetic or
environmental factors.
In contrast with reactive arthritis and Reiter's syndrome, there are no reports of
a microorganism being directly implicated in the onset of AS. A case of
prostatitis due to Trichmonas vaginalis (a protozoan) causing AS has been
reported, but it likely that this patient had incomplete Reiter's syndrome
(Kuberski, 1981).
1.7.5 HLA-B27 association
Human leucocyte antigens (HLA), originally defined as the major
transplantation antigens, are the products of genes in the major
histocompatibility complex (MHC) on chromosome 6. Over 60 diseases are
associated with particular HLA alleles (Engelman et al., 1984). These include:
putatively autoimmune diseases such as rheumatoid arthritis, Graves disease
and Goodpasture's syndrome which have a primarily MHC class II association;
diseases associated primarily with a HLA-B locus antigen such as AS, Reiter's
syndrome, acute anterior uveitis and subacute thyroiditis; and diseases for
which the actual susceptibility gene might lie outside the MHC but is in linkage
disequilibrium with a particular HLA allele e.g., haemochromatosis
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susceptibility gene is linked to HLA-A3. In 1973 the strong association between
AS and HLA-B27 antigen was made.
1.7.5.1 The structure and function of HLA antigens
The HLA class I molecules consist of a polymorphic 45kD glycosylated heavy
chain that spans the cell membrane, noncovalently linked to an invariant llkD
light chain, [^-microglobulin. The gene for {^-microglobulin is found outwith
the MHC. The HLA class I genes are present at three loci and code for the heavy
chain of the HLA-A, -B and -C molecules. The extracellular part of the heavy
chain consists of 3 domains each of approximately 90 amino acids, al, a2 and a3.
The o3 domain is closest to the membrane and, with {52-microglobulin, shows
structural homology to the constant region domains of immunoglobulins. The
3-dimensional structure of a class I molecule (HLA-A2), as visualised by X-ray
crystallography, has revealed that the al and al domains are spatially related to
form a platform of an 8-stranded beta-pleated sheet supporting 2 alpha helices
(Bjorkman et al., 1987). In the centre of this platform lies a groove in which
electron dense material lies. It is this groove which is thought to be the site
where binding of antigen fragments for presentation to CD8-positive T cells
occurs. Virtually all positions of high variability in HLA-A, -B and -C antigens
are located in and around the groove. These amino acid substitutions are
thought to influence the peptides that can interact with the HLA molecules and
which might play a role in determining the T cell receptor repertoire.
The only known function of MHC class I antigens is to present peptides derived
from endogenous antigens to specific receptors on CD8-positive (cytotoxic) T
cells. Endogenous proteins are degraded into peptides in the cytoplasm of the
antigen presenting cell (APC). These peptides enter the endoplasmic reticulum
(ER) where they associate with class I molecules and (32-microglobulin and are
transported through the Golgi apparatus to the cell membrane (Ploegh, 1990).
Drugs that inhibit protein synthesis or block the transport of freshly synthesised
proteins out of the ER inhibit presentation of antigen by class I molecules.
HLA class II molecules (HLA-DP, -DQ or -DR) are composed of two polypeptide
chains of molecular weight 28kD and 32kD. Class II molecules present degraded
forms of exogenous proteins to CD4-positive (helper) T cells. It is thought that
exogenous antigen is internalised by endocytosis into the APC and degraded in
lysosomes. The resultant peptides are then bound by class II molecules in an as
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yet undefined compartment before being transported to the cell membrane.
Class Il-mediated antigen presentation, in contrast to that of class I, is unaffected
by inhibitors of protein synthesis, but is sensitive to lysosomotropic agents,
while class I-mediated presentation is not.
As has been stated, class I antigens present endogenous peptides. The question
arises as to why there is an association of class I antigens with a number of
diseases. In the case of HLA-B27, it is possible that an arthritogenic organism
damages tissues and results in the formation of peptides not otherwise produced
in that tissue. T cell activation might lead to cross-reactions with similar
peptides present on cells elsewhere in the body, such as the enthesis, synovial
membrane or uvea.
1.7.5.2 Epidemiology of HLA-B27
The strong association of HLA-B27 with AS explained the early studies noting
familial aggregation of the disease. HLA-B27 is an autosomal dominant
characteristic and is present in 50% of first degree relatives of HLA-B27-positive
AS probands. Although the strength of the association varies with different
ethnic groups, the association of AS with HLA-B27 is found worldwide. In
blacks, 40-50% of AS patients are HLA-B27-positive compared with less than 1%
in the control population. In Japan, 66% of AS patients are HLA-B27-positive
compared with less than 1% in the control population (Sonozaki et al., 1975). In
Mexico, the Mestizo population (a mixture of Spanish and American Indians)
has a HLA-B27 gene frequency of 4%; HLA-B27 is found in 80% of Mexican AS
patients (Arellano et al., 1984). In Hungary, the HLA-B27 antigen is found in
93% of AS patients compared with a prevalence of 13% in the general
population (Gomor et al., 1977). There is no significant difference in the
frequency of HLA-B27 between males and females with AS.
While HLA-B27 is an undisputed susceptibility factor for AS, it is clear that
possession of this MHC class I molecule is not sufficient per se to cause the
disease as healthy individuals also express this antigen. Conversely, HLA-B27
itself is not necessary for the development of the disease as 5% of Caucasians
with AS and approximately 50% of black American AS patients are HLA-B27-
negative. This suggests the possibility of some aetiological heterogeneity
between HLA-B27-positive and HLA-B27-negative patients. Heterogeneity in
clinical presentation is recognised. HLA-B27-negative cases have a later age of
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onset, less severe disease, a lower incidence of affected relatives and are more
likely to have inflammatory bowel disease or psoriasis than their HLA-B27-
positive counterparts (Linssen, 1990). Acute anterior uveitis is more common
in HLA-B27-positive AS patients than those who are HLA-B27-negative (Khan,
1977).
While over 70% of patients with Reiter's syndrome are HLA-B27-positive, most
do not develop sacroiliitis. It is unexplained why two North American Indian
tribes, the Pima (Lisse et al., 1982) and the Haida, both with a high frequency of
HLA-B27 and sacroiliitis, develop Reiter's syndrome only rarely. In contrast, the
Alaskan Inupiat Eskimos who have a very high population frequency of HLA-
B27 of 25%, develop Reiter's syndrome more frequently than AS (Boyer et al.,
1988). Both AS and Reiter's syndrome tend to 'breed true' within families
(Calin et al., 1984).
Psoriatic spondyloarthropathy and spondylitis associated with inflammatory
bowel disease are associated with an increased frequency of HLA-B27, 60% and
50% respectively (Brewerton et al., 1974). These associations with HLA-B27 are
weaker than that with primary AS suggesting that genes involved in the
aetiology of IBD and psoriasis might contribute to susceptibility for AS. Another
possibility is that a critical part of the HLA-B27 gene is inserted into other alleles
and expressed (gene conversion), but no evidence for this has been found (Pease
et al., 1988).
Several studies performed to assess the risk of developing AS in HLA-B27-
positive individuals have provided conflicting data. The prevalence of disease
in HLA-B27-positive first degree relatives of HLA-B27-positive AS probands
varies from 8% (Christiansen et al., 1977) to 35% (Kidd et al., 1977). Similarly,
the prevalence of AS in HLA-B27-positive individuals who form part of the
general population varies from 1.3% (van der Linden et al., 1984b) to 18% (Calin
and Fries, 1975). The conflicting results are due to a number of factors.
Differences in study design could have influenced the results; some surveys
used non-selected population-based studies (van der Linden et al., 1984b) while
others extrapolated data from blood donors and factory workers and applied
these figures to the general population (Calin and Fries, 1975). Another factor
lies in the criteria employed to diagnose AS. The diagnosis relies on the
presence of radiological sacroiliitis. Interobserver variation in the radiographic
interpretation of sacroiliitis contributes considerably to the discrepancies in the
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prevalence estimates for AS (Hollingsworth et al., 1983; van der Linden et al.,
1984b). This was minimised by van der Linden et al. (1984b) as all X rays were
read by 5 rheumatologists and a majority decision made on diagnosing
sacroiliitis.
The risk of a HLA-B27-positive relative of a HLA-B27-positive AS patient
developing AS, is 20 times greater than for HLA-B27-positive relatives of HLA-
B27-positive healthy individuals (Calin et al., 1983).
1.7.6 Theories to explain the association of HLA-B27 with AS
There have been two main models proposed to explain the association between
HLA-B27 and AS: the two gene theory or linkage disequilibrium hypothesis,
and; the one gene theory of which there are 4 variants.
1.7.6.1 The two gene theory
The two gene theory was proposed in 1974 by McDevitt and Bodmer who
suggested that the HLA-B27 gene itself is not the causative gene for AS; but that
it is in linkage disequilibrium with a second gene which is responsible for the
disease. The association of AS with HLA-B27 is found worldwide in different
ethnic groups. If 2 genes were responsible for the disease, this would imply an
extremely marked degree of linkage disequilibrium maintained over
generations and under different selective conditions. It would be imply that that
these genes (HLA-linked or non-HLA-linked) would be more prevalent in
probands and relatives of probands than in HLA-B27-positive individuals
without disease; and it would be expected that in some families these genes
would occasionally become separated.
A search for restriction fragment length polymorphisms using different
endonucleases and cDNA probes has failed to reveal either a HLA-B locus with
a greater relative risk than HLA-B27, or evidence of an additional locus such as
HLA-D or -DR genes contributing to susceptibility to AS (Dejelo et al., 1978).
There has been no report of a family showing genetic recombination between
HLA-B27 and a hypothetical closely-linked locus (Woodrow et al., 1983).
Families were studied for co-segregation of alleles belonging to non-HLA-linked
polymorphisms with AS but none was found (de Jongh et al., 1990). In addition,
familial aggregation of HLA-B27-negative AS individuals does not appear to
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occur. This suggests that the gene responsible for AS and HLA-B27 gene are the
same.
If a second gene was responsible for the disease, there should be no difference
between HLA-B27-positive and HLA-B27-negative AS patients. There is,
however, clinical and genetic heterogeneity between the 2 groups.
In view of these considerations, the two gene theory is no longer accepted as a
likely explanation of the HLA-B27-AS association.
1.7.6.2 The one gene theory
The one gene theory postulates that the HLA-B27 gene itself is directly involved
in the development of AS. The variants of this theory are the molecular
mimicry or cross-tolerance theory; the receptor theory; Geczy's plasmid theory
and the chemotaxis theory.
Molecular mimicry theory
The molecular mimicry theory (Ebringer et al., 1976) suggests that the HLA-B27-
positive host is colonised by microorganisms which express antigens that
partially resemble HLA-B27, but which are sufficiently different from HLA-B27
to generate an immune response. The antibacterial antibodies produced cross-
react with HLA-B27 molecules and activate complement with resultant
inflammation. To explain the distribution of spinal involvement in AS, it is
postulated (Ebringer, 1983) that if the bacteria are enteric organisms, they would
induce a local gut mucosal antibody response; and, because of lymphatic
drainage, the antibodies would 'home in' on the nearby sacroiliac joints and
lumbar spine. This mechanism does not explain the involvement of peripheral
joints or the uveal tract, or why most other tissues in the body which also
express HLA-B27 molecules are unaffected by the inflammatory process.
Molecular mimicry between viral or bacterial antigens and vertebrate host self
antigens is not uncommon (Oldstone, 1989). The classic example of a cross-
reactive autoimmune disease is rheumatic fever in which the M protein from
Group A (3-haemolytic Streptococcus pyogenes and human cardiac myosin share
antigenically similar epitopes (Dale and Beachey, 1986). The demonstration of
antigenic similarity between host and organism, however, does not necessarily
mean that this is of significance in disease pathogenesis.
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Evidence for cross-reactivity between HLA-B27 and enteric bacteria does exist.
Sera from rabbits which had been immunised with HLA-B27-positive
lymphocytes were found to react with Klebsiella and Yersinia in
immunodiffusion assays (Ebringer et al., 1976) and this was confirmed using
haemagglutination and radiobinding assays by the same group. Rabbit anti-
Klebsiella sera had cytotoxic activity against HLA-B27-positive lymphocytes
from AS patients (Welsh et al., 1980). Polyclonal human tissue typing sera from
gravid women which had anti-HLA-B27 activity bound to Klebsiella antigens
(Avakian et al., 1980). A criticism of this work is that naturally occurring
antibacterial antibodies are known to be present in allo-antisera; therefore, it is
difficult to be certain that the reactions observed were due to the anti-HLA-B27
antibodies and not to these other antibodies (Ogasawara et al., 1986).
With the advent of monoclonal antibodies, binding of monoclonal anti-HLA-
B27 antibodies (Ml and M2) was demonstrated to Klebsiella pneumoniae K21
and K43, and to antigens of Shigella flexneri (molecular weight 20,000 kD) and
Yersinia enterocolitica (molecular weight 16,000) (van Bohemen et al., 1984). A
monoclonal anti-Yersinia antibody (Ye-1) cross-reacted with all 12 HLA-B27-
positive lymphoblastoid cell lines but only 4/31 HLA-B27-negative ones; 3/4 of
the reactive HLA-B27-negative cell lines were HLA-B7-positive. A HLA-B27-
positive cell line which lost its HLA-B27 expression because of experimentally-
induced mutation, became unreactive with Ye-1 (Kono et al., 1985). Cross-
reactivity between HLA-B27 and K. pneumoniae (but not other Gram-negative
bacteria) was demonstrated with a monoclonal anti-HLA-B27 antibody (M2) in
an ELISA using absorption experiments to ensure the validity of the results
(Ogasawara et al., 1986). Chen et al. ( 1987) used a Western blot technique and a
monoclonal anti-HLA-B27 antibody generated in their own laboratory to
demonstrate cross-reactivity between a 19,000 kD outer membrane component of
Y. pseudotuberculosis and HLA-B27. A rabbit antiserum prepared against this
19,000 kD protein was selectively reactive against HLA-B27-positive cells.
Molecular similarity between HLA-B27 and other proteins was sought by
computer analysis using the Dayhoff Protein Sequence Database. An identical
hexamer amino acid sequence was found which was shared by both HLA-B27.1
(residues 72-77) and K. pneumoniae nitrogen reductase enzyme (residues 188-
193) (Schwimmbeck et al., 1987). The sequence is Glutamine-Threonine-
Aspartate-Arginine-Glutamine-Aspartate and is known as QTDRED. To
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investigate the significance of this shared sequence, synthetic peptides
representing HLA-B27.1 (residues 69-84) and K. pneumoniae nitrogen reductase
(residues 184-193) both containing the hexamer, were made and the sera of
patients were tested by ELISA for antibodies to the peptides. Sera from 18/34
(53%) patients with Reiter's syndrome and 7/24 (29%) AS patients contained
antibodies to the HLA-B27-derived peptide compared with none of the 22
controls. Over 40% of HLA-B27-positive patients with AS or Reiter's syndrome
had antibodies to the Klebsiella-dehved peptide while none of the controls did.
This evidence appeared to support the cross-reactivity theory. The inability to
detect antibodies in some AS and Reiter's syndrome patients was suggested to
relate to poor immune responses or low affinity responses.
Other laboratories, however, using similar techniques have been unable to
confirm these results. The sera of patients with AS and Reiter's syndrome from
Norway and New Mexico were tested by ELISA for antibodies to synthetic
peptides sharing the QTDRED hexamer (Tsuchiya et al., 1989). Among
Norwegian males, 1/8 (12.5%) of Reiter's syndrome and 14/60 (23.3%) of AS
patients had antibodies to the HLA-B27 peptide compared with 4% of male
controls. None of 8 patients with Reiter's syndrome, only 2/26 (7.7%) of AS
patients and 2/38 (5.3%) of male controls in New Mexico were positive.
Antibodies to the HLA-B27.1 peptide were found in 20% of normal female
controls with at least one previous pregnancy. Anti-Klebsiella peptide
antibodies were neither significantly elevated in AS nor correlated with anti-
HLA-B27.1 peptide antibodies either in Norwegian or in New Mexico
populations. The difference between these results and those of Schwimmbeck et
al. (1987) might be due to more stringent precautions taken to minimise non¬
specific serum binding, or to differences in HLA-B27 subtypes in the two
populations.
In another study, failure to confirm Schwimmbeck's results was thought to be
due to a high degree of non-specific serum binding in the sera of 93 patients with
AS and 38 with Reiter's syndrome (de Vries et al., 1990). This group also
reported the absence of cross-reactivity between the HLA-B27.5 peptide
containing the mimicry epitope and antibodies raised in rabbits to the Klebsiella
peptide containing the epitope. They concluded that the molecular mimicry
between the two proteins does not have any biological significance and is not
involved in the pathogenesis of HLA-B27-related rheumatic disorders.
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Further evidence against cross-reactivity existing between HLA-B27 and
arthritogenic enteric bacteria came from the finding of anti-HLA-B27 cross-
reactive antibodies in only 2/63 patients recently infected with S. flexneri, C.
jejuni or Y. enterocolitica who had significantly elevated antibody titres to the
infecting bacterial species (Cavender and Ziff, 1986). This was supported by
further studies in which lymphocytes from HLA-B27-positive patients with AS
and Reiter's syndrome and matched controls were stimulated in vitro with
polyclonal mitogens (Cavender and Ziff, 1988). There was no significant
difference in the level of immunoglobulins produced between patients and
controls and only negligible amounts of IgA, IgG or IgM antibodies to Shigella,
Campylobacter and Yersinia were found. No anti-HLA-B27 antibodies were
produced by any of the patients.
There is another piece of evidence against molecular similarity bearing any
relationship to the pathogenesis of AS. The K. pneumoniae nitrogen reductase
enzyme is present in only 10% of K. pneumoniae isolates and the gene is only
expressed when the bacteria are in a nitrogen-free environment (Yu, 1988). In
the human host, one must accept that this gene is not expressed. It is possible,
though, that similar sequences are present in proteins of other (enteric) bacteria
and are expressed under conditions that exist in the intestinal tract.
In summary, there is experimental evidence that molecular similarity does exist
between the HLA-B27 antigen and some Gram-negative bacteria, but the
pathological significance of this molecular mimicry is not clear.
The receptor theory
The receptor theory: This is the most favoured theory at present and is based on
the suggestion that the HLA-B27 molecule itself presents specific polypeptides
derived from bacteria or from a specific type of collagen, to CD8-positive T cells.
More sophisticated analytical techniques have identified subtypes of HLA-B27
that have slight modifications in their amino acid sequences. These techniques
include one-way mixed lymphocyte cultures (Breuning et al., 1982); monoclonal
antibodies (Grumet, 1983); and isoelectric focussing gel analysis of HLA-B27
immunoprecipitates (Choo et al., 1986).
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There are 6 HLA-B27 subtypes (Lopez de Castro, 1989) and a seventh variant
(B27HS) already identified. The subtypes (B*2701-06) differ from each other in 1-
6 amino acid residues and B27HS is identical to B*2705 in the al domain and to
HLA-Bw61 in the a2 (Choo and Hansen, 1989). The positions that are
polymorphic (59, 74, 77, 80, 81, 114, 116 and 152) are all located in the peptide
binding groove of the molecule; and all except one (residue 59), are located in
the right hand side of the groove. Most are located at the surface of the molecule
potentially influencing interactions with processed antigen by being accessible to
antibody and T cell receptor binding.
There are, however, 5 residues which are unique to HLA-B27 (Benjamin and
Parham, 1990) and which are totally conserved in all subtypes. These residues
(positions 24, 26, 35, 45 and 67) are spatially in close proximity near the mouth of
the '45 pocket' in the al helix and situated at the left side of the peptide binding
groove, clearly separated from the region where most of the subtype
polymorphism occurs. One of these conserved residues is a cysteine at position
67 (Cys 67); and, although it is not part of the antigen binding groove, it has a
strong influence on the conformation of the a-1 helix. Cys 67 has a reactive
sulphydryl side chain which points into the antigen binding groove.
The common subtypes (B*2702 and B*2705) are found in over 99% of white
populations (Breur-Vriesendorp et al., 1987) and there is no difference in the
relative frequencies of these subtypes in AS and in controls. This suggests that
the structural differences between subtypes have little bearing on the disease
mechanism (Parham, 1990; Lopez de Castro et al., 1990); and it is not the variable
but the conserved regions of the subtypes which are important in pathogenesis.
The unique characteristics of the HLA-B27 peptide binding groove indicate that
HLA-B27 will bind antigenic peptides which cannot be bound by other HLA-A, -
B or-C molecules. If peptides from joint-specific proteins were bound by HLA-
B27, then these complexes could stimulate and be the target for autoimmune T
cell responses. As most HLA-B27-positive individuals do not develop disease,
additional factors must be involved. It is possible that certain joint-specific
peptides not normally produced or only produced in low amounts, are produced
in response to an environmental stimulus such as infection or trauma. It is
postulated that the reactive sulphydryl group on Cys 67 could bind such joint-
specific proteins (Parham, 1990), a cysteine-containing bacterial peptide (Stieglitz
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et al., 1988), or even control the access of peptides to the HLA-B27 binding site
(Benjamin and Parham, 1990).
An alternative explanation is that activated cytotoxic T cells, stimulated against a
bacterial or other foreign peptide, recognise the joint peptide and HLA-B27
complex (Parham, 1990) and instigate a T cell-mediated autoimmune response.
Although HLA-B27 is a well-established serologic specificity, most human
alloantisera do not distinguish between subtypes but only recognise the shared
HLA-B27 determinant. Some alloantisera, however, can detect subtype
polymorphism.
A study of alloreactive cytotoxic lymphocyte clones (Lopez de Castro et al., 1990)
demonstrated that polymorphism at residues 74-81 of the HLA-B27 molecule
affected the pattern of reactivity of most of the T cell clones. Some HLA-B27
subtypes are recognised by T cells as being as different from each other as from
any other MHC class II alloantigen; therefore, subtype differences have the
potential to alter peptide binding and T cell recognition.
The chemotaxis model
This model suggests that an increased inflammatory response by HLA-B27-
positive neutrophils to some arthritogenic bacteria could explain the increased
proportion of Yersinia reactive arthritis in HLA-B27-positive hosts (Repo et al.,
1983). By extrapolation, similar responses to other bacteria in HLA-B27-positive
individuals could be involved in the pathogenesis of AS. An increased
polymorph motility has been found in both HLA-B27-positive AS patients and
HLA-B27-positive healthy controls (Pease et al., 1984). A HLA-B27-linked
enhanced inflammatory response mediated by neutrophils is thus invoked to
explain the association of the MHC class I antigen with AS. The corollary of this
is that HLA-B27-positive individuals would be expected to show increased
inflammatory responses to a number of infectious agents, but there is no
evidence that this is the case.
The plasmid-associated model
The work performed by Dr A Geczy's group showed that rabbit antisera raised
against a Klebsiella isolate (427) were cytotoxic for lymphocytes from HLA-B27-
positive AS patients but not for lymphocytes from healthy individuals either
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HLA-B27-positive or -negative (Seager et al., 1979). The cytotoxic activity was
removed only by HLA-B27-positive lymphocytes from AS patients and not by
HLA-B27-positive (or negative) lymphocytes from controls. This suggested that
some Klebsiella antigens cross-react not with the HLA-B27molecule per se but with a
gene product closely associated with HLA-B27 or possibly a Klebsiella-modified
HLA-B27 alloantigen complex. Incubation of HLA-B27-positive lymphocytes from
healthy subjects with Klebsiella K43 culture supernatants resulted in 'transformation'
of these lymphocytes. They were lysed by anti-Klebsiella K43 antiserum in a
cytotoxicity assay (Geczy et al., 1980). None of the cells of HLA-B27-negative AS
patients were lysed by the antisera which suggested that the HLA-B27 antigen was
being modified by soluble factors from the bacteria.
One hypothesis to explain these findings was that a bacterial plasmid present in
Klebsiella coded for a factor able to modify HLA molecules so that HLA-B27
expressed bacterial antigens (Cameron et al., 1983). Klebsiella antigens or fragments
would be present on the cells of HLA-B27-positive AS patients and absent from
HLA-B27-positive healthy controls. If the plasmid theory was correct, anti-
Klebsiella antisera would bind more to HLA-B27-positive lymphocytes from patients
than from healthy HLA-B27-positive controls or HLA-B27-negative cells. There
was no difference in binding of anti-Klebsiella antisera to HLA-B27-positive
lymphocytes regardless of their clinical source; but, HLA-B27-positive lymphocytes
from patients or controls bound the antisera to a significantly greater extent than
HLA-B27-negative lymphocytes, suggesting a recognition by anti-Klebsiella sera of
some structure on HLA-B27-positive lymphocytes (Baines et al., 1990). These
results support the molecular mimicry theory.
Several attempts in laboratories all over the world have failed to reproduce Geczy's
results. The hypothesis of a plasmid-mediated modification of HLA-B27-positive
cells is no longer an accepted hypothesis to explain the AS-B27 association.
1.7.6.3. Animal models (see Page 27a)
1.7.7 Faecal flora in AS
From Ebringer's work demonstrating cross-reactivity between rabbit antiserum
raised to human HLA-B27-positive lymphocytes and K. pneumoniae, Enterobacter
aerogenes and Y. enterocolitica (Ebringer, 1976), it was a logical step to examine for




The importance of the HLA-B27 molecule in disease has been explored using animal
models. HLA-B27 and human [32-microglobulin genes were injected into the male
pronucleus of fertilised mouse eggs which were transferred to pseudopregnant foster
mothers. This procedure gave rise to mice expressing the products of both genes on cell
surfaces, so-called transgenic animals. Although the HLA-B27 gene product was
functional in both hybrid and inbred mice (Taurog et al., 1988)*, no true similarity of
features of HLA-B27-associated disease has been reported in transgenic mice.
Nickerson et al. (1990)* reported that mice transgenic for the HLA-B2705 subtype
when injected intravenously with Y. enterocolitica developed paravertebral abscesses
more frequently and were more susceptible to the lethal effects of the pathogen than
were nontransgenic controls. This work has not, however, been confirmed. These
results suggested that susceptibility to spondyloarthropathies might not be related to
the B27 gene.
By contrast, when HLA-B27 and human (^-microglobulin genes were introduced into
rats, 2 transgenic lines spontaneously developed a number of features similar to those
observed in the spondyloarthropathies (Hammer et al., 1990)*. Diarrhoea was
invariable with chronic inflammation histologically particularly of the colon and mostly
in the lamina propria. Arthritis of the tarsal joints occurred lasting a few days to
several weeks and histologically the changes were similar to those seen in AS, with
hyperplastic synovium and infiltration of large numbers of neutrophils, lymphocytes,
and plasma cells. Inflammatory changes in the outer aspects of the annulous fibrosis
and its attachments to vertebral endplates were identified. Hyperkeratosis of the tail,
nail dystrophy, orchitis and epididymitis were common. Inflammatory lesions in the
myocardium were identified in a few cases.
These results support a direct role for the HLA-B27 molecule in pathogenesis. Not all
transgenic rat lines have developed such inflammatory disease and this may be due to
quantitiative or qualitative differences in expression of the transgenes or to differing
effects of the transgene on the host genome. The disease in transgenic rats arose
spontaneously in the apparent absence of infection, but it is possible that interaction
occurred between HLA-B27 and commensal bacteria. Results on studies on germ-free
transgenic rats are awaited with interest. * p.196
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In their initial study, Ebringer and colleagues (1977) based disease activity on the
presence of active peripheral manifestations, duration of early morning stiffness
and anti-inflammatory and analgesic requirement. Klebsiella were isolated
from the stools of 13/14 (93%) patients with active spondylitis, 10/21 (48%)
patients with probably active disease, and in 1/28 (4%) of those with inactive
spondylitis. This compared with an isolation rate of 47/124 (38%) in controls. It
was concluded that carriage of Klebsiella was associated with active AS. If all AS
patients, however, were taken as a group, the Klebsiella isolation rate was
practically identical to that of controls. The interpretation of the findings
depends on the criteria for defining 'active' disease, and there remains no
consensus on the definition of disease activity in AS.
In a larger sequential study on 163 AS patients, the rate of Klebsiella isolation
again correlated with disease activity and it was suggested that in those with
inactive spondylitis the finding of Klebsiella in the stool was associated with a
subsequent increase in inflammatory disease (Ebringer et al., 1978). In a survey
of Navajo Indians in Arizona, 25 with AS and 18 with Reiter's syndrome
(Kuberski et al., 1983), there was no significant difference in overall frequency of
faecal Klebsiella in patients compared with controls. When the patients were
divided on the basis of disease activity, however, significantly more Klebsiella
were identified in the group with active AS or active Reiter's (54%) than in the
inactive group (12%) or in the controls (13%). This applied to both AS and
Reiter's patients. In this study active disease was determined by the presence of
early morning stiffness with axial and/or peripheral joint involvement
requiring non-steroidal anti-inflammatory drugs (NSAID).
Several other studies have shown no association of faecal Klebsiella with AS or
any relationship between Klebsiella carriage and active spondylitis. These
studies have been performed in many different laboratories including ones in
London (Warren and Brewerton, 1980), Winnipeg (Hunter et al., 1981), Leeds
(Eastmond et al., 1980) and the Netherlands (van Kregten et al., 1991). Recently
in Brazil, a complete assessment of Gram-negative enteric bacteria in AS
patients and healthy controls revealed no significant differences either
qualitatively or quantitatively in Klebsiella isolation between the two
populations. There was no association between the presence of Klebsiella and
clinical or laboratory parameters of active disease (Ferraz et al., 1990).
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An attempt to reduce Klebsiella carriage and so influence disease activity has
been tried by dietary manipulation, but this met with no success (Shinebaum et
al., 1984).
Increased carriage of Klebsiella has, however, been reported in the first week
following acute anterior uveitis (AAU) especially in HLA-B27-positive or B7-
CREG-positive patients (Ebringer, 1988). An earlier survey (Warren and
Brewerton, 1979) did not show any association between Klebsiella and AAU, but
in this case faecal samples were obtained up to 1 month after AAU started.
1.7.8 Humoral response to enteric bacteria
Another way of assessing the involvement of enterobacteria in the pathogenesis
of AS has been to examine the humoral immune response to microorganisms.
The evidence has been conflicting. Raised IgA antibodies to Klebsiella have
been identified in patients with active spondylitis by a number of different
techniques: enzyme linked immunsorbent assay (ELISA) (Trull et al., 1983; Trull
et al., 1984; Khalfapour et al., 1988; Maki-Ikola et al., 1991); bacterial absorption
(Ebringer et al., 1985); indirect Coombs' bacterial agglutination (Ebringer et al.,
1985); and immunoblot (Shodjai-Moradi et al., 1992). Raised IgA, but not IgG,
antibodies to K. pneumoniae K43 were similarly demonstrated by ELISA in AS
patients compared with healthy controls (Cooper et al., 1988); but, they were also
elevated in ulcerative colitis, Crohn's disease and rheumatoid arthritis. There
was no correlation between disease activity (defined by a combination of clinical
criteria and an elevated ESR) and titres of anti-K43 IgA antibodies. These results
suggested that in AS there is a subclinical bowel inflammation which allows the
penetration of bacteria across the mucosa to stimulate antibody production. The
same group found that titres of IgM anti-K43 antibodies were significantly lower
in AS and ulcerative colitis than in controls, but the reason for this was not clear
(Cooper et al., 1988).
In contrast, a study using an ELISA to measure serum antibodies to sonicated
(rather than whole) Gram-negative bacteria showed that there was no difference
in IgA antibody titres to K. oxytoca K9 or E. coli in AS patients compared with
healthy controls. There was, however, a slightly elevated mean anti-Yersmza
titre in AS patients due to a few patients with raised levels. Salivary IgA
antibodies to the three bacterial species were similar for patients and controls
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(Pease et al., 1987). Another group failed to demonstrate specific IgA antibodies
to K. pneumoniae K21, S. flexneri 2a, Y. enterocolitica 09 or E. coli in AS
patients as a group, though it was observed in individual patients. These results,
in conjunction with the elevated total IgA in these patients, suggested that a
non-specific stimulation of the IgA system might occur in AS (van Bohemen et
al., 1986).
The search for antibodies to other enterobacteria has, in general, been
unrewarding. IgA antibodies to Y. enterocolitica, S. typhimurium or P.
aeruginosa in active spondylitis were not elevated compared to controls (Trull et
al., 1984). A wider survey by a Finnish group showed that the IgA level to
Campylobacter jejuni, Proteus mirabilis, Chlamydia trachomatis, Borrelia
burgdorferi, Yersinia and Salmonella did not differ in AS patients compared
with controls (Maki-Ikola et al., 1991). Andreasen et al. (1991) agreed that there
was no role for C. jejuni in the pathogenesis of AS.
Raised antibody levels to B. burgdorferi have been reported in AS patients and
their relatives but the results were inconclusive (Blaauw et al., 1990). In contrast
with the Finnish workers, a more frequent occurrence of specific C. trachomatis
antibodies in AS compared with untyped healthy blood donor controls was
reported suggesting a possible aetiological role for this intracellular organism
(Csango et al., 1987). Streptococci have also been implicated in the pathogenesis
of AS (Zilko et al., 1977).
Rather than measure antibodies to a particular bacterium, van Bohemen and
colleagues (1988) measured serum antibodies to one of the major outer
membrane proteins (h-momp) which constitutes a large part of the cell
envelope structure. H-momp is cross-reactive among many Enterobacteriaceae;
raised antibody titres to it would therefore reflect exposure to several different
bacterial species. AS patients had over twice the level of IgA anti-h-momp
antibodies than hospitalised controls who did not have arthritis or
gastrointestinal disease. IgG and IgM anti-h-momp antibodies did not differ
between the two populations.
Intestinal humoral immunity has been investigated by only one group
(O'Mahony et al., 1992). High serum IgA antibodies to K. pneumoniae K43 in
gut lavage fluid (measured by ELISA) were found in both AS patients with
active disease and patients with Crohn's disease compared with controls. The
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categorisation of active disease for AS patients was based on an ESR >15 and
serum IgA > 3g/l, similar to Ebringer's classification, but not accepted
universally. The Crohn's group also had high serum IgG titres to K43.
Intestinal IgA antibody levels to K43 were similar in the 3 study groups, but
Crohn's patients had high intestinal IgM and IgG antibody titres to K43. The
rises in intestinal IgA antibody levels to K43 were not, therefore, specific to AS
and it was suggested that they probably related to the passage of bacterial antigens
across inflammed gut mucosa. There was no evidence for an abnormal
intestinal IgA response to K43 in AS patients.
Raised serum antibody levels to specific bacteria might indicate that the bacteria
are involved in the pathogenesis of AS, but there is no direct evidence for an
antibody- or complement- mediated disease process.
1.7.9 Total serum antibodies in AS
1.7.9.1 IgA
Elevated levels of total serum IgA in AS patients compared to controls have
been reported in several studies (Veys and van Laere, 1973; Kinsella et al., 1975;
Cowling et al., 1980b; Calguneri et al., 1981; Laurent and Panayi, 1983; Neumann
et al., 1984; Trull et al., 1984; Franssen et al., 1985; van Bohemen et al., 1986; Pease
et al., 1987; Sanders et al., 1987; Mackiewicz et al., 1989). This has been postulated
to reflect stimulation by enterobacterial antigens via the gastrointestinal tract as
IgA is the main immunoglobulin concerned with mucosal immunity.
In some studies no correlation of serum IgA with disease activity was made
(Kinsella et al., 1975; Sanders et al., 1987). In others, the raised serum IgA was
associated with active disease as determined by the laboratory parameters of an
elevated ESR (Cowling et al., 1980b; Trull et al., 1983); an elevated CRP (Cowling
et al., 1980b; Trull et al., 1984; Collado et al., 1987); or both an elevated ESR and
CRP (Calguneri et al., 1981).
When disease activity is assessed by clinical criteria, some groups have shown
no relationship between serum IgA and active disease (Laurent and Panayi, 1983;
Pease et al., 1987). This contrasts with the results of a longitudinal study in
which changes in serum IgA over time correlated with changes in disease
activity assessed by a combination of subjective and objective clinical parameters
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(Franssen et al., 1985). The highest levels of IgA were present in those patients
with the most extensive radiological changes.
van Bohemen and colleagues (1986) found elevated levels of serum IgA in
active AS patients as determined by a combination of clinical criteria and raised
CRP.
Measurement of total salivary IgA in AS patients has revealed conflicting
results. Similar (Calguneri et al., 1981; Pease et al., 1987) and elevated
(Neumann et al., 1984) levels of salivary IgA in AS patients compared with
controls have been found.
The IgA subclasses produced in AS have been examined (van den Wall Bake et
al., 1988). An increase in serum IgA restricted to IgAl subclass was found in
patients with AS compared with controls. An in vitro study of
immunoglobulin synthesis by peripheral blood mononuclear cells (PBMC) in
these patients established that there was no increase in IgA synthesis in either
unstimulated or pokeweed mitogen-stimulated cultures. There was, however,
an increase in the ratio of IgAl to total IgA production in pokeweed mitogen
(PWM)-stimulated PBMC cultures which was reflected in the raised serum
IgAl /total IgA levels.
1.7.9.2 IgG
A mixed picture emerges for the total serum IgG in AS. No significant
difference in total serum IgG was found between AS patients and controls
(Kinsella et al., 1975; Cowling et al., 1980b). Calguneri and colleagues (1981)
reported that the mean total IgG was similar for AS and control populations, but
those patients with a raised ESR and CRP had significantly higher IgG levels
than controls. Other groups have reported elevated total serum IgG in AS
patients compared with controls (Veys and van Laere, 1973; Trull et al., 1984;
Sanders et al., 1987). Only AS patients with iritis or peripheral arthritis had
higher total IgG levels than controls (Laurent and Panayi, 1983). Total IgG
correlated with disease activity as determined by a raised CRP (Trull et al., 1984),
but not as determined by either a combination of clinical and laboratory




Most studies have shown no significant difference in total serum IgM between
AS patients and controls (Kinsella et al., 1975; Cowling et al., 1980b; Calguneri et
al., 1981; Laurent and Panayi, 1983; Trull et al., 1984). Elevated total IgM in AS
patients compared with controls (Veys and van Laere, 1973) and compared with
patients with rheumatoid arthritis (RA) and controls (Franssen et al., 1985) have
been reported.
A significantly decreased production of IgM in unstimulated cultures of PMBC
from AS patients has been described (van den Wall Bake et al., 1988). In a
previous study (Vuento et al., 1984) a similar decrease in IgM production was
evident in PWM-stimulated cultures; the addition of hydrocortisone to the
cultures led to normalisation of IgM synthesis suggesting a role for suppressor
cells.
1.7.10 Autoimmunity in AS
In view of the association of prostatic infection in AS and Reiter's syndrome
(Mason et al., 1958), Grimble et al. (1964) searched for autoantibodies to prostate
antigen and found them in most Reiter's syndrome patients and patients with
AS but not in those with RA.
An antibody was identified in the sera of 39% AS patients which reacted with
the 93kD heat shock puff of polytene chromosomes from larval salivary glands
of Drosophila melanogaster (Lakomek et al., 1984). Heat shock proteins are
produced by cells in response to physiological stress. Some act as molecular
chaperones protecting immature proteins during the final stages of protein
synthesis and transport. They may also be a source of antigenic target, modulate
T cell function and might protect cells from free radicals at sites of
inflammation.
Lakomek's group subsequently (1991) found that serum samples from 32/95
(34%) patients with AS and 15/34 (44%) from patients with either Crohn's or
psoriatic spondyloarthropathy reacted with a 36kD drosophila antigen (not a
heat shock protein). Antibodies purified from the 36kD antigen reacted
specifically with a 69kD antigen present in separations of total protein
preparation from human lymphocytes and HeLa cells. This antibody is in effect
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an autoantibody. It was not found in 29 patients with RA or in 38 healthy
controls and was found in similar proportions in HLA-B27-positive and -
negative patients. The presence of anti-36kD antibodies did not correlate with
the patients' age, sex or ESR and are distinct from those autoantibodies described
by Schwimmbeck et al. (1987) which recognised 12kD and 45kD moeities of HLA-
B27 antigen. It was postulated that there might be a defect in cell-mediated
immunity resulting in an immunoreactive lymphocyte clone producing
antibody to this 36kD antigen. The structure and function of the 69kD
lymphocyte protein to which the 36kD antibody binds is not known.
Raised serum IgA immune complexes detected by PEG precipitation and
pepsinogen binding have been associated with peripheral synovitis, but the
correlation with other clinical and laboratory indicators of disease activity is
poor (Maclean et al., 1992). There was no evidence for Klebsiella antigens in
these complexes.
1.7.11 Cell-mediated immunity and B lymphocytes in AS
T lymphocyte numbers in AS have been studied by a few groups. Normal T cell
counts (Hickling et al., 1982), a reduced T cell count (Fan et al., 1977) and an
increase in the proportion but not the total numbers of helper T cells have all
been reported (Veys et al., 1983).
Elevated levels of serum immunoglobulins have been considered an expression
of B lymphocyte hyperreactivity. Raised B cell numbers (in association with
raised serum IgG and IgA) have been found in active AS (Hickling et al., 1982).
Increased proportions of peripheral B cells (Byrom et al., 1979) and
immunoblasts (Eghtedari et al., 1976) have been noted. More recently, a normal
proportion of circulating B cells was described in AS (Barbieri et al., 1990).
Tests of lymphocyte function have yielded conflicting results.
Phytohaemagglutinin and aggregated human gammaglobulin caused increased
transformation responses in PBMC from AS patients in a lymphocyte
transformation (LT) test (Kinsella, 1979). An increased proliferative response
and in vitro production of immunoglobulins from lymphocytes from AS
patients to the Staphylococcus aureus strain Cowan I (a T cell independent B cell
activator) was found (Barbieri et al., 1990). This hyperresponsiveness was
associated with disease activity. No differences were found in the response to
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pokeweed mitogen (PWM) and protein A (both T cell dependent polyclonal B
cell activators). There was no difference in T cell responses to mitogens in
patients and controls.
Following work by Nikbin and colleagues (1975) who showed a reduced LT
response to a Yersinia immunogen (a formalinised mixture of Y. enterocolitica
03 and 09 and Y. pseudotuberculosis type 1), Sheldon et al. (1985) sought to
determine whether AS lymphocytes showed fundamental differences in their
response to enteric organisms, either commensals or pathogens compared with
healthy individuals. PBMC from AS patients responded less well in a LT test to
Y. enterocolitica 03, and 06 and K. pneumoniae antigens than did PBMC from
patients with reactive arthritis, Reiter's syndrome or controls. There was a
statistically significant hypo-responsiveness of AS PMBC to K. pneumoniae
compared with controls. This agrees with the report that AS lymphocytes were
hypo-reactive to 5 different Klebsiella species compared with those of HLA-B27-
positive and HLA-B27-negative controls in a LT assay (Seager et al., 1979).
Impaired PBL transformation by Klebsiella from autogenous or heterogenous
sources was not seen in AS patients or controls in a LT assay (Kinsella et al,
1984). No difference in reactivity in a LT assay to S. flexneri, S. typhi, Y.
enterocolitica, K. pneumoniae or C. trachomatis was noted for cells from
patients with AS or controls (Enlow et al., 1982). K. pneumoniae when added to
mononuclear cell cultures with Y. enterocolitica had an adjuvant effect on
transformation of the lymphocytes (Sheldon, 1985).
There was a poor proliferative response to a variety of cell preparations of
Klebsiella K43 with peripheral blood lymphocytes from patients with AS,
Yersinia reactive arthritis, those recovering from Klebsiella infection and
controls (Gross et al., 1988). Compared with healthy controls, however, there was
increased leucocyte migration inhibition factor (LIF) production from PBMCs
from patients with yersiniosis and Yersinia arthritis in response to Yersinia,
Klebsiella and protein I of the outer membrane. In contrast, enterobacterial
common antigen did not induce LIF production in cells from patients or healthy
individuals.
Peripheral blood T lymphocytes specific for cartilage proteoglycans (a major
component of articular cartilage) have been reported (Mikecz et al., 1988). There
was no significant difference in response, however, of either PBMC or synovial
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fluid mononuclear cells to 5 preparations of human cartilage proteoglycans
compared with that of normal and disease controls suggesting that autoimmune
responses to cartilage proteoglycans are unlikely to be involved to a significant
extent in the pathogenesis of AS (Jobanputra et al., 1992).
An investigation into the cellular mechanism of reduced rheumatoid factor
(RF) production in AS showed that either spontaneous or PWM-induced total
IgG and IgM production by PBMCs was similar for patients with AS, rheumatoid
arthritis and controls (Yu et al., 1989). IgM-RF synthesis was significantly
reduced in AS compared with controls and RA patients. Subsequent co-culture
experiments adding T or B cells from normal subjects to B cells of AS patients
revealed a diminished T cell helper function of AS lymphocytes. Suppressor T
cell function and B cell function were normal. The deficiency of helper function
was not due to a serum blocking factor.
When Epstein-Barr virus infects B lymphocytes in vitro proliferation and
lymphoblastoid formation occurs. T cells normally control this and inhibit the
proliferative response about day 12 of culture. With mononuclear cells from
patients with AS, rheumatoid arthritis and multiple sclesosis no such regression
occurs and cultures outgrow into lymphoblastoid cell lines at high frequency
(Robinson and Panayi, 1986). In rheumatoid arthritis this defect has been
identified to a deficiency in cytotoxic T cell response and it would not be
unreasonable to predict a similar defect in AS.
1.8 Susceptibility Factors for Disease
Susceptibility to disease is dependent on both genetic and environmental factors.
The HLA-B27 phenotype is a genetic factor and infection is possibly an
environmental factor in the aetiology of AS. Susceptibility to certain diseases is
associated with particular blood group phenotypes and in some cases to the
ability of individuals to secrete ABO blood group antigens into their body fluids.
1.8.1 Blood groups in susceptibility to disease
Blood group phenotypes differ considerably in frequency between different
populations but there has been no unifying hypothesis to explain this.
Although about 20 independent blood group systems have been recognised, the
physiological functions of blood group antigens remain to be discovered. Blood
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group antigens are major transplantation antigens, they might be involved in
tissue differentiation and may have evolved to play a role in conferring
resistance to disease (reviewed by Marsh, 1990).
ABO blood group antigens are associated with a number of diseases, the most
striking of which is that of diseases of the upper gastrointestinal tract. Duodenal
ulcer is seen 40% times more frequently in individuals of blood group O than of
other groups (Roberts, 1959). There is a marked association of blood group A
and gastric carcinoma (Aird et al., 1953). ABO blood group antigens are also
associated with thromboembolic disease (Mourant et al., 1978).
1.8.1.1 Historical review
In 1900 Landsteiner discovered the human ABO blood group system. Ten years
later, von Dungren and Hirzfeld showed that these blood groups were inherited
in a Mendelian pattern (reviewed by Mourant et al., 1978). The presence of A
and B antigens in semen and saliva was first noted in 1926 by Yamakami, but it
was not realised until 1930 when Lehrs and Putkonen (cited by Mourant et al.,
1978) independently discovered that some individuals do, and others do not,
secrete antigens corresponding to their ABO blood group into their saliva. This
ability to secrete blood group antigens into body fluids was found to be inherited
as a Mendelian dominant character (reviewed by Race and Sanger, 1975). In
Europeans about 80% are secretors and 20% are non-secretors (Mourant et al.,
1978). Different ethnic groups show different proportions of secretors and non-
secretors (Mourant et al., 1978).
The Lewis blood group system was identified initially by the discovery of the
antibody, anti-Lewis3, by Mourant in 1946. This was complemented by the
discovery by Andresen in 1948 of anti-Lewis*3. Secretors, in addition to the
presence of ABH antigens, have either Lewis*3 antigen or Lewis*3 with variable
amounts of Lewis3 antigen in their body fluids. Non-secretors have only Lewis3
in body fluids (Race and Sanger, 1975).
The ABH blood group antigens are more correctly termed histo-blood group
antigens (Clausen and Hakomori, 1989) as they are found on most tissues of the
body and indeed evolved earlier on epithelial cells than on blood cells.
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1.8.1.2 Biochemistry of ABH antigens
ABH blood group determinants consist of carbohydrate chains bound to
glycolipids and glycoproteins in cell membranes and predominantly to
glycoproteins in secretions. They also exist in secretions as free oligosaccharides.
They have a short basic precursor carbohydrate chain to which are added
particular monosaccharides by specific glycosyltransferases, the primary products
of the A, B and H genes.
There are 4 types of carrier precursor chains (Rege et al., 1963; Donald, 1981;
Bremer et al., 1984) of which Type 1 and Type 2 precursors carry most of the ABH
antigens in cells and in secretions. Type 1 chains have a D-galactose residue
joined by a (31-3 linkage to N-acetyl-D-glucosamine, whereas in the Type 2 chain
these two sugars are joined by a (31-4 linkage (Figure 1.1). Type 1 is the main
carrier of ABH determinants in secretions and in endodermally-derived tissues
such as lining epithelium; and Type 2 is the main carrier in mesodermally- and
ectodermally-derived tissues, including red blood cells (Oriol et al., 1986). H
Type 1 and 2 molecules are formed by the fucosylation of the respective
precursor chains at the terminal D-galactose residue by the fucosyltransferase
coded by the H gene (Figure 1.2). The H antigen is the substrate for
glycosyltransferases coded by the A and B genes to form A or B determinants
respectively. The biochemical pathways by which ABH antigens are formed is
shown in Figure 1.3.
1.8.1.3 Genetic control of ABH antigens
The ABO locus was thought for years to be present on chromosome 9
(Westerveld et al., 1976), but it was not until recently that by cloning and
sequencing of complementary DNAs for A and B glycosyltransferases, the
expression of these enzymes has definitely been shown to be controlled by this
locus (Yamamoto et al., 1990). The ABO locus has 4 alleles; Al and A2 (the two
subgroups of blood group A), and B which all code for a different
glycosyltransferase; and, the O allele which does not give rise to a functional
product.
The antigen known as H is present on red blood cells of practically all humans.
It was previously thought to be the product of the O gene, but the discovery of
the rare Bombay blood group (genotype h h) which lacks this antigen, has
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Figure 1.1: Diagram of the two types of carbohydrate chain endings






















Figure 1.2: Structure of H, A and B determinants based
on Type 1 and Type 2 carbohydrate chains.
The symbols for the constituents of precursor




A antigen B antigen
Figure 1.3: Biochemical pathway for the formation of H, A & B
antigens. The symbols for the constituents of the
precursor chains are the same as in Figures 1.1 and 1.2.
H transferase (H) transfers fucose from guanosine
diphosphate (GDP) L-fucose to the precursor chain. A
transferase (A) transfers N-acetylgalactosamine from
uridine diphosphate (UDP) N- acetylgalactosamine to
the H structure. B transferase (B) transfers galactose
from uridine diphosphate (UDP) D-galactose to the H
structure.
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clarified its nature (Bhende et al., 1952, as reviewed by Race and Sanger, 1975).
The H gene has only recently been isolated (Ernst et al., 1989). It is located on
chromosome 19 and is present in almost all individuals. It codes for a
fucosyltransferase which produces the substrate (H) for the A and B transferases.
The h gene is a rare silent allele of H. Individuals who have the Bombay
phenotype can have A and/or B glycosyltransferases, but do not have A or B
antigens as the absence of the H gene means that there is no substrate for the A
and B transferases (Figure 1.4).
In AB individuals, competition between the glycosyltransferases coded by these
genes for H Type 2 results in some molecules bearing the A determinant and
some the B determinant (Watkins, 1980). The A and B determinants are found
on different carrier molecules on human erythrocytes of blood group AB and
approximately half of the blood group glycoproteins carry group A determinants
and half carry group B determinants (Viitala et al., 1986). This contrasts with
saliva where A and B specificities are carried on the same macromolecules
(Morgan and Watkins, 1948). Individuals of group O express unmodified H on
their cells as they have a non-functional gene at the ABO locus.
In secretors the Type 1 precursor chain is fucosylated by the fucosyltransferase
encoded by the Se gene to form H Type 1 determinant (Watkins et al., 1988)
(Figure 1.5). This acts as a substrate for A and B glycosyltransferases to form A
and B determinants. In non-secretors the enzyme coded for by the Se gene is
absent, and so the fucosylation of Type 1 precursor and subsequent modification
to form A and B antigens does not take place in secretions.
1.8.1.4 Lewis antigens
Unlike ABH antigens, Lewis antigens on erythrocytes are not synthesised by the
red blood cells, but are passively acquired from plasma (Sneath and Sneath, 1955)
where they are present as glycosphingolipids (Marcus and Cass, 1969). In
secretions they are carried on the same types of glycoprotein molecules as the
ABH determinants (Watkins, 1974). Neither the site of synthesis of the Lewis
antigens nor the type of attachment they have to cells is known. They might
bind through specific receptors or by non-specific attachment. Lewis antigens are
generated by the product of the Lewis (Le) gene which codes for a






Figure 1.4: Diagram showing the production of A, B and H
determinants on Type 2 chains. Symbols as in
Figures 1.1 and 1.2. The arrows represent the
reactions possible in individuals possessing the genes











Lewisb antigen Lewis3 antigen
Figure 1.5: The pathway of production of H, A, B and Lewis
determinants in secretions. Symbols as in Figures 1.1 and
1.2. The arrows represent the reactions possible in
individuals possessing the genes indicated by the letters.
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N-acetylglucosamine of H Type 1 precursor chains to form Lewis*3 (Le*3) and
precursor Type 1 chains to form Lewis3 (Lea) (Figure 1.5).
1.8.1.5 Secretor and Lewis genes
Secretor status is controlled by the secretor gene (Se) on chromosome 19 and is
inherited as a Mendelian dominant character (reviewed by Watkins, 1980).
Secretors can be homozygous (SeSe) or heterozygous (Sese) for the Se gene.
Non-secretors are homozygous (sese) for the silent allele. The Se gene is closely
linked to the H gene on the short arm of chromosome 19 (Oriol et al., 1981;
Oriol et al., 1984) suggesting that it might have arisen by Se gene duplication
during evolution (Le Pendu, 1985).
While both H and Se gene products fucosylate precursor chains to form the H
determinant, the Se gene product has a higher affinity for the Type 1 precursor
than for the Type 2 precursor. The H gene product preferentially fucosylates
Type 2 precursor chains. Individuals with the genotype hh/SeSe or hh/Sese
have an active Se gene but inactive H gene and will express Type 1 chain-based
blood group antigens in their secretions but will have no ABH on their red cells.
This is known as the para-Bombay phenotype. In Bombay individuals (hh/sese
genotype) both Se and H genes are inactive and ABH antigens are not expressed
in cells or secretions (Oriol et al., 1986).
The Le gene is also located on chromosome 19 and is linked to the loci for H
and Se genes (Elberg et al., 1983). The Le gene encodes a fucosyltransferase which
acts on Type 1 precursor chains.
1.8.1.6 Interaction of the ABH,Se and Le genes
The assembly of blood group antigens is a complex process requiring the
sequential action of a series of enzymes. This is shown in Figure 1.5. The
fucosyltransferases coded for by the Se and Le genes compete for the same
substrate (H Type 1). If the Se enzyme acts first, the resultant structure can be
fucosylated by the Le enzyme to produce the Le*3 antigen. If, however, the
precursor is first fucosylated by the Le enzyme, the resultant Lea antigen is
unsuitable for further modification by the Se enzyme. Thus, both Le^and Lea
are found in secretors, the relative amounts of each depend on the efficiency of
the competing enzymes (Watkins et al., 1988). In non-secretors, if the Le gene is
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present, it can act unopposed by the Se gene on Type 1 precursors so that only
Lea antigen is formed.
There is also competition between the A and B transferases and Lewis enzymes
for H Type 1. Once the determinant is converted to Leb, it cannot act as a
substrate for the A and B enzymes. The A and B determinants, however, can act
as substrates for the Lewis enzyme to form ALeb or BLeb.
If Se and Le genes are both absent, secretions will contain unconverted Type 1
precursor chains.
In ectodermal tissues ABH antigens are expressed independently of the Se gene
although the Se gene can quantitatively influence their expression (Dabelsteen
et al., 1982). Endodermal tissues express ABH and Lewis antigens under the
control of the products of the both Le and Se genes (Oriol, 1987). The
differences in the expression of the blood group antigens between secretors and
non-secretors are summarised in Table 1.5.
Table 1.5
Blood group antigens found on cells and in body fluids
of secretors and non-secretors
Secretors Non-secretors
Antigen Cells Secretions Cells Secretions
H (A/B) + + + -




+/- Present in small amounts
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1.8.2 Secretor status and susceptibility to disease
Epidemiological studies have found associations between the inability to secrete
blood group antigens into body fluids (non-secretion) and various diseases.
There is a striking association between duodenal (but not gastric) ulcers and
non-secretion (Clarke et al., 1959). Non-secretors are more susceptible to certain
bacterial and superficial yeast infections and also to those autoimmune diseases
which have a proposed infectious trigger (Blackwell, 1989). Non-secretors are
over-represented in patients with infections due to Streptococcus pyogenes in
rheumatic fever and rheumatic heart disease (Havercorn and Goslings, 1969); E.
coli urinary tract infections (Kinane et al., 1982); oral and genital infections due
to Candida albicans (Thorn et al., 1989); invasive disease due to Haemophilus
influenzae (Blackwell et al., 1986b), S. pneumoniae and Neisseria meningitidis
(Blackwell et al., 1986a). There are two recent reports of associations between
secretor status and patients with viral infections, with secretors rather than non-
secretors being over-represented. This has been seen with respiratory viral
disease (Raza et al., 1991) and among individuals who have acquired the human
immunodeficiency virus through heterosexual intercourse (Blackwell et al.,
1991).
Non-secretors are more common among patients with insulin-dependent
diabetes (Blackwell et al., 1987a), a disease in which viruses are implicated in the
aetiology and Graves' disease (Collier et al., 1988) in which Yersinia infection is
suggested to have a role. There is no association between secretor status and
autoimmune diseases which epidemiologically are most unlikely to have an
infective aetiology.
A marked preponderance of non-secretors was reported in ankylosing
spondylitis (49%) and in Reiter's syndrome (45%) compared to the control
population (27%) (Shinebaum et al., 1987b). This study gave support to the
hypothesis of an infective aetiology in this disease.
1.8.2.1 Blood group antigens as receptors for microorganisms
One possible mechanism to explain the association of secretor status with
infection is that the ABH or Lewis determinants serve as receptors for
microorganisms. Blood group antigens are found on the surface of many
tissues, including the surface of epithelial cells which form the site of
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colonisation for many microorganisms. The secretor gene controls the
expression of blood group antigens in secretions and some of these secreted
antigens are passively adsorbed onto the cell surface. Carbohydrates which are
present in abundance on cell surfaces act as receptors for bacteria and their
products (Lark, 1986) and a number have been identified; several bacterial
species bind specifically to mannose (reviewed by Bock et al., 1988); the
ganglioside GM1 acts as a specific receptor for Vibrio cholera toxin (Eidels et al.,
1983). Fucose, which is the immunodominant sugar of the H and Lewis blood
group antigens, might be a receptor for some Candida species (May et al., 1989).
Although blood group antigens are expressed in high density on cell surfaces,
are distributed widely in the body and are postulated to act as receptors for
microorganisms, there is little evidence for this. The Duffy blood group
determinants Fya orFy^are the erythrocyte receptors for Plasmodium knowlesi
merozoites (Miller et al., 1975); H. influenzae binds to the Anton blood group
antigen on oropharyngeal epithelial cells (van Alphen et al., 1986); the P antigen
(Kallenius et al., 1980) and the M antigen (Vaisanen et al., 1982) act as receptors
for uropathogenic strains of E. coli. It has been suggested that Lea antigen acts as
a receptor for C. albicans (May et al., 1989) and also for Staphylococcus aureus
(Saadi et al., in press).
1.8.2.2 Humoral immune responses of secretors and non-secretors
A second mechanism proposed to explain the increased susceptibility of non-
secretors to infection is that non-secretors have an impaired ability to generate a
humoral immune response to bacteria. This followed from the observations of
increased susceptibility of non-secretors to rheumatic fever and rheumatic heart
disease which occurs following a streptococcal throat infection (Clarke et al.,
1960). Lower serum immunoglobulin levels were found in non-secretors
compared with secretors. It was postulated that if a humoral response is
important in the defence against streptococci, the lower immunoglobulins of
non-secretors could result in their being more susceptible to streptococcal
infection and consequently developing rheumatic heart disease. Although the
low immunoglobulin levels in non-secretors were demonstrated in serum, it
was deemed reasonable by these authors that similar findings were likely in the
throat secretions which form the first line of mucosal defence against the
streptococcus (Clarke et al., 1960).
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Another group reported lower levels of total serum IgG and IgG anti-B
isohaemagglutinin in non-secretors than secretors (Grundbacher and Shreffler,
1970). Total serum IgA (in blacks and whites) and total serum IgG (in whites
only) were similarly lower in non-secretors than in secretors when a population
of children > 5 years of age and young adults were studied (Grundbacher, 1972).
IgA (as secretory IgA) is the main immunoglobulin in exocrine body fluids and
is protective against a variety of foreign antigens including bacteria. Total
salivary IgA was significantly lower in non-secretors than secretors (Waissbluth
and Langman, 1971). Among adolescents, total salivary IgM and salivary IgM
antibodies to N. lactamica and N. meningitidis were significantly lower in non-
secretors compared with secretors (Zorgani et al., in press). In infants secretory
IgM is necessary to protect mucosal surfaces as very little IgA is present
(Mellander et al., 1984). This might explain the increased susceptibility of non-
secretors to colonisation and disease by N. meningitidis (Blackwell et al., 1990).
Other researchers have shown different results regarding immunoglobulin
levels in secretors and non-secretors. Total serum IgA, M and G were similar in
both secretors and non-secretors (Zorgani et al., in press). In another survey two
groups of women with recurrent urinary tract infection (UTI) were studied; one
group had recently been referred to the clinic and the other had been monitored
for 20 years. The proportion of non-secretors was increased in both groups
compared with controls (Blackwell et al., 1987b). There was no difference in total
serum IgA or IgG between secretors and non-secretors in the recently-referred
group. In women who had been monitored long-term, however, non-secretors
had significantly higher levels of total serum IgA and IgG than secretors. It was
postulated that if the lower serum immunoglobulins in non-secretors reported
in previous studies (Clarke et al., 1960; Grundbacher and Shreffler, 1970;
Grundbacher, 1972) predispose to initial infections, then non-secretors would be
more prone to UTI. Repeated UTI would result in high immunoglobulin levels
as found in women in the long-term group. Although there was no difference
in the total IgG and IgA between secretors and non-secretors in the recently-
referred group, it is suggested that the increased UTI rate in this group results in
a total immunoglobulin level comparable to that in secretors.
In a study at Stonehouse, Gloucestershire, on the carriage of N. meningitidis,
total salivary IgA in non-carriers was similar in secretors and non-secretors,
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while among carriers, non-secretors had higher levels of salivary IgA than
secretors (Blackwell et al., 1989a). In non-carriers the serum IgA, however, was
significantly lower in non-secretors than in secretors. There was no significant
difference in serum IgA of secretors carrying serogroupable or non-
serogroupable strains when compared with secretor controls. Non-secretor
carriers of serogroupable strains had a significantly higher serum IgA than did
non-secretor controls. It was postulated that in carriers, either the meningococci
caused polyclonal B cell activation, or the increased total immunoglobulin
levels reflected an increased specific response.
At present, therefore, there is no clear evidence relating serum or secretory
immunoglobulin levels with secretor status.
1.9 Aims of the Study
The aetiology of AS remains unknown. Interaction of genetic and
environmental factors are involved. The most likely environmental trigger is
infection. There is no hard evidence to implicate a particular organism
although many have suggested Klebsiella species as the most likely candidate.
There is no agreement on this hypothesis and it is more likely that a number of
bacteria could be involved.
The aims of this work were:
1. to re-assess the association of non-secretion of ABO blood group substances
in a cohort of patients with spondyloarthropathy;
2. to correlate the disease activity as assessed clinically, of non-secretors and
secretors with the erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) as laboratory parameters of inflammation.
3. to study the faecal flora in a cohort of patients with spondyloarthropathy,
with particular reference to known arthritogenic bacteria and to compare it
with that of healthy controls;
4. to determine the prevalence of bacteria expressing molecules with
structural similarities to the HLA-B27 antigen;




Secretor Status in the Spondyloarthropathies
2.1 Introduction
Non-secretion of ABO blood group substances has been identified as a
susceptibility factor for infection of mucosal surfaces (Blackwell, 1989). One
hypothesis to explain this is that non-secretors are more easily colonised by
some pathogens. Microbial adhesins preferentially bind to carbohydrates rather
than to peptides (Lark, 1986). ABO and Lewis antigens are well-characterised
carbohydrates and it was suggested that the different distribution of Lewis
antigens between secretors and non-secretors might be involved in susceptibility
to colonisation. The H type I structure in the body fluids of secretors might bind
to adhesins on the surfaces of microorganisms that bind to H antigen on
epithelial cells and interfere with their attachment; colonisation and
consequently infection would be reduced. As Lea antigen found on the cells of
non-secretors appears to be a receptor for some strains of Candida albicans (May
et al., 1989) and Staphylococcus aureus (Saadi et al,. in press), it might also be
one of the receptors for some arthritogenic bacteria. The report by Shinebaum et
al. (1987b) of an association between non-secretion and AS provided
circumstantial evidence in support of the hypothesis that there is an infective
aetiology in AS.
One possible explanation for the increased susceptibility of non-secretors to AS
could be that these individuals are colonised more readily by arthritogenic
bacteria. A patient and a control population were therefore recruited to
investigate the prevalence of potential pathogens with reference to secretor
status. If a difference was found, then the role (in bacterial attachment) of those
blood group antigens which vary between secretors and non-secretors would be
investigated. Since a large patient and control population was available for
investigation, the prevalence of secretors and non-secretors in those groups was
re-examined. The secretor status was determined by the standard
haemagglutination inhibition assay (HAI) and an enzyme-linked
immunosorbent assay (ELISA) for Lewis antigens.
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A study of 86 girls with urinary tract infections reported elevated inflammatory
responses (temperature, ESR, urinary leucocyte count and especially CRP) in
non-secretors compared with secretors. It was postulated that an over-reactive
acute phase response could predispose to the later development of renal scarring
(Lomberg etal., 1989). Accordingly, CRP and ESR were measured in all patients
with spondyloarthropathy and correlated with disease activity.
Disease activity in AS is well-recognised to be difficult to assess (Scott et al., 1981;
Anonymous, 1987; Zukovskis et al., 1991). The difficulties have arisen partly
because of the heterogeneity of the disease (Calin, 1989). Some individuals have
disease confined to the sacroiliac joints, while others have extra-pelvic spinal
involvement with or without peripheral joint involvement or systemic
complications. In general, disease activity is easier to define in those with extra¬
articular features than those with predominantly spinal disease. Back pain in
AS patients might relate to acute inflammation or be of a mechanical nature due
to damage incurred as a result of repeated bouts of inflammation.
The methods used to determine disease activity have included clinical and
laboratory criteria either singly or in combination. In some studies disease
activity assessment has been based solely on clinical features such as duration of
morning stiffness and pain, the use of non-steroidal anti-inflammatory drugs
(NSAID), the presence of uveitis or synovitis or worsening back pain (Ebringer
et al., 1977; Ebringer et al., 1978; Cowling et al., 1980a; Warren and Brewerton,
1980; Hunter et al., 1981; Trull et al., 1983; Nashel et al., 1986; Pease et al., 1987).
Visual analogue scales have been employed for pain measurement.
Some studies (notably by Ebringer's group) have used solely laboratory criteria.
Patients were divided on the basis of an elevated ESR and total IgA (Ebringer
and Ghuloom, 1986; Ghuloom and Ebringer, 1987; Shodjai-Moradi et al., 1992);
on an elevated ESR and CRP (Khalafpour et al., 1988); or, on a raised CRP (Trull
et al., 1984). Maki-Ikola et al. (1991) also graded patients on the basis of both an
elevated ESR and CRP.
Other workers have used a combination of clinical and laboratory assessments;
clinical parameters with an elevated ESR (Cooper et al., 1988), or clinical criteria
with a raised CRP (van Bohemen et al., 1986).
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Radioisotope scanning has been used as an aid to diagnosis in early sacroiliitis
but not in the routine assessment of disease activity (Spencer et al., 1979).
In an attempt to measure disease activity at the enthesis which is the site of
pathological damage in AS, an enthesis index (EI) was devised in Newcastle by
Mander and colleagues (1987). This is a 3 min evaluation of the degree of
tenderness on over 70 sites of tendon or ligament insertion. The EI was
recorded by one observer on 18 AS patients and it correlated with the severity of
pain and stiffness (as determined by visual analogue scales) but not with the
ESR. The EI was then measured on 18 AS patients by 3 observers on 3 visits in a
single 'observer blind' crossover study in which patients were on/off NSAID
therapy and vice versa. The EI scores improved with NSAID treatment.
Unfortunately, no controls were measured in this study for validation of the EI,
nor was there, as pointed out previously (Anonymous, 1987), a placebo group
included in the NSAID crossover part of the assessment; therefore, the observed
fall in EI with treatment might simply reflect expectation. It is also possible that
patients with other inflammatory joint disorders would score highly even
though they have synovial rather than enthesopathic disease. As with most
subjective methods of assessment of inflammatory joint disease such as the
Ritchie index (Ritchie et al., 1968), interobserver variation is inevitable and it is
difficult to standardise the amount of pressure applied. Mander and colleagues
found interobserver variation in the EI only on the first visit.
A subsequent longitudinal study over 1 year by the Newcastle group showed
that each AS patient's profile of disease activity was practically unique (Goodacre
et al., 1991). Dawes et al. (1987) independently developed a similar EI assessed on
52 AS patients and also found a positive correlation between their index and
pain and severity of morning stiffness but not with ESR, CRP or measurements
of spinal movement.
None of these assessments of disease activity takes into account functional
capabilities. This has been addressed by means of a self-administered
questionnaire which is reproducible and which correlates with radiological and
metrological evaluation (Nemeth et al., 1987).
For the purpose of this present study, clinical disease activity was based on
clinical parameters, and functional assessments were not formally addressed.
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The aims of this part of the study were:
1. to re-assess the association of non-secretion of ABO blood group substances
in a large cohort of patients with spondyloarthropathy. An ELISA for
Lewis antigens was used as a control for secretor status which was
determined by the standard haemagglutination inhibition assay;
2. to compare secretors and non-secretors of ABO blood group substances
with regard to clinical disease activity and with reference to ESR and CRP
as laboratory indicators of inflammation;
3. to correlate disease activity with ESR and CRP irrespective of secretor
status;





The clinical and laboratory information for all subjects was coded for
confidentiality and stored in a Database 3 plus database.
2.2.1.1 Characteristics of controls
Controls (103) were healthy university staff and students and hospital nursing,
medical, administrative, secretarial and portering staff. The age and sex of the
controls are shown in Table 2.1. The erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP) were not measured in controls.
Table 2.1
Characteristics of controls
Sex Number Mean age (years)
Total 103
Female (F) 54 32.8
Male (M) 49 32.8
Ratio M:F 0.9:1
2.2.1.2 Characteristics of patients
Patients with spondyloarthropathies who were currently attending or who had
attended rheumatology outpatient clinics within the past 5 years were invited by
letter to take part in this study. Of patients on the Rheumatic Disease Unit AS
register compiled in 1987, 43 agreed to take part; the remainder either refused,
had moved address, failed to respond to a second invitation or were deceased. A
further 69 patients who had been referred to the Unit since 1987 were recruited.
The patients were classified into four categories: ankylosing spondylitis (n = 92)
all of whom satisfied the New York criteria (Bennett and Burch, 1967) and the
modified criteria (van der Linden et al., 1984a); spondylitis associated with
inflammatory bowel disease (IBD) (n = 6); post-infective reactive
spondyloarthropathy (ReA) (n = 8); and psoriatic spondyloarthropathy (PSA) (n




Number AS IBD ReA PSA
Total 112 92 6 8 6
Female (F) 25 21 4 0 0
Male (M) 87 71 2 8 6
Ratio M: F 3.5:1 3.4:1 1:2 8:0 6:0
Mean age (years) 42.0 43.4 35 - -
Mean age (years) 40.4 40.8 28.5 40.7 39.8
AS Ankylosing spondylitis
IBD Inflammatory bowel disease
ReA Reactive arthritis
PSA Psoriatic spondyloarthropathy
Patients were seen on 2 occasions. At the initial visit (visit 1) a full history and
examination were undertaken, clinical disease activity was assessed and a
sample of saliva was obtained for secretor status analysis. Blood samples were
taken for ESR, CRP, ABO blood group testing and serum was stored for antibody
determination. Patients were assessed 6-8 months later (visit 2) as part of a
longitudinal study to note any changes in clinical disease activity and to see if
these changes related to changes in ESR, CRP or immunoglobulin levels
(Chapter 5).
2.2.2 HLA-B27 antigen status
Several of the patients had previously been typed for the HLA-B27 antigen. The
HLA-B27 status was determined in a number of the others by the standard
microlymphocytotoxicity assay of Terasaki and Park (1976) by the Scottish
National Blood Transfusion Service at the Royal Infirmary, Edinburgh. The
analysis was incomplete in 20 patients due to technical factors.
2.2.3 Assessment of clinical disease activity
Patients were assessed for the duration of early morning stiffness (EMS), their
requirement for a NSAID, the presence of worsening back pain over the
previous 2-3 weeks and the presence of iritis or synovitis. Using a classification
of disease activity similar to that used in previous studies (Ebringer et al., 1977;
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Warren and Brewerton, 1980; Cowling et al., 1980a; Kuberski et al., 1983) patients
were classified into one of three categories:
a) Inactive disease - little or no back pain or EMS (< 30min), and requiring no
or infrequent use of a NSAID;
b) Probably active - significant EMS (30-60min) and requiring a regular
NSAID for control of symptoms;
c) Active disease - prolonged EMS (> 60min), or worsening back pain over the
previous 2-3 weeks, or the presence of iritis, synovitis or significant pain
on sacroiliac compression.
2.2.4 Determination of ABO blood group
ABO blood groups were determined by a slide agglutination technique with
monoclonal anti-A and anti-B antibodies (Scottish National Blood Transfusion
Service). To one volume of antiserum on a slide an equal volume of 10% red
blood cell suspension from a test sample was added. Appropriate controls of
known ABO blood groups were included. After rocking the slide gently to mix
well, the slide was examined within 2-5min for agglutination.
2.2.5 Determination of secretor status
Secretor status was determined on saliva samples by HAI and confirmed by an
ELISA for Lewis3 and Lewis'3 antigens on a sample-blind basis. Analysis was
complete in 109 patients; the specimens from 2 patients with AS and 1 with ReA
were insufficient for testing.
2.2.5.1 Processing of saliva samples
Fresh unstimulated saliva specimens (5-10ml) were collected and kept at 4°C
prior to centrifugation for 15min at lOOOg. Supernatants were transferred to
glass universal containers and placed in a boiling water bath for 25min to
inactivate enzymes and bacteria. They were stored at -20°C prior to testing. The
time from collection of saliva sample to storage did not exceed 5hr.
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2.2.5.2 Haemagglutination inhibition assay (HAI)
All procedures were carried out at room temperature. Three dilutions (25 pi) in
phosphate buffered saline (PBS) (pH 7.2) of monoclonal anti-A and anti-B
antisera (Scottish National Blood Transfusion Service) (previously titred against
known A and B red blood cells) and two dilutions (25gl) in PBS (pH 7.2) of Ulex
europaeus lectin (Sigma, Poole, Dorset) were added to separate wells in
microtitre plates. Boiled saliva (25gl) from each subject was added to wells
containing the above reagents for 30min. Standard red blood cells (25pl)
(Scottish National Blood Transfusion Service) of the appropriate group diluted
in saline (1/5) were then added to the wells. The plates were allowed to stand
for 2hr and were examined for agglutination of red blood cells. The pattern of
haemagglutination expected is given in Table 2.3.
Table 2.3
Expected pattern of results in HAI
Category Anti-A Anti-B Ulex
A secretor - + -
B secretor + - -
AB secretor ...
O secretor + + -
Non-secretor + + +
(all ABO groups)
Agglutination is represented by + and non-agglutination by -.
2.2.5.3 ELISA for the detection of Leioisa and Lewis^ antigens
Materials:
Coating buffer
This buffer (pH 9.6) contained 15mM sodium carbonate, 35mM sodium
bicarbonate and 3mM sodium azide.
Washing buffer
For washing procedures, 0.01M PBS (pH 7.2) containing 0.1% (w/v) bovine
serum albumen (BSA) and 0.05% (v/v) Tween 20 was used.
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Blocking buffer
Blocking buffer (pH 7.2) is composed of 0.01M PBS containing 1% (w/v) BSA.
Phosphate citrate buffer (PCB)
PCB was composed of 0.1M sodium hydrogen phosphate and 0.1M citric acid and
the pH was adjusted to pH 5.
Substrate solution
The substrate solution used to detect horseradish peroxidase (HRP) contained
40mg O-phenylenediamine (Sigma, Poole, Dorset) in 100ml of 0.1M PCB and was
activated immediately prior to use by adding 40pi H2O2 (30%,v/v).
Method:
The wells of polystyrene plates (Dynatech, Billinghurst, Sussex, UK) were coated
overnight at 4°C with lOOpl of affinity-purified monoclonal anti-Lewis3 antibody
diluted in coating buffer (1/50) or affinity-purified monoclonal anti-Lewis
antibody diluted in coating buffer (1/20) (Dr R. Fraser, Glasgow and West of
Scotland Blood Transfusion Service, Carluke, Lanarkshire). All subsequent
procedures were carried out at room temperature. The wells were washed 3
times with washing buffer and sites unoccupied by anti-Lewis antisera were
blocked with blocking buffer (lOOpl) for 30min. One hundred microlitres of each
test saliva sample diluted in blocking buffer (1/100 for Lewis3 ; 1/20 for Lewisb)
were added to the appropriate wells. Dilutions of saliva from known secretors
and non-secretors were used in each plate as controls. The plates were incubated
for 2hr, the saliva removed and the wells washed 3 times with washing buffer.
Goat polyclonal anti-Lewis3 antibody (100pi) diluted in blocking buffer (1/500) or
goat polyclonal anti-Lewisb antibody (lOOpl) diluted in blocking buffer (1/250)
(Behring Diagnostics, Hounslow, Middlesex) was added for 30min. After
washing 3 times with washing buffer, 100pi of HRP-conjugated polyclonal
donkey anti-sheep/goat IgG (Scottish Antibody Production Unit, Carluke,
Lanarkshire) diluted 1 /250 in blocking buffer was added to the appropriate wells.
The plates were incubated for 2hr and washed 3 times. Activated substrate
(lOOpl) was added to each well. The orange/yellow colour reaction was allowed
to develop in the dark for 10-15min and stopped by adding 50pl sulphuric acid
(12.5%, w/v) to each well. The absorbance at 490nm was measured with a
Dynatech MR700 plate reader.
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2.2.6 The effect of storage conditions on the HAI assay
An experiment was set up to determine whether the results of the HAI assay
would be affected by (i) boiling saliva samples at different times after collection
eg., within a few hours of collection or 24 hours later, and (ii) subjecting the
samples to different temperatures. Saliva (10ml) from known secretors was
collected over l-2hr and centrifuged at lOOOg for 15min. Each supernatant was
divided into 2 equal volumes of 4-5ml. One volume was boiled at 100°C for
20min; half was stored at 4°C overnight and the other half frozen at -20°C. The
unboiled 4-5ml was divided into 3 equal volumes, each stored overnight at a
different temperature: 4°C, 22°C and 37°C. The HAI assay was performed the day
after processing specimens.
2.2.7 Determination of ESR and CRP
ESR and CRP values were determined by clinical laboratories from venous
blood (4ml) added to a tube containing EDTA for ESR measurement
(Westergren) and clotted blood (4ml) for serum CRP measurement (fluorescence
polarisation immunoassay using TDx System, Abbott Laboratories).
2.2.8 Statistical methods
Patient groups were compared for prevalence of non-secretors by chi-squared
tests with Yates' correction. For 2x2 tables, associations between disease activity,
ESR and CRP were tested by Spearman rank correlations. Correlations between
ESR and CRP were determined by the Kendall correlation coefficient.
Differences between secretors and non-secretors with regard to disease activity,
ESR and CRP were determined by Mann-Whitney tests. Comparison of the
HLA-B27 antigen prevalence between disease categories was analysed by the
Kruskel-Wallis test. Correlations between the HLA-B27 antigen status and ESR,
CRP and disease activity were done by Wilcoxon rank sum test.
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2.3 Results
2.3.1 ABO blood group distribution
The ABO blood groups of the patients and controls are shown in Table 2.4. There
was no significant difference in the distribution of ABO blood groups between
the total patient group and controls (X2 = 2.61 with 3 DF) or between AS patients
and controls (X2 = 2.08 with 3DF). The number of patients in each subgroup of
AS (in association with other disease) was too small to make separate
comparisons with controls.
Table 2.4
Distribution of ABO blood groups in patients and controls
Subject O A B AB NK* Tot
Controls 42 (48.3)** 26 (29.9) 17(19.5) 2 (2.3) 16*** 103
Patients
Total 53 (50.5) 38 (36.2) 11 (10.5) 3 (2.8) 112
AS 45 (52.3) 29 (33.7) 10(11.6) 2 (2.3) 6 92
IBD 2 4 0 0 0 6
ReA 3 2 1 1 1 8
PSA 3 3 0 0 0 6
* Not known
* * Figures in parentheses represent the percentage of the 'known' total.
*** In the controls ABO blood group was determined by HAI of boiled saliva and
confirmed by slide agglutination of red blood cells. For 16 individuals (all non-
secretors by HAI and ELISA) blood samples were not obtained.
* * * * Of the 7 patients whose ABO blood group was unknown, 5 were non-secretors by HAI
and ELISA but a blood sample had not been obtained for ABO blood group testing. In
the other 2 patients, the secretor status in addition to the ABO blood group was not
known (the saliva sample was insufficient for analysis and a blood sample was not
collected for ABO testing).
2.3.2 Secretor status
The secretor status of patients and controls was determined by HAI and
confirmed by ELISA. There were 4 Lewis negative individuals (1 AS patient and
3 controls) who were secretors by HAI. There were no discrepancies between the
two methods for the other 208 specimens tested. There was no significant
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difference in the proportion of non-secretors in either the total patient
population, or in any of the disease subgroups, compared with that of the
control population (Table 2.5). 5 of the 80 patients who were secretors and 8 of
the 72 controls who were secretors had small amounts of Lewis3 in addition to
Lewis*5 in the ELISA.
Table 2.5
Secretor status of patients and controls
Subject No. tested No. non-secretors (%)
Controls 103 29 (28)
Total patient group 109 29 (26.6)
AS 90* 25 (27.7)
IBD 6 0(0)
ReA 7* 2 (28.6)
PSA 6 2 (33.3)
* 2 patients with AS and 1 with ReA were unable to provide a satisfactory saliva
sample for analysis of secretor status.
2.3.3 The effect of different storage conditions on the HAI
The aliquots of the samples which had been boiled and frozen were taken as the
reference, as all secretor status typing in the present study was done on samples
processed in this way. These aliquots were confirmed to be from secretors on
HAI. Storing the samples overnight at 4°C after boiling, or storing the unboiled
fractions at 4°C or 22°C did not alter the HAI result. 5 of the 13 aliquots
incubated overnight at 37°C, however, were interpreted as non-secretors in the
HAI assay.
2.3.4 Prevalence of the HLA-B27 antigen
The distribution of the HLA-B27 antigen in the patient population is shown in
Table 2.6. There was no significant difference in the HLA-B27 antigen
prevalence between any of the disease categories (P = 0.19).
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Table 2.6
Prevalence of HLA-B27 antigen in the patient population
Disease category
HLA-B27 AS IBD ReA PSA Total
No.(%) No.(%) No.(%) No.(%) No.(%)
Positive 61 (85)* 5 (83) 8 (100) 5 (83) 79 (86)
Negative 11 (15) 1(17) 0 1 (17) 13 (14)
Not known 20 0 0 0 20
Total 92 6 8 6 112
* The figures in parentheses represent percentages within each disease category of the
'known' status.
2.3.5 Comparison of ESR and CRP in different disease categories
The ESR and serum CRP levels of patients were determined at the first visit and
at a second visit 6-7 months later. At the first visit, comparison of the mean ESR
and mean CRP in patients with primary AS or secondary AS showed that there
was no significant difference in ESR or CRP between any of the disease categories
(Table 2.7). Similar results were found at visit 2 for ESR and CRP and no overall
change in values was found between both visits.
Table 2.7
Mean ESR and CRP for each disease category
Visit Mean value AS IBD ReA PSA
1 ESR 25.9* 23.7 25.6 19.5
2 ESR 23.2 26 14.7 25
1 CRP 2.33 2.05 2.55 1.82
2 CRP 2.16 1.67 1.93 3.0
* 4 blood samples were clotted and therefore unsuitable for ESR analysis.
2.3.6 Correlation of disease activity with ESR and CRP
There was a significant correlation between disease activity and ESR for both the
total patient group (P < 0.001, r = 0.47) (Table 2.8) and the group with only AS (P
< 0.001, r = 0.48) (Table 2.9), and there was also a significant correlation between
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disease activity and CRP for both the total patient group (P < 0.001, r = 0.36)
(Table 2.8) and the group with only AS (P < 0.01, r = 0.28) (Table 2.9). When this
was further analysed, the difference between the inactive and the probably active
AS patients is significant for ESR (P < 0.001) but not for CRP. The ESR and CRP
correlated significantly with each other (P < 0.001, r = 0.51,) in the total group and
the AS patients. The two parameters correlated significantly with each other
within all three levels of disease activity: inactive (P < 0.001, r = 0.62); probably
active (P < 0.01, r = 0.45); and active (P < 0.01, r = 0.75) categories.
Table 2.8
Disease activity, ESR and CRP in total patient group (visit 1)
Disease activity No. Mean ESR (95%CI)* No. Mean CRP (95% CI)
Total group 108** 112
Inactive 49 17.3 (12.3-22.3) 51 1.8 (1.4-2.2)
Probably active 46 26.0 (20.8-31.2) 48 1.9 (1.5-2.3)
Active 13 54.5 (37.3-71.7) 13 5.9 (2.5-9.3)
CI, confidence interval
4 blood samples clotted
Table 2.9
Disease activity, ESR and CRP in AS patients (visit 1)
Disease activity No. Mean ESR (95%CI)* No. Mean CRP (95% CI)
Total group 88** 26.0 (21.2-30.8) 92 2.3 (1.7-2.9)
Inactive 43 18.4 (12.8-24) 45 1.8 (1.4-2.2)
Probably active 36 27.8 (21.4-34.2) 38 1.9 (1.5-2.3)
Active 9 54.7 (33.9-75.5) 9 6.5 (1.7-11.3)
* CI, confidence interval
* * 4 blood samples clotted
The disease activity for each AS patient at visit 1 was compared with that at visit 2
(Table 2.10). 53 patients remained within the same disease activity classification:
26 inactive; 25 probably active; 2 active. There were 13 patients who improved: 8
probably active and 2 active at the first visit who all became
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inactive at the second; and 3 active at the first visit who were probably active at
the second. 6 patients deteriorated from being inactive at the first visit to
probably active at the second.
Table 2.10
Disease activity in AS patients in visits 1 and 2
VISIT 2
Inactive Probably Active Total
active
Inactive 26 6 0 32
VISIT 1 Probably active 8 25 0 33
Active 2 3 2 7
Total 36 34 2 72
The changes in ESR correlated with changes in disease activity between both
visits (P = 0.002, r = 0.29), and changes in CRP correlated with changes in disease
activity (P= 0.017, r = 0.24). The change in ESR correlated with the change in CRP
CP = 0.002, r = 0.27).
Significant correlations between both changes in ESR and changes in CRP with
changes in disease activity were also found with the total group of
spondyloarthropathies.
Correlations of disease activity, ESR and CRP were examined in patients < 40
and > 40 years of age as it had previously been suggested that younger patients
who have had the disease for a shorter duration were more likely to have active
disease than older patients in whom the disease is likely to have 'burnt out'
(Ebringer et al., 1977). Correlations of disease activity, ESR and CRP with disease
duration was examined independently. Equal numbers of AS patients were < 40
years and > 40 years of age and equal numbers of patients had the disease for < 10
years and >10 years (Table 2.11). As expected, a greater proportion of AS patients
< 40 years old had had the disease for <10 years compared with those > 40 years
old. Conversely, a higher proportion of those > 40 years old had had the disease
for > 10 years than those < 40 years old.
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Table 2.11
Age and disease duration in AS patients
Disease duration
Age (years) No. < 10 years No. > 10 years Total
<40 29 17 46
>40 17 29 46
Total 46 46
There was a significant correlation between disease activity and ESR regardless
of the patients' age and regardless of the duration of disease (Table 2.12). A
significant correlation between disease activity and CRP was present in those >
40 years old (but not in those < 40 years old) and in those with disease duration
>10 years (Table 2.13).
Table 2.12
Correlations of disease activity and ESR
with respect to age and disease duration in AS
Age/ disease duration (years) No.* Mean ESR P r**
Age < 40 43 29.2 <0.001 0.48
Age > 40 45 23.0 <0.01 0.39
Disease duration <10 44 25.4 <0.05 0.36
Disease duration >10 44 26.6 <0.001 0.49




Correlations of disease activity and CRP
with respect to age and disease duration in AS
Age/disease duration (years) No. Mean CRP P r
Age < 40 45 2.24 NS* 0.20
Age > 40 47 2.41 <0.01 0.46
Disease duration <10 46 1.79 NS 0.28
Disease duration >10 46 2.8 <0.05 0.38
* Not significant
2.3.7 Correlation of secretor status with ESR, CRP and clinical disease activity
Although the proportion of non-secretors in the patient group did not differ
from that in the controls, the results were analysed to determine whether non-
secretors had more active disease than secretors as assessed clinically or as
reflected in the ESR and CRP. For both the total patient group and AS patients
alone, no significant difference was found between non-secretors and secretors
with regard to disease activity, ESR, or CRP (P < 0.3 for each variable). (Tables
2.14 and 2.15 for results pertaining to the total patient group).
Table 2.14
Secretor status and disease activity in total patient group
Secretor status Inactive Probably active Active Total (%)
No.(%) No.(%) No.(%) No.(%)
Secretors 39 (49)* 35 (44) 6 (7) 80 (100)
Non-secretors 13 (45) 10 (34) 6 (20) 29 (100)
Total 52 45 12 109
67
Table 2.15
Secretor status and ESR and CRP in total patient group
Secretor status Number Mean CRP Mean ESR
Secretors 80 2.04 (1.63)* 24.2 (22.7)**
Non-secretors 29 3.08 (4.62) 28.1 (23.4)
Total no. 109
* Figures in parentheses represent the standard deviation from the mean
* * 4 samples from secretors were clotted
2.3.8 Correlation of HLA-B27 antigen status and ESR, CRP and clinical disease
activity in AS patients
There was no correlation between the HLA-B27 antigen status and the ESR or
CRP; neither did patients who were HLA-B27-positive have more clinically




There are equivalent numbers of individuals in the control and patient
populations. There is a male preponderance in the patient population, whereas
the sex ratio is equal in controls. The mean age is higher in patients than in
controls with the exception of the few males with ReA. There is no association
between adult age or sex and either ABO blood group or secretor status (Mourant
et al., 1978), therefore valid comparisons can be made between the two groups.
The distribution of ABO blood groups was similar for patients and controls and
agrees with the findings of Shinebaum et al. (1987b). A normal distribution of
MN, Rhesus and I blood groups in AS patients has been reported in Norway, but
this study did not examine for ABO blood group antigens (Kornstad et al., 1968).
The results of the present study show that there is no increase in the proportion
of non-secretors of ABO blood group substances in this population of patients
with ankylosing spondylitis. This agrees with the results with the results of
Moller (1990) in Norway. The secretor status of 104 HLA-B27-positive first
degree relatives of AS patients was determined by Lewis red blood cell
agglutination. Of the relatives who also had AS, 4/18 (22%) were non-secretors
(Lewis3 positive) compared with 19/86 (22%) of the relatives without AS
(Moller, 1990).
The current findings are, however, in contrast to the earlier UK report in which
49% of AS patients were non-secretors in comparison to 27% of controls
(Shinebaum et al., 1987b). The results of both studies are tabulated for
comparison (Table 2.16). The main differences between the 2 studies are in the
types of control population, the method of collecting the saliva sample and the
techniques used to determine secretor status.
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Table 2.16
Results of two studies on secretor status in spondyloarthropathies
PREVIOUS STUDY PRESENT STUDY
Subjects No. tested No. (%)
non-secretors
No. tested No. (%)
non-secretors
Controls 334 84 (27) 103 29 (28)
Patients
total 114 54 (47) 109 29 (27)
sacroiliitis 97 46 (47) 109 29 (27)
AS 84 41 (49) 90 25 (28)
IBD 3 1 (3) 6 0 (0)
ReA 20 9 (45) 7 2 (29)
PSA 7 3 (43) 6 2 (33)
The number of controls (historical) in the original study was over 3 times the
number of patients in that study and also over 3 times the number of controls in
the current work. The proportion of non-secretors in controls, however, is
virtually the same in both surveys. With the exception of the ReA subgroup,
the numbers of patients in each disease category are similar. There is a
significant difference in the numbers of non-secretors in the total patient groups
between the two studies (X2 = 9.41, P < 0.01). This is also found comparing the
AS patients alone (X2 = 9.08, P < 0.01).
The reason for this discrepancy was explored. Of 112 patients in the present
study, 43 had been included in the previous investigation and could be
considered as an 'overlap' group; 22 of these 43 patients had previously been
typed as non-secretors and 21 as secretors. On re-testing the secretor status of
these patients in the present study, 6 of the 22 patients typed originally as non-
secretors were revealed to be secretors. All 21 patients originally typed as
secretors were confirmed as such in the present analysis. The secretor status in




Secretor status of patients in overlap group as assigned in the present
study and original study (in parentheses)
Disease Category
Secretor status AS IBD ReA PSA Total
Non-secretor 13 (16) 0 (1) 1 (2) 2 (3) 16 (22)
Secretor 19 (16) 3 (2) 3 (2) 2 (1) 27 (21)
Total 32 (32) 3 (3) 4 (4) 4 (4) 43 (43)
In no instance was a non-secretor wrongly typed as a secretor in the earlier study.
This indicates that 6/22 (27%) of non-secretors in the sample of 43 patients from
the first study were really secretors. If this error rate is extrapolated to the
remainder of the patient group, it suggests that the true proportion of non-
secretors in all patients with spondyloarthropathy studied was 35%. There is no
way, however, of determining the correct value for the original patient group.
The mistyping suggests that in the earlier study blood group antigen activity was
lost in a proportion of saliva specimens prior to testing for secretor status.
The control samples in Shinebaum's study were historical controls and
therefore not subjected to the same conditions as the patients' samples. One can
speculate that if they had been treated in the same way, some of the control
specimens would also have been mistyped and perhaps no significant difference
would have been found between the two groups. In that event, an unusually
high proportion of non-secretors in controls would have alerted the
investigators and resulted in checking of samples.
Review of the procedures used in sample collection in Shinebaum's study (Dr R
Shinebaum, personal communication) suggests that enzymatic degradation of
blood group antigens in some saliva specimens might have resulted from
inadequate cooling prior to processing and storage. In that survey, saliva
samples were collected by several clinicians at the hospital and were not always
refrigerated. They were then sent across the city to the University. If the
samples arrived 'out of hours' they were left overnight unrefrigerated. The
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transit time, in addition to delays at the clinic and the University, might have
been sufficient for enzymatic degradation of the carbohydrate blood group
antigens in the saliva; therefore, a secretor would be typed as a non-secretor. In
the present survey samples were collected by only one person and refrigerated
promptly prior to boiling thereby minimising such enzyme activity.
The work of Raza et al. (1991) showed that Lewis antigens were not detected in a
significant number (192/584; 33%) of upper respiratory tract secretions which
had been subject to transport delays. In the current work, a proportion (5/13) of
secretor saliva samples incubated overnight at 37°C, but not at 4°C or 22°C, lost
detectable blood group antigen activity (as measured by HAI). This emphasises
that for reliable determination of secretor status from saliva, rapid processing of
specimens or inhibition of degradative enzymes prior to storage and testing is
essential. It also emphasises the importance of collecting samples from controls
and patients under the same conditions and in the same time period and not
relying on historical controls for comparison with new data.
In the original paper (Shinebaum et al., 1987b) secretor status was determined by
HAI alone; the ELISA method for Lewis antigens had not been devised. In
contrast, in the current work saliva specimens were tested by HAI, confirmed by
Lewis antigen ELISA and repeated by both methods in a sample-blind manner.
4/212 (1.9%) of subjects were Lewis negative by ELISA, therefore the secretor
status could not be determined by this method in these subjects. 100%
concordance was found between the HAI and ELISA in the other 208 saliva
specimens. This compares with 97% concordance for both techniques performed
on 1089 saliva samples (Raza et al., 1991). These workers reported that most of
the mismatched pairs (27/31) were 'false secretors', of Lea phenotype but
secretors by HAL The other 4/31 of their mismatched pairs were 'false non-
secretors', of Le^ phenotype by ELISA, but non-secretors by HAI (Raza et al.,
1991).
The finding of 'false secretors' in the HAI has been suggested to be due to blood
contamination of saliva from poor oral hygiene (Blackwell et al., 1989b; Raza et
al., 1991). This hypothesis has been tested formally by heavily contaminating
known non-secretor saliva specimens with blood; non-secretors did not
'become' secretors (Dr J Stewart, personal communication). The presence of
'false non-secretors' in the HAI assay has been attributed to the dilution of small
samples (Raza et al., 1991).
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The HAI assay is quicker to perform than the ELISA and is reliable. Experience
is needed to determine the presence of agglutination in the microtitre wells. An
advantage is that in secretors the ABO blood group is also determined, whereas
the same is not true for non-secretors. The ELISA for Lewis antigens determines ^
the secretor status by Lewis phenotype unless the patient is Lewis negative
(normally approximately 4% of the north European population (Mourant et al.,
1978)). The Lewis antigen ELISA, of course, does not identify the ABO blood
group. Less than 2% of patients and controls were Lewis negative in the present
study.
In view of the absence of association of non-secretion of ABO blood group
antigens with AS, there was no longer any indication to investigate the binding
of arthritogenic bacteria to blood group antigens. These negative results do not
provide evidence to support an infective aetiology in AS.
2.4.2 ESR and CRP
In the current study laboratory measurements such as ESR, CRP and serum IgA
were not included in the assessment of disease activity, although other groups,
in particular that at the Middlesex Hospital, have used levels of acute phase
reactants with (Ghuloom and Ebringer, 1987; Khalafpour et al., 1988; Shodjai-
Moradi et al., 1992) or without (Trull et al., 1984; van Bohemen et al., 1986)
serum IgA as sole criteria for assessment of disease activity. In this study clinical
parameters alone were used to assess disease activity and a high ESR did not
preclude a classification of inactive disease.
There has been no uniform consensus regarding the value of ESR and CRP as
markers of clinically assessed disease activity in AS. This present report of a
positive correlation between both ESR and CRP with clinical disease activity
agrees with some authors (Cowling et al., 1980a) but disagrees with others
(Laurent and Panayi, 1983; Sheehan et al., 1986) who have all used essentially the
same criteria to classify patients as in the present study. In other surveys, no
correlation between ESR and clinically-assessed disease activity was found
(Kendall et al., 1973; Hunter et al., 1981). Kendal et al. (1973) employed only a
pain scale and Hunter et al. (1981) used a pain scale with EMS duration and
NSAID/analgesic requirement, to determine disease activity. In the latter study,
numbers were small (17), with only 6 patients having active disease. CRP, but
73
not ESR, correlated strongly with disease activity in an American survey in
which a median CRP value of 1.8 mg/ml (measured by rate nephelometry) was
found in the active group and a median value of 0.65 mg/ml in the inactive
group (Nashel et al.,1986). This compares with a mean value of 6.5 mg/ml for
AS patients with active disease and 1.8 mg/ml for those with inactive disease in
the present report. The different results between separate groups can partly be
explained by differences in criteria used to assess disease activity. Technical
factors such as different methods of CRP determination could contribute to the
disparity. CRP has, however, shown a significant correlation with clinical
disease activity in patients with juvenile spondyloarthropathies (Hussein et al.,
1987).
The significant correlation of ESR with disease activity was present irrespective
of the patients' age or duration of disease. The positive correlation of CRP and
disease activity was found only in those > 40 years of age and only in those with
disease duration >10 years.
It has been suggested that there is no correlation between either CRP levels or
ESR and AS activity except in those individuals with peripheral arthritis (Scott
et al., 1981; Laurent and Panayi, 1983). In the present work, of the AS patients
with clinically active disease, similar numbers of those with peripheral synovitis
(4) and those with only spinal symptoms (3) were found (Table 2.18). Those with
peripheral synovitis had a higher mean ESR (74.5) than those with only spinal
symptoms (47). The converse was true for the CRP. The patient with iritis had
clinically quiescent spinal disease and no peripheral arthropathy. The patient
who had marked unilateral sacroiliac joint tenderness had had no exacerbation
of low back pain or peripheral arthritis. There were only 2 patients with active
disease at visit 2; therefore, no conclusions can be drawn.
Table 2.18
AS patients with active disease
No. Mean ESR Mean CRP No. ESR CRP
Knee synovitis 4 74.5 5.45 1 100 9.9
Spinal 3 47 11.1 1 35 2.0
Iritis 1 40 1.4
Sacroiliitis* 1 13 2.1
This patient had marked unilateral sacroiliac joint tenderness.
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From the present results, there is no evidence in AS patients that non-secretors
have a more intense acute phase response than secretors; there was no
significant difference in ESR or CRP values in non-secretors compared with
secretors. This is in contrast to the previous report of elevated ESR and CRP
levels in non-secretors with urinary tract infections (Lomberg et al., 1989).
There was no correlation in AS patients between HLA-B27-positivity and ESR,
CRP or clinical disease activity. HLA-B27-positive patients were not more likely
to have active disease than HLA-B27-negative patients. This is in contrast to the
report of a correlation of disease activity and CRP only in HLA-B27-positive, and
not in HLA-B27-negative AS patients (Reynolds et al., 1991). The clinical criteria
used to assess disease activity in the latter survey were not dissimilar to those
employed in the present report, so the reason for the disparity in the results is
not clear.
The main conclusions that can be drawn are:
1. there is no association between non-secretion of ABO blood group
substances and ankylosing spondylitis;
2. for reliable determination of secretor status from saliva, rapid processing
of specimens or inhibition of degenerative enzymes prior to storage and
testing is required;
3. there is no significant difference between non-secretors and secretors with
respect to ESR, CRP or clinically-assessed disease activity;
4. in patients with spondyloarthropathy, ESR and CRP both correlate with
clinical disease activity;




Faecal Flora in Ankylosing Spondylitis
3.1 Introduction
AS and reactive arthritis have several features in common both in clinical
expression of disease (enthesitis, sacroiliitis, spondyloarthropathy, peripheral
arthritis and uveitis) and in the strong association with HLA-B27. The
observation that reactive arthritis often followed an enteric infection, led to
speculation that AS might also be triggered by a gut infection.
Serological cross-reactivity between HLA-B27 and K. pneumoniae (Ebringer et
al., 1976; Avakian et al., 1980; Welsh et al., 1980) prompted several groups to
study the faecal flora of individuals with spondyloarthropathy. Increased
prevalence of faecal Klebsiella in AS patients with active disease (Ebringer et al.,
1977; Ebringer et al., 1978; Kuberski, 1983) was noted, but if the patients were not
categorised by disease activity, the isolation of Klebsiella in patients was similar
to that of controls. Several investigators worldwide have not confirmed this
association of Klebsiella with AS (Eastmond et al., 1980; Warren and Brewerton,
1980; Hunter et al., 1981; Ferraz et al., 1990; McLellan, 1990; van Kregten et al.,
1991).
Ebringer et al. (1978) reported that the isolation of Klebsiella from the stools of
patients with inactive disease was associated with a flare-up of the disease 2 to 3
months later and suggested that K. pneumoniae may be an initiating agent in
AS. The interpretation of the results of this survey are controversial but
nevertheless excited considerable interest.
The disparity in results between surveys of faecal flora might be due to a
combination of several factors: differences in stool collection and culture
methods between studies; different types of controls used for comparison with
patient groups eg., healthy individuals, hospital in-patients or out-patients;
different regions within the UK; different countries. Most studies after
Ebringer's original findings, concentrated on isolating Klebsiella and paid little
attention to other enterobacteria. Only a Brazilian study (Ferraz et al., 1990) has
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extensively examined the range of enterobacteria from AS patients and found
essentially no difference in the type of organisms isolated compared with that of
normal controls.
Although Klebsiella are gut commensal organisms, they have been implicated
as pathogens in cases of neonatal enterocolitis (Reisner and Garty, 1977). They
have also assumed increasing importance (with other Gram-negative bacilli) as
causes of infection in hospital patients (Steinhauer et al., 1966) including
intensive care patients (Casewell and Phillips, 1978). Such hospital-acquired
Klebsiella infections are common; 16% of coliform infections of urine, wound,
respiratory or other infection were identified as Klebsiella (Cooke et al., 1979).
In approximately 50% of patients, Klebsiella of the same serotype was identified
in the bowel as in the infection. Spread of Klebsiella to patients can arise from
the hospital environment or from personnel (Gardner et al.,1969), but the
gastrointestinal tract is usually assumed to be the source of these bacteria and the
source of Klebsiella in the gut is likely to be from food.
Only patients and controls who had not taken antibiotics for the previous 3
months were included in the present study; antibiotic therapy is well-known to
suppress normal faecal flora and allow the emergence of resistant or abnormal
organisms. Proteus, Pseudomonas, Klebsiella, Candida and Staphylococci are
the most frequently observed organisms emerging on broad-spectrum antibiotic
treatment (Finegold et al., 1966).
Antibiotic therapy in patients who underwent haemodialysis followed by renal
transplantation was associated with an increase in numbers of Klebsiella in
faecal flora (Montgomerie et al., 1970). This suggested that bacteria sensitive to
the antibiotics were replaced by Klebsiella.
The aims in the present survey were;
1. to examine in a semi-quantitative manner the faecal flora of patients with
spondyloarthropathy and compare it with that of healthy controls;





All plates used for culture media were Sterilin 90mm diameter triple-vented
disposable Petri dishes.
Inositol agar
This was prepared by the Department of Medical Microbiology, University of
Edinburgh, and consisted of 1% inositol in a nutrient agar base (Oxoid,
Basingstoke, Hampshire) and neutral red as an indicator. This agar detects
inositol fermenters such as Klebsiella species, some bacteria belonging to the
Enterobacter, Serratia, Yersinia and Citrobacter species and some members of
uncommon species such as Cedecea and Providentia. Formal identification of
inositol fermenters was done by Analytical Profile Index (API) 20E identification
kits (API Laboratories Ltd., Basingstoke, Hampshire).
Beta glucuronidase agar (BGA)
This agar consisted of a solution 0.03% p-nitrophenyl p-D-glucuronide (Sigma,
Poole, Dorset) in a proteose peptone No.2 agar base (Difco Laboratories, East
Molesley, Surrey) and was used for the detection of E. coli.
MacConkey agar
MacConkey agar (without salt) was prepared as per manufacturer's instructions
(Oxoid, Basingstoke, Hampshire) for the cultivation of enterobacteria. This agar
contains a bile salt to inhibit non-intestinal bacteria, and lactose with neutral
red to distinguish the lactose-fermenting coliforms from the lactose non-
fermenting salmonella and dysentery groups.
Yersinia selective agar
This was prepared as per manufacturer's instructions (Oxoid, Basingstoke,
Hampshire) for the isolation of Yersinia species.
Bacterial diluent
This consisted of 20% (v/v) nutrient broth No.2 (Oxoid, Basingstoke,
Hampshire) in physiological saline (0.85%).
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3.2.2 Collection of faecal sample:
Each person was provided with a sterile universal container, a sterile disposable
wooden spatula, a sealable plastic bag and a padded envelope with a Biohazard
label. The instructions were to sit forward on the toilet seat so that the stool
specimen landed on the downward slope of the toilet bowl. Faeces (3-4 scoopfuls
from the surface of the sample) was placed in the universal container, sealed in
the bag and posted first-class mail by patients. Controls delivered their sample to
the laboratory and were received within 3 hr of defecation.
3.2.3 Preparation of stool sample
Faeces (lg) was weighed in a sterile universal container and thoroughly mixed
with 10ml of bacterial diluent using a Vortex mixer. Ten-fold dilutions to 10^
were made in the diluent using a sterile plastic pipette. Each dilution was mixed
by rolling the bottle several times on the bench top to avoid undue aeration.
3.2.4 Inoculation of culture media
From the original undiluted suspension, 20pl were plated onto inositol agar and
onto Yersinia selective agar. The inositol plate was incubated under standard
conditions, and the Yersinia plate incubated at 37°C
3.2.5 Incubation conditions
Standard incubation conditions, unless otherwise stated, were overnight at 37°C
in an aerobic C02-enriched (10%) humidified atmosphere.
3.2.6 Identification of colonies on inositol plates
Plates were examined for colony types. Gram stains were made of each type and
examined microscopically under oil immersion x 100 (Leitz Laborlux).
Any colonies with a mucoid appearance and consisting of Gram-negative bacilli
were subcultured onto MacConkey agar and then formally identified by API 20E
strips. Non-mucoid colonies consisting of Gram-negative bacilli were
subcultured onto BGA, incubated overnight and the plate examined for colour.
A yellow-green colour indicated the presence of beta glucuronidase and that the
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bacterium was almost certainly E. coli. If no colour appeared, formal
identification was done by API 20E strips.
3.2.7 Identification of colonies on Yersinia selective agar
These plates (incubated at 35°C) were examined daily for 7 days for the
appearance of red bullseye colonies. Gram stains were made of suspect colonies
and Gram-negative bacilli identified by API 20E.
3.2.8 Testing for urinary tract infection
A midstream specimen of urine (MSU) was obtained from each patient and
cultured by the hospital microbiology laboratory using standard procedures.
MSUs were not obtained from controls.
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3.3 Results
3.3.1 Characterisation of patients and controls
a) Patients
Stool samples were collected from 82 patients; 66 males and 16 females (sex
ratio; male: female, 5.1: 1). The disease category and age of these
individuals are shown in Table 3.1. The mean age of all the patients was
41.8 years, range 21-63 years.
b) Controls
Stool samples were obtained from 36 healthy individuals with no present
or past history of rheumatic disease; 29 males and 7 females (sex ratio;
male: female, 5.1: 1). The mean age of the group was 36.3 years, range 22-62
years.
None of the patients or controls had received antibiotics within the previous 2
months.
Table 3.1
Characterisation of patients providing faecal sample
Disease category
Patients No. AS IBD ReA PSA
Total 82 67 4 6 5
Male (M) 66 54 1 6 5
Female (F) 16 13 3 0 0
Mean age (years) 42.3 37.1 39.5 40.8
3.3.2 Diet
Of the 36 controls, all except 1 vegetarian ate a mixed diet. Hospital food was
eaten 1 to 3 times per week by 5 controls. None of the patients, all of whom
were out-patients, had eaten hospital food.
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3.3.3 Growth on inositol agar
a) Patients
Stool samples from 82 patients were analysed. Of these, 8 samples had no
growth on inositol (< 500 organisms per gram of faeces) and 74 samples grew at
least 1 organism. A total of 93 different organisms were identified from the 74
stool samples; 58 samples grew 1 species of bacteria, 13 samples grew 2 species
and 3 samples grew 3 species. The range of organisms identified is shown in
Table 3.2.
b) Controls
All 36 samples produced colonies on the inositol plates. A total of 57 different
bacteria were isolated from these stool samples. 1 species was isolated from each
of 18 stool samples. 2 species grew from each of 15 stools and from the
remaining 3 samples, 3 species per sample were isolated. The range of
organisms identified is shown in Table 3.2.
7/82 (8.5%) stool samples from patients grew Klebsiella compared with 7/36
(19.4%) of samples from controls. Of the 7 controls from whose faeces Klebsiella
were isolated, 2 ate hospital food once or twice per week.
3.3.4 Growth on Yersinia selective agar
Yersinia were not isolated from any of the patients' stool samples but Y.
enterocolitica was isolated from the stool of a control individual. This
individual had experienced some abdominal discomfort which he felt was
insignificant 2 weeks prior to providing a stool specimen. The discomfort
became more severe and he then presented to his general practitioner. A stool
sample sent by the general practitioner to the routine microbiology laboratory
also grew Y. enterocolitica.
3.3.5 Urine culture
None of the patients had a urinary tract infection.
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Table 3.2
Bacteria isolated from patients' and controls' stools
Species Patients (n = 82) Controls (n = 36)
E. coli 69 30
Enterococci 13 15
Klebsiella oxytoca 4 2
Klebsiella pneumonia e 3 5
Citrobacter freundii 1 1
Citrobacter diversus 0 1
Kluyvera 1 0
Aeromonas hydrophilia 1 0
Proteus 1 0
Enterobacter cloacae 0 1
Salmonella group C* 0 1
Yersinia 0 1
Total 93 57
2 weeks prior to providing a stool sample for this study, this control had vomiting
and diarrhoea for 1-2 days. He was asymptomatic at the time of stool collection.
The Public Health Department was notified and the likely source of the
Salmonella gastro-enteritis traced to a contaminated hamburger.
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3.4 Discussion
3.4.1 Influence of diet on Klebsiella carriage
All types of hospital food, particularly salads and cold meat, may become
contaminated with Klebsiella organisms. In one study, Klebsiella were widely
distributed in the hospital kitchen environment which was considered at least
in part to be the source of the bacteria in hospital food (Cooke et al., 1980). From
the present data, 5/36 controls ate hospital food at least once per week in contrast
to the patients, none of whom had eaten hospital food. Klebsiella was isolated
from the stool samples of 2 of these 5 controls.
One might expect that when patients are admitted to hospital the carriage of
faecal Klebsiella would increase. Datta (1969), however, found no increased rate
of faecal carriage of Enterobacter, Klebsiella, Citrobacter, Proteus or
Pseudomonas in patients admitted to hospital.
The incidence of faecal Klebsiella was examined in renal patients who later
received a transplant (Montgomerie et al., 1970). There was no significant
difference in the incidence of Klebsiella whether these patients were admitted to
hospital or seen as out-patients. Transplantation with immunosuppressive
therapy also did not affect the appearance of Klebsiella in the faeces.
3.4.2 Klebsiella isolation
There was no increased isolation of Klebsiella from the faecal samples of AS
patients than from controls. This supports the findings of many others
(Eastmond et al., 1980; Warren and Brewerton, 1980; Hunter et al., 1981; Ferraz et
al., 1990; McLellan, 1990; van Kregten et al., 1991). Indeed, Klebsiella were
isolated significantly less frequently from patients' stools (8.5%) than controls'
samples (19.4%). The method of collection in both groups was the same.
Because of the wide geographical area of patient recruitment, for practical
reasons, stool specimens were sent by post and therefore were 24-48hr old at the
time of processing. By contrast, delivery of control specimens was within 3hr of
defecation. The delay in arrival and possible lower temperature exposure of
samples in the post might explain why; 8 patients' samples did not grow any
bacteria on inositol; fewer species of bacteria were isolated from patients' stools;
84
and, the isolation rate for Klebsiella in patients' specimens was lower than that
of healthy individuals.
The Klebsiella isolation rate of 19.4% in control samples in this study is
comparable with those of other studies eg. 13% in Arizona (Kuberski, 1983) and
22.2% in Brazil (Ferraz et al., 1990); is lower than that in two English surveys,
38% (Ebringer et al., 1977) and 37% (Ebringer et al., 1978); and considerably lower
than in a Dutch investigation (60%) (van Kregten et al., 1991).
Apart from possible geographical variations in Klebsiella prevalence and
differences in culture methods, these control populations differed widely from
each other. In the two studies of Ebringer's (Ebringer et al., 1977; Ebringer et al.,
1978) the control groups were not a homogeneous population but included as
well as healthy individuals, convalescent hospital in-patients. These in¬
patients, while they did not have arthritis, were in a hospital environment and
thus were not strictly comparable with the patient group who were all out¬
patients. Hospital out-patients without arthritis or sacroiliitis formed the
control group in another survey (Kuberski, 1983) and Hunter and colleagues
(1981) used individuals with mechanical back pain for comparison with AS
patients. Healthy relatives of patients attending general practitioner clinics have
also been used as controls (Ferraz et al., 1990). van Kregten et al. (1991), by
contrast, used rheumatology out-patients with a variety of inflammatory
arthritides and gout as controls. It could be argued that this control group
consisted of a group of diseased individuals who were not really comparable to
another diseased population (although the authors state that the controls were
chosen to anticipate a possible effect of a hospital visit on faecal carriage of
Klebsiella).
A much higher Klebsiella isolation rate in controls (60%) was noted by a Dutch
group (van Kregten et al., 1991), but this did not differ significantly from that in
the patient population. The culture method employed a liquid and a solid phase
enrichment medium to potentiate the growth of Klebsiella organisms.
The Klebsiella isolation rate in AS patients shows variation between different
studies: 8.5% in the current work; 27% (Eastmond et al., 1980); 27% (Warren and
Brewerton, 1980; 32% (Ferraz et al., 1990); 38% (Ebringer et al., 1977; 40%
(Kuberski et al., 1983); 54% (van Kregten et al., 1991). The only other study of
faecal flora in AS patients which has been performed in Scotland was in
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Glasgow and an isolation rate of 17.6% was found (McLellan, 1990). No controls
were done in this latter survey.
3.4.3 Faecal sampling and culture methods
The method of faecal sampling has differed between previous studies. Fresh
faeces delivered or posted by subjects, or collected by investigators have been
most commonly employed (Ebringer et al., 1977; Ebringer et al., 1978; Ferraz et
al., 1990; van Kregten et al., 1991). Rectal swabs (Kuberski, 1983; Hunter et al.,
1981; McLellan, 1990) which can be done by the investigators or by the subjects
themselves, are less messy to collect than faecal samples and are probably more
acceptable to subjects. The ability of subjects, however, to accurately and
comparably use a rectal swab is open to question.
In the present study a faecal specimen was necessary as it was required to be
processed in a number of ways and the amount of material on a swab would
have been insufficient. Analysis of stool samples of patients and controls was
done during the same period to avoid any seasonal variation in faecal flora
which might have biased the results.
Different culture methods have been used. MacConkey-inositol-carbenicillin
(MIC) agar was developed in 1970 (Thorn) as a nutrient medium selective for the
isolation of Klebsiella from faeces. This was based on MacConkey agar in which
lactose was replaced as a carbon source by 1% inositol and lOOmg/ml of
carbenicillin was added. About 97-99% of Klebsiella strains and only 0-1% of E.
coli strains are able to ferment inositol and appear as pink colonies. Most
strains of E. coli are susceptible to carbenicillin, so the medium is selective for
Klebsiella. This concentration of carbenicillin will, however, prevent the
growth of 10-15% of Klebsiella strains (depending on the geographical area) so
some investigators have reduced the concentration of carbenicillin to lOmg/ml.
van Kregten and colleagues (1991) (who found particularly high Klebsiella
isolation rates in patients and controls) used Simmons citrate agar (SCA) with
1% inositol but without antibiotics, because of the risk of missing susceptible
strains. An advantage of using the medium SCA with inositol, is that the two
carbon sources, citrate and inositol, can be utilised by nearly all K. pneumoniae
and K. oxytoca strains but not by E. coli.
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A comparative study of 15 methods to isolate Klebsiella from faeces was made
using different types and combinations of media (Cooke et al., 1979). The solid
media producing the highest isolation rates were MIC and SCA and the highest
isolation rates overall were obtained by subculturing citrate broth to MIC agar
and SCA. There was no difference in isolation rate by inoculation of the media
with a suspension of faeces or by inoculation with a swab (Cooke et al., 1979).
van Kregten et al. (1984) also compared the ability of different media and media
combinations to grow Klebsiella from faecal samples. They found that the
selectivity of the SCA with inositol for Klebsiella equalled that of MIC and SCA
combined, but SCA with inositol was more efficient than the latter combination.
Most culture techniques used in the studies of faecal flora in AS have employed
a differential medium containing inositol (Ebringer et al., 1977; Ebringer et al.,
1978) and standard identification methods including API 20E strips.
Alternatives have been; to culture specimens on MacConkey and Hektonen
enteric media prior to growing in Gram-negative enrichment broth (Kuberski,
1983); to simply inoculate faeces onto either MacConkey agar (Ferraz et al., 1990)
or both blood agar and MacConkey agar plates (Hunter et al., 1981) and identify
organisms by standard methods, van Kregten's group (1991) refrigerated faecal
specimens at 4°C prior to processing but do not comment on the duration of
refrigeration, lg faeces was added to a liquid enrichment medium for isolation
of Klebsiella. An aliquot of this was inoculated onto a solid phase (SCA with 1%
inositol), incubated at 37°C and examined 48hr later. After overnight
incubation, a second aliquot of the faecal suspension was subcultured onto a
SCA with inositol plate and examined 48hr later for Klebsiella.
In the present work the objectives were to examine stool specimens of patients
and controls not only for Klebsiella but also to determine if any other organism
was more prevalent in the faecal flora in AS patients compared with healthy
individuals. For this reason a medium selective for the growth of Klebsiella
was not chosen. The medium chosen was inositol-containing nutrient agar
with a neutral red indicator. This is not selective per se for Klebsiella as it
allows the growth of many other bacterial species, but it allows the easy
identification of inositol fermenters such as Klebsiella. By making serial
dilutions of faecal samples, it was calculated that the detection rate was 500
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organisms/g of faeces. Carbenicillin was not incorporated to avoid missing
carbenicillin-sensitive Klebsiella strains.
By these methods, no significant difference between the faecal flora of patients
with AS and healthy subjects was found.
3.4.4 Yersinia isolation
The absence of Yersinia in the patient group in the present study is in
agreement with others (Ebringer et al., 1977; Hunter et al., 1981; Kuberski, 1983).
The optimum conditions for isolation of Yersinia are considered to be
incubation at 35 °C for 24-48hr and enrichment culture using phosphate buffered
saline pH 7 at 4°C for 3 weeks (Pai et al., 1979). In our hospital microbiology
department faecal specimens suspected of harbouring Y. enterocolitica are
routinely subcultured onto Yersinia selective agar and incubated at 37°C for
48hr. If no growth occurs, the sample is regarded as being negative for Yersinia
organisms. Prolonged cold incubation is not performed as it is considered that
any growth significant to cause disease will grow under the conditions
employed. This practice agrees with the conclusions by Pai et al. (1979) that cold
enrichment is not indicated for the culture of Y. enterocolitica from diarrhoeal
stools. The most common diarrhoeal strain is serotype 03 and as samples are
submitted during the acute phase of the illness, direct plating is sufficient to
recover the 03 serotype. Cold enrichment methods, however, increase
considerably the sensitivity of Y. enterocolitica isolation in convalescent and
asymptomatic subjects but only minimally in patients with diarrhoea caused by
serotype 03. Recovery of non-03 serotypes of Y. enterocolitica is increased by
cold enrichment but the clinical significance of these isolates is uncertain.
A criticism of the present study would be that cold enrichment methods were
not used for the isolation of Yersinia. The culture conditions employed
however did succeed in isolating Y. enterocolitica from the stool sample of a
control who had abdominal pain 2 weeks prior to providing a faecal sample.
3.4.5 Urinary tract infection
A link between chronic genitourinary infection and the development of
sacroiliitis has been speculated from the observation of an increased prevalence
of sacroiliitis in Reiter's disease (Ford, 1953; Wright, 1963). This was suggested to
be due to venous drainage from the prostate and seminal vesicles which pass
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directly over the sacroiliac joints (Oates and Young, 1959). The finding of an
increased incidence of chronic prostatitis in AS patients (Mason et al., 1958)
suggested that AS might be due to chronic genitourinary infection. Another
piece of evidence that initially suggested continued antigenic challenge from the
urinary tract might in some way initiate inflammatory change in the sacroiliac
joints, was the identification of sacroiliac joint changes (similar to those in AS)
in paraplegics (Abramson and Kamberg, 1949; Abel, 1950). Paraplegics have a
high incidence of urinary tract infections. Wright et al. (1965) , however, made a
detailed study of 36 paraplegics and concluded that the sacroiliac joint changes
observed were distinct from those of AS and Reiter's syndrome.
None of the patients in the present study, however, had a urinary tract infection
which is in agreement with a earlier report (Ebringer, 1977).
The conclusions that can be drawn are:
1. the faecal flora (as determined by the media employed) of the patient
population and the healthy controls was essentially similar;
2. there was no increase in the isolation rate of Klebsiella in this population
of patients with spondyloarthropathy compared with healthy controls;
3. of the patients in whom Klebsiella was identified there was no relationship
with its presence and disease activity;
4. no proposed arthritogenic organism or any other organism was found in
increased numbers in patients with spondyloarthropathy.
89
Chapter 4
Cross-Reactivity Studies on Enteric Bacteria
in Ankylosing Spondylitis
4.1 Introduction
Much work has been done on the molecular mimicry hypothesis of disease since
cross-reactivity of antibodies to HLA antigens and bacterial components was
demonstrated (Hirata et al., 1973). Integral to the molecular mimicry theory of
AS is the existence of antigenic similarity between HLA-B27 and bacteria. Cross-
reactivity between Klebsiella and HLA-B27 has been reported by several groups.
Rabbits injected with HLA-B27-positive cells developed antibodies reactive
against K. pneumoniae and Y. enterocolitica (Welsh et al., 1980). Beukelman et
al. (1988) immunised several rabbits with vaccines prepared from enterobacteria
isolated from the stools of AS patients and tested the antisera in a cytotoxicity
assay with mononuclear cells of HLA-B27-positive AS patients and controls.
3/12 rabbit sera were lytic for the cells of HLA-B27-positive patients. At least 1 of
these discriminated between the cells of patients and controls.
The observation that faecal carriage of Klebsiella was higher in AS patients with
active disease (Ebringer et al., 1977) or who were about to become active
(Ebringer et al., 1978), than it was in non-spondylitic controls or in patients with
inactive disease, suggested a possible pathogenic role for antigenic similarity
between HLA-B27 (carried by the majority of AS patients) and enteric bacterial
antigens in the development of AS.
A number of workers (Eastmond et al., 1980; Warren and Brewerton, 1980;
Hunter et al., 1981; Ferraz et al., 1990; van Kregten et al., 1991), however, have
been unable to confirm the findings of Ebringer (1977) that Klebsiella is found
more frequently in the stools of AS patients than in healthy individuals. This
led to speculation that if enteric bacteria are involved in the pathogenesis of AS,
it might be that there is a factor(s) common to several bacterial species which is
important rather than a factor(s) present on members of a single species.
Serological cross-reactivity among members of the Enterobacteriaceae is well-
established (Pease et al., 1988).
90
This study investigated the presence of bacteria showing antigenic similarity to
HLA-B27 in the faecal flora of patients with spondyloarthropathy and healthy
controls. It was of interest to determine if such bacteria were only found in
patients with spondyloarthropathy, or if they were also found in healthy
individuals. If such bacteria were found in HLA-B27-positive AS patients, it is
possible that because of the antigenic similarity, the host might show a degree of
tolerance to these organisms rather than mounting an immune response
against them. This would allow the bacteria to colonise the gut mucosa leading
to inflammation. Identification of the bacterial species expressing these antigens
was of interest to determine whether these antigens were present only on
known arthritogenic organisms such as Klebsiella, Yersinia and Shigella or
whether they were present on gut commensal organisms.
In previous studies of enteric bacteria in AS, the role of anaerobic organisms
(which comprise the majority of faecal flora) has been neglected. This is
probably because of time factors involved as anaerobes take considerably longer
to grow in the laboratory, and also because anaerobes have more fastidious
growth requirements than aerobes. It seemed appropriate in this study to
investigate for cross-reacting epitopes on anaerobes as well as aerobes.
HLA-B27 cross-reactive epitopes have previously been identified on Klebsiella
and Shigella (van Bohemen et al., 1984) and Yersinia (van Bohemen et al., 1984;
Chen et al., 1987). In this study, once the organisms were isolated and identified,
the epitope that the anti-HLA-B27 antibody bound to would be characterised.
Possible sites could be on the outer membrane component of the bacterial cell
wall, or indeed the epitope could even be internal and secreted, or only released
on cell death.
The immunoblotting procedure employed to identify colonies was the same as
that devised by a Dutch group (Groeneweld et al., 1990) and used to identify
colonies of H. influenzae (van Alphen et al., 1991). The immunoassay was
modified in the present study by using a monoclonal anti-HLA-B27 antibody as a
probe instead of monoclonal antibodies directed against epitopes on the outer
membrane of H. influenzae. (There were no commercially-available polyclonal
anti-HLA-B27 antibodies).
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The principle of the technique is as follows:
MC27 (an IgG antibody) is added to bacteria (or outer membrane peptidoglycan).
If a suitable receptor is present, MC27 will bind to it. The enzyme amplification
step involves the addition of protein A conjugated with horseradish peroxidase
(HRP). Protein A (a cell wall component of certain strains of staphylococci)
binds immunoglobulin molecules, especially IgG, with high affinity. Therefore,
the protein A-HRP complex will bind to immunoglobulins already bound to
bacteria. When the hydrogen peroxide-activated substrate for HRP is added, the
reaction results in a colour change: a blue/green colour indicates that the protein
A-HRP complex has bound.
The aims of this part of the study were:
1. to examine the faecal flora of healthy individuals and patients with
spondyloarthropathy for bacteria (aerobes and anaerobes) with epitopes
cross-reactive with the HLA-B27 antigen;
2. to identify such bacteria by standard bacteriological methods;
3. to isolate and characterise these epitopes if found.
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4.2 MATERIALS AND METHODS
4.2.1 Immunoblotting of bacterial colonies
4.2.1.1 Materials
Blood agar
The blood agar was composed of a Columbia agar base prepared as per
manufacturer's instructions (Oxoid, Basingstoke, Hampshire) with the addition
of 6% horse blood.
Phosphate buffered saline (PBS) (pH 7.2)
PBS contained 0.01M phosphate buffer pH 7.2 with 0.15M NaCl.
High salt buffer (HSB)
HSB was composed of PBS containing 1M NaCl and Tween 20 (0.5%, v/v) (BDH,
Poole, Dorset).
Barbitone complement fixation test diluent (BCFD)
This was prepared as per manufacturer's instructions (Oxoid, Basingstoke,
Hampshire).
Mouse monoclonal anti-human HLA-B27 antibody (MC27)
The monoclonal IgG2a anti-human HLA-B27 antibody (Code no. MCA 116 from
Serotec, Kidlington, Oxford) was diluted 1/250 in HSB. It is a cytotoxic antibody
directed against an epitope common to HLA-B27 molecules of healthy controls
and patients with spondyloarthropathy (Trapant et al., 1983).
Protein A-horseradish peroxidase (protein A-HRP)
Protein A-HRP (Sigma, Poole, Dorset) was diluted 1/5 in BCFD and stored at -
20°C. Prior to use, the protein A-HRP was diluted a further 100 times in HSB to
make an overall dilution of 1 /500.
Anti-mouse gammaglobulin conjugated with horseradish peroxidase
This was obtained from the Scottish Antibody Production Unit, Carluke,
Lanarkshire) and diluted 1/100 in PBS.
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ELISA buffer
ELISA buffer contained 24.3ml 0.1M citric acid (BDH, Poole, Dorset), 25.7ml 0.2M
Na2HP04 (BDH, Poole, Dorset) and 50ml H2O.
Substrate
The substrate solution used to detect protein A-HRP activity contained 160mg
dioctyl sulfo-succinate (DONS) (Sigma, Poole, Dorset) and 49mg tetramethyl




The mixture was placed in a water-bath at 60°C for about 30min to solubilise the
DONS and TMB. The substrate was activated prior to use by adding 60 jxl
hydrogen peroxide (H2O2) (0.3%, v/v).
4.2.1.2 Methods
Bacterial culture
A 20pl sample from the 10~2 and the 10"3 dilutions of each faecal suspension (see
chapter 3) was spread over the surface of separate blood agar plates using a sterile
glass rod and incubated overnight under standard conditions. In the same way,
20gl from the 10"3 and the 10"6 dilutions were plated out onto two blood agar
plates and incubated anaerobically at 37°C for 7 days.
Immunoblotting
For each individual, one plate incubated aerobically and one incubated
anaerobically were selected for immunoblotting with Biotrace NT nitrocellulose
(NC) membrane (Gelman Sciences, Northampton). The plates selected were
those in which the colonies were separate from each other and not too
numerous to facilitate identification of positive colonies.
The NC membrane was cut into circles (90mm diameter) and two small V-
shaped incisions made in the membrane for orientation purposes. The circle
was carefully placed on top of the colonies with alcohol-flamed (and cooled)
forceps. An indelible mark was made on the side of the Petri dish corresponding
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to the notches on the NC membrane to allow later identification of positive
colonies.
After 3min, the NC membrane was lifted carefully off the plate with clean
forceps and transferred to a clean Petri dish with the adherent colonies facing
upwards. The membrane was immersed in HSB for 1 to 2min.
Excess bacteria were gently wiped off into the HSB. The membrane was washed
again in HSB and the fluid discarded. The membrane was submerged in HSB
and incubated for 30min at 37°C. It was then rinsed twice in HSB and the fluid
discarded.
MC27 (1ml) diluted 1/250 in HSB was added to each membrane and incubated at
37°C for lhr. The antiserum was washed off by immersing the membrane in
HSB for 15min and then running it under tap water for lmin. The water was
discarded and the membrane placed in HSB immediately.
Protein A-HRP (1ml) diluted 1/250 in HSB was added to each membrane and
incubated for lhr at 37°C. After another washing step with HSB, 3 to 4ml of
activated substrate was poured over each NC blot and left at room temperature
for 5min.
Positively-stained colonies appeared as green-blue dots on the NC (Plate 4.1).
The reaction was stopped by washing with tap water. Positive colonies were
identified on the original blood agar plate, a mirror image of the NC blot. These
colonies were subcultured and identified by routine bacteriological methods
(section 4.2.3).
4.2.2 Dot-immunoblotting
4.2.2.1 Preparation of bacterial suspensions
A heavy bacterial suspension was made by aseptically transferring several
colonies with a wire loop from a subculture plate to a tube containing 200 pi PBS






A stock culture of S. epidermidis was stored on blood agar at 4°C.
Anti-staphylococcal antibody
Hyperimmune mouse serum obtained after 6 weekly injections of S.
epidermidis (2 x 109/ml) was kindly donated by Dr J Stewart and diluted 1/10 in
PBS.
Bovine serum albumen (BSA)
A 1 % (w/v) solution of BSA in distilled water was used.
Klebsiella K43 and K30 strains
These were laboratory stock strains grown on egg slopes and stored at room
temperature.
Protein A
Staphylococcal protein A (Sigma, Poole, Dorset) was diluted 1/250 in HSB.
4.2.2.3 Method
The NC membrane was cut into rectangles to fit into split plates and a notch was
made at the top for orientation purposes. Circles (diameter 0.5cm) were drawn
in pencil on the shiny side of the membrane. These circles marked the areas or
wells to which the bacteria were added.
A sample (10 pi) of each bacterial suspension was added to similarly-positioned
circles on each rectangular strip of NC membrane which was due to receive
different treatments. Controls (BSA or S. epidermidis suspensions) were added
to the strips in a similar manner. The strips were incubated for 10-15min at37°C
until nearly dry. Antibody (10pi) or HSB as appropriate was added to particular
circles and incubated at 37°C for lhr. A washing stage in HSB followed for
15min and the fluid was then discarded. The strips were immersed in tap water
for l-2min and placed in HSB immediately. HSB was discarded and protein A-
HRP (0.5ml) was added and incubated at 37°C for lhr. After a final wash in HSB,
2ml of substrate were added and left at room temperature for 5-10min for colour
to develop. The reaction was stopped by washing with water.
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In some experiments anti-mouse gamma-globulin-HRP (1/100) was used as the
enzyme amplification system as an alternative to protein A-HRP.
4.2.2.4 Blocking experiments to investigate the non-specific binding of protein
A-HRP
The non-specific binding of protein A-HRP to whole bacteria and outer
membrane peptidoglycan (OMPG) complexes was investigated initially by
attempting to block possible binding sites on bacteria for protein A-HRP (1 /500)
with protein A (1/250). This was repeated with protein A-HRP at the same
concentration and protein A (1/5). A dot-blot technique was used. Test samples
included whole bacteria (E. coli MS and Acinetobacter calco. var. anitratus), the
prepared OMPG from these bacteria and Klebsiella K43 and K30 strains). BSA
and mouse anti-BSA antibody (1/10 dilution in PBS) were controls (Table 4.1).
Table 4.1
Scheme to test protein A as a blocking agent
bacteria/ bacteria/ bacteria/ bacteria/
OMPG/BSA OMPG/BSA OMPG/BSA OMPG/BSA
STEP 1 protein A HSB HSB protein A
STEP 2 MC27* MC27* HSB HSB
STEP 3 protein A-HRP protein A-HRP protein A-HRP protein A-HRP
STEP 4 substrate substrate substrate substrate
4.2.2.5 The effect of different concentrations of protein A-HRP
It was possible that at the concentration of protein A-HRP used (1/500), the
protein A-HRP could still bind to sites on the bacteria not blocked by protein A.
A dot-blot experiment was set up adding a standard concentration of MC27
(1/250) and different concentrations of protein A-HRP (1/250, 1/500, 1/1000,
1/2000, 1/4000) to whole bacteria or OMPG. BSA and S. epidermidis and their
respective antibodies were used as controls (Table 4.2).
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Table 4.2
Dot-blot scheme for testing effect of different concentrations
of protein A-HRP
Test Control Control Control
STEP 1 bacteria/OMPG bacteria/OMPG BSA BSA
STEP 2 MC27 HSB anti-BSA HSB
STEP 3 protein A-HRP protein A-HRP protein A-HRP protein A-HRP
dilution dilution dilution dilution
STEP 4 substrate substrate substrate substrate
4.2.2.6 To test for the presence of peroxidase
The presence of peroxidase was investigated in 11 bacteria isolated from patients'
stools and in 7 laboratory strains (N. meningitidis type B:4; N. meningitidis
type C:4; H. influenzae type b; Salmonella enteritidis; Klebsiella K30; Klebsiella
K43; E. coli MS) which were stored on egg slopes at room temperature. The dot-
blot technique was used.
4.2.2.7 lnactivation of peroxidase
An attempt was made to inactivate peroxidase by treating the bacteria
impregnated in the nitrocellulose paper with 0.3% H2O2 in methanol (Table 4.3).
Table 4.3
Scheme for inactivation of peroxidase with 0.3% H2O2 in methanol
Test Control Control
bacteria bacteria bacteria
0.3% H2O2 in methanol HSB HSB
substrate substrate HSB
This was repeated, but this time the bacteria were fixed in coating buffer to an
ELISA plate instead of to nitrocellulose paper. The bacteria were treated with
0.3% H2O2 in methanol and TMB/DONS was used as substrate.
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Further attempts were made to inactivate bacterial peroxidase by buffered
paraformaldehyde (PFD). This chemical impairs movement of proteins within
the bacterial cell wall by cross-linking them. If the peroxidase enzyme requires
such movement to be biologically active, then the paraformaldehyde would




This was composed of Tris 0.605g, sodium chloride 0.85g, 0.1N hydrochloric acid
(HC1) (4ml) and distilled water (96ml).
Diaminobenzidine
Stock Tris-HCl (5ml) was added to 1 bottle of diaminobenzidine (20mg) and the
mixture added to 20ml Tris-HCl. This was activated prior to use by the addition
of 1 drop of neat H2Q2.
Acetate buffer
This consisted of 1M sodium acetate (50ml), 1M HC1 (10ml) and distilled water
(200ml).
Amino ethyl carbazole
This consisted of amino ethyl carbazole (0.4%) in dimethyl formamide made up
to 1/10 solution in acetate buffer and activated just prior to use by the addition of
1 drop of neat H2O2.
Method
A dot-blot assay was used (Table 4.4). Bacterial suspension (lOpl) was added to
NC dots and incubated for 30min at 37°C. Buffered paraformaldehyde (3ml) was
added to test NC strips and HSB to control NC strips. After 20min at room
temperature, NC membranes were washed twice with HSB and substrate added.
3 different chemicals which are known peroxidase substrates were tested to
determine if the reaction was more pronounced with one substrate than
another; TMB/DONS; diaminobenzidine; amino ethyl carbazole.
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Table 4.4
Scheme for inactivation of peroxidase with buffered paraformaldehyde
(a) (b) (c)
Test Control Test Control Test Control
bacteria bacteria bacteria bacteria bacteria bacteria
PFD HSB PFD HSB PFD HSB
TMB/DONS diaminobenzidine amino ethyl carbazole
4.2.3 Identification of colonies that were positive in the immunoblot assay
4.2.3.1 Aerobic bacteria
Catalase test
This is performed to distinguish staphylococci from streptococci. A few colonies
from a pure culture of an organism are transferred by a flamed (and cooled) wire
loop to a drop of distilled water on a clean slide. 1-2 drops of H2O2 are added and
a cover slip placed on top. If bubbles appear these are due to hydrogen released
from the breakdown of H2O2 by catalase (peroxidase) in staphylococci.
Streptococci do not have this enzyme and so no bubbles materialise.
Method
Bacteria from positively-staining colonies were subcultured onto blood agar
plates and a Gram film made. Gram-negative bacilli were further subcultured
onto BGA plates to determine if the isolate was E. coli. If the Gram-negative
bacilli were not E. coli, the organisms were identified by API 20E. If Gram-
positive cocci were found, a catalase test was performed to differentiate
staphylococci from streptococci. The organism was then identified by either API




Anaerobic organisms were identified to genus level by examination of a
combination of cellular morphology, Gram stain reaction and short-chain fatty
acid end-products of glucose metabolism (Brown et al., 1989). Blood agar plates
were inoculated from frozen stock cultures of the test strains and incubated
anaerobically at 37°C in an atmosphere containing 10% hydrogen, 10% carbon
dioxide and 80% nitrogen in an anaerobic cabinet (Forma Systems). Single
colonies were subcultured from the plates into 5ml volumes of prereduced
Proteose Peptone Yeast extract broth containing 1% glucose and incubated
anaerobically for 48 or 96hr. These cultures were examined in Gram-stained
films and the pH was recorded before they were processed for gas
chromatographic examination. Ether extractions were made by the method of
Thomann and Hill (1986), and the chromatography was performed on a Perkin
Elmer model 8410 gas chromatograph fitted with a flame ionisation detector,
AS8300 autosampler and integrator computer. The column was 2m x 4mm
glass, containing 15% SP1220 + 1% HP04 on 100/120 mesh Chromosorb WAW.
Operating conditions were 120°C for 1.5min, rising at 4°C/min to 160°C and held
for 2.5min. Injection and detector temperatures were 160°C and 300°C
respectively. Flow rates were 35ml/min for the oxygen-free nitrogen carrier gas
and 500ml/min for air. The hydrogen flow rate was adjusted to give the most
sensitive response. The injection volume was 0.5pl. Identification and
quantification of the separated components was done by comparison of their
retention times and peak areas with those of known standards.
4.2.4 Storage of bacteria which stained positively in the immunoblot assay
4.2.4.1 Cooked meat broth (CMB)
The modification of 'Robertson's bullock-heart' medium by Lepper and Martin
as detailed by Collee and Marr (1989) was used.
4.2.4.2 Method
Bacteria from positively-staining colonies on immunoblot assay were
subcultured onto a blood agar plate. A few of these colonies were transferred
aseptically to a glass universal containing CMB and stored at room temperature
until required.
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4.2.5 Preparation of outer membrane peptidoglycan (OMPG) complexes
In order to identify the component of the bacteria that was responsible for the
positive reaction in the immunoblot assay, the protein component parts of the
outer membrane peptidoglycan were separated by polyacrylamide gel
electrophoresis (PAGE). The bands that bound MC27 were identified by Western
blotting using protein A-HRP as the enzyme amplification step. The two
bacteria chosen were those which had produced the most vivid reaction in the
immunoassay; E. coli MS and Acinetobacter calco. var. anitratus.
Nutrient broth No.2 (500 ml) (Oxoid, Basingstoke, Hampshire) was inoculated
with a few colonies of bacteria from a blood agar plate and incubated at 37°C in a
Gallenkamp orbital incubator with continuous gentle shaking. The bacteria
were harvested at 48hr by centrifugation at 3000g for 20min and washed twice in
PBS at 4°C. The bacteria were resuspended in 20ml PBS (pre-cooled to 4°C) and
transferred to a sterile glass universal container which was placed in a beaker of
ice. The resuspended bacteria were broken up by sonication at an amplification
of 6 microns for five lmin periods with 30sec intervals between each sonication
period to allow cooling. Unbroken cells were removed by centrifugation at 5000g
and the supernatant mixed with 5ml of 22% sodium N-lauryol sarcosinate
(Sigma, Poole, Dorset) for 30min at room temperature to solubilise the
cytoplasmic membranes. The OMPG complexes were pelleted by centrifugation
at 40,000g for 45min, resuspended in 0.5ml PBS and stored at -70°C prior to
analysis.
4.2.6 Preparation of the polyacrylamide gels
4.2.6.1 Materials
Acrylamide stock solution
This contained 30g acrylamide and 0.8g methylene bisacrylamide (both from
FSA Laboratory Supplies, Loughborough, Leicestershire) in 100ml distilled
water.
Resolving gel buffer
This consisted of 3.0M Tris-HCl (BDH) at pH 8.8.
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Stacking gel buffer
This consisted of 0.5M Tris-HCl (BDH) at pH 6.8.
Sodium dodecyl sulphate (SDS) stock solution
This consisted of a 10% (w/v) solution of SDS (Sigma, Poole, Dorset) in distilled
water.
Ammonium persulphate stock solution
A 1.5% ammonium persulphate solution (Fisons Fine Chemicals,
Loughborough, Leicestershire) was made in distilled water.
4.2.6.2 Method
The resolving gel and the stacking gel were prepared by mixing the constituents
listed in Table 4.5.
Table 4.5
Contents of resolving gel and stacking gel




Acrylamide stock solution 10 2.5
Resolving gel buffer 3.75 —
Stacking gel buffer — 5.0
SDS stock solution 0.3 02
Ammonium persulphate 1.5 1.0
solution
TEMED 0.015 0.015
Distilled water 14.45 11.3
4.2.7 Preparation of samples for polyacrylamide gel electrophoresis
4.2.7.1 Materials
Samples
There were 5 molecular weight markers varying from 14,300 to 71,500kDa (BDH,
Poole, Dorset).
104
Bovine serum albumen (BSA)
A 10% (w/v) solution of BSA (Sigma, Poole, Dorset) was prepared in PBS.
Test samples
Outer membrane peptidoglycan prepared from E. coli MS and A. calco. var.
anitratus.
Sample buffer
Sample buffer (pH 6.8) consisted of 0.125M Tris-HCl (BDH) at pH 6.8 containing
4% (w/v) SDS (BDH Specially Pure), 20% (v/v) glycerol (BDH), 2% (v/v) 2-
mercaptoethanol (BDH) and 0.002% (v/v) bromophenol blue (BDH).
4.2.7.2 Method
Equal volumes of bacterial OMPG and sample buffer were mixed and placed in a
boiling water bath for 3min. Boiling SDS (a detergent) inactivates bacterial
autolytic enzymes which otherwise would degrade peptidoglycan.
4.2.8 Polyacrylamide gel electrophoresis (PAGE) and Western blotting
4.2.8.1 Materials
Electrode buffer
Electrode buffer (pH 8.3) consisted of 0.025M Tris (BDH) in which 0.192M glycine
(BDH Chromatographically Pure) and 0.1% (w/v) SDS (BDH) were added.
4.2.8.2 Method
Proteins were separated by SDS-PAGE using the continuous buffer system of
Laemmli (1970) on a mini-protein II cell (Biometra, Maidstone, Kent). The
resolving gel solution was poured between alcohol-treated glass plates of the slab
gel electrophoresis equipment. The gel was overlayed with water-saturated
butan-2-ol (BDH) and allowed to polymerise for 30min. The butan-2-ol was
removed and the stacking gel poured onto the resolving gel. A comb was
introduced and the stacking gel allowed to set. After removing the comb, the
gel was fitted into an electrophoresis tank and the electrode buffer added.
Samples were loaded into the wells of the stacking gel and electrophoresis
carried out at a constant voltage of 60V. When the blue dye front had reached
the bottom of the stacking gel, the voltage was increased to 150V to allow
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electrophoresis through the resolving gel. The gel was removed from the PAGE
apparatus and cut in 2 parts. One part was stained for proteins and the other part
used for Western blotting.
4.2.9 Staining of polyacrylamide gels for protein
4.2.9.1 Materials
The following solutions were made up in distilled water:
1 25% (v/v) propan-2-ol (BDH General Purpose), 10% (v/v) glacial acetic acid
(BDH General Purpose) and 0.05% (w/v) Coomassie brilliant blue (BDH).
2. 10% (v/v) propan-2-ol, 10% (v/v) glacial acetic acid and 0.005% (w/v)
Coomassie blue.
3. 10% (v/v) glacial acetic acid and 0.0025% (w/v) Coomassie blue.
4. 40% (v/v) methanol (BDH General Purpose) and 10% (v/v) glacial acetic
acid.
5. 10% (v/v) glacial acetic acid.
4.2.9.2 Method
The gel was placed in solution 1 overnight and then sequentially through stains
2-5, each for 45-60min at room temperature with gentle shaking throughout.




This buffer (pH 9.2) contained 39mM glycine, 48mM Tris, 0.0375% (v/v) SDS and
20% (v/v) methanol in distilled water.
4.2.10.2 Method
The second part of the gel was laid on top of a square of nitrocellulose
membrane which was on 4 sheets of Whatman No.3 filter paper, all of which
had been presoaked in transfer buffer. An additional 4 sheets of filter paper were
laid on top of the gel and the 'sandwich' trimmed with an alcohol-treated
scalpel blade. The sandwich was then placed in an Ancos Semi-Dry
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Electroblotter. A constant current of 0.8mA/cm2 was applied for lhr at room
temperature.
4.2.11 Visualisation of antibody-antigen reactions
4.2.11.1 Materials
Mouse anti-BSA antibody
Mouse hyperimmune serum (kindly donated by Dr J Stewart) was produced by
injection of 0.2ml BSA (lmg/ml) intraperitoneally each week for 6 weeks. The
blood was collected 1 week after the last injection, allowed to clot and the serum
stored at -20 °C.
Blocking buffer (i)
This consisted of 4% (w/v) ovalbumen (Sigma, Poole, Dorset) in PBS.
Blocking buffer (ii)
This contained 0.05% (v/v) Tween in PBS.
4.2.11.2 Method
After electrophoretic transfer of proteins, the NC membrane was cut into 3 strips
and all were soaked in blocking buffer (i) for 15min. The strips received the
following treatments:
Strip 1: Mouse anti-BSA antibody (1/40 in PBS)
Strip 2: MC27 (1 /250 in PBS)
Strip 3: Blocking buffer (ii).
The strips were incubated overnight at room temperature, washed in blocking
buffer (ii) for 15min and rinsed in tap water for l-2min. They were incubated
with protein A-HRP (1/250 in HSB) for 30-60min at 37°C. Activated substrate
was added and colour change noted after 10-15min. The reaction was stopped by
the addition of tap water.
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4.2.12 Flow cytometry to investigate the presence of a HLA-B27 cross-reactive
epitope on bacteria
The presence of a HLA-B27 cross-reactive epitope on the bacteria was
investigated by flow cytometry.
4.2.12.1 Materials
Anti-N. meningitidis antibody
Polyclonal rabbit antiserum to group C polysaccharide of N. meningiditis was
obtained from Wellcome Diagnostics, Beckenham, Kent.
Anti-rabbit immunoglobulin FITC (Fab fragment)
This was obtained from the Scottish Antibody Production Unit (SAPU) (Carluke,
Lanarkshire) and diluted 1/10 in HSB.
Anti-mouse immunoglobulin conjugated with fluorescein isothiocyanate
(FITC) (Fab fragment).
This was obtained from Sigma (Poole, Dorset) and diluted 1/50 in HSB.
Bacteria
Aerobic (32) and anaerobic (34) isolates, strains from both patients and controls
which had stained positively in the original immunoblot assay, were tested.
4.2.12.2 Method
A heavy suspension of each bacterial strain was made in PBS. Equal volumes
(50pi) of test bacterial suspension and either HSB or MC27 (1/250 in HSB) were
incubated together for lhr (Table 4.6).
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Table 4.6
Scheme for flow cytometry experiment
Test Test Control Control
(a) (b) (c) (d)
bacteria bacteria bacteria bacteria
MC27 (20gl)* MC27 (40 (il)* HSB HSB
anti-mouse Ig anti-mouse Ig anti-mouse Ig
FITC** FITC* FITC* HSB
or anti-neisseria antibody or anti-staphylococcal antibody
or anti-rabbit immunoglobulin FITC
Positive controls were (i) N. meningitidis serogroup C serotype 4 and antibody
for the C capsular polysaccharide, and (ii) S. epidermidis with its corresponding
antibody.
The samples were washed twice (1500g for 15min) in HSB and 50(0.1 of FITC-
conjugated antibody added for lhr at 37°C. After washing twice (1500g for
15min) in HSB, 0.5ml of buffered paraformaldehyde was added to each bacterial
pellet and the samples stored at 4°C prior to analysis by flow cytometry.
4.2.13 Analysis of bacteria by flow cytometry
Analysis was done on an Electronically Programmable Immunofluorescent Cell
Sorter (EPICS) 'C' flow cytometer (Coulter Electronics, Luton, UK) equipped with
a 5 watt laser using a power output of 300mw at 488nm. The bacteria were
selected from a display of forward angle light scatter by means of a cursor set to
eliminate debris. The percentage of cells showing fluorescence greater than the
background level was recorded on a one parameter histogram measuring




4.3.1 Analysis of faecal flora of patients and controls for bacteria with antigens
cross-reactive with HLA-B27
Stool samples were obtained from 82 patients and 36 controls. The details of
these individuals are recorded in Table 4.7. The plates tested in the
immunoassay were those with 50-100 colonies per plate.
Table 4.7
Characteristics of patients and controls providing faecal sample
Patients
No. AS IBD ReA PSA Controls
Total 82 67 4 6 5 36
Male 66 54 1 6 5 29
Female 16 13 3 0 0 7
Mean age (years) 41.8 42.8 37.1 39.5 40.8 36.3
4.3.1.1 Aerobic bacteria
27/36 (75%) stool samples from controls and 42/82 (51%) stool samples from
patients contained aerobic colonies which were positive in the immunoblot
assay. One of the patients' stools contained 2 species that were positive.
4.3.1.2 Anaerobic bacteria
Of 36 stool samples from controls, 18 (50%) grew anaerobes which reacted in the
immunoblot assay. A total of 23 different bacteria were grown from these 18
samples. 23/82 (28%) of the patients' samples produced positive colonies on
anaerobically-incubated plates. One sample grew 2 different positively-staining
organisms.
All bacteria which were positive on the immunoblot assay were purified after
initial identification and stored in cooked meat broth (CMB) at room
temperature for 5-6 months until screening was complete.
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4.3.2 Identification of organisms that were positive in immunoblot assay
4.3.2.1 Aerobic bacteria
The range of aerobic bacterial species which were identified are shown in Table
4.8. Two organisms isolated from controls' samples died before identification
could be made. The most commonly identified aerobe in both populations was
E. coli. The range of species was similar for the two groups and included a
number of types of Streptococcus and Enterobacter species as well as a few other
species. Two species of Klebsiella were identified in the assay from the patient
population.
Table 4.8
Aerobic bacteria that were positive in the screening assay
with anti-HLA-B27 antibody
No. of times isolated
Organism Controls (n = 27) Patients (n = 42)
Escherichia coli 12 30
Streptococcus salivarius 3 0
Streptococcus mitis 1 0
Streptococcus bovis 1 1
Streptococcus lactis 1 0
Streptococcus sanguis 1 0
Enterococcus durans 2 1
Enterococcus intermedium 0 1
Enterococcus avium 1 0
Enterococcus faecium 0 2
Enterobacter cloacae 1 0
Escherichia adecarboxylata 1 0
Morganella morganii 1 0
A. calco. var. anitratus 0 2
Citrobacter freundii 0 2
Staphylococcus spp. 0 2
Klebsiella oxytoca 0 1
Klebsiella pneumoniae 0 1
Total 25* 43
2 organisms died before identification could be made.
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4.3.2.2 Anaerobic bacteria
The range of anaerobic bacteria identified are listed in Table 4.9. The most
commonly identified anaerobe in the assay from both patients and controls, was
Bacteroides spp. followed by Lactobacillus spp. which are the two most
common anaerobes in gut flora.
Table 4.9
Anaerobic bacteria that were positive in the immunoblot assay
No. of times isolated










4.3.3 Ability of bacteria to remain positive on immunoblot assay on
subculture
Bacteria from the positively-staining colonies were subcultured and re-tested
with monoclonal anti-HLA-B27 antibody (MC27) to see if they retained the
ability to bind the antibody.
4.3.3.1 Aerobic bacteria
On initial subculture, 14/25 bacteria from control samples were able to bind
MC27; 11 were not. These 14 were repeatedly subcultured and the binding ability
tested on each subculture (Table 4.10). After the second subculture, 12/14 had
retained the ability to react positively in the assay; on third subculture, only 1 of
these 12 isolates retained the ability and this was lost on the next subculture.
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Table 4.10
Reactivity of aerobic isolates in the immunoblot assay
following subculture
No. of isolates






24/43 bacteria from patients' samples were able to bind MC27 on initial
subculture; 19 were not. The results of repeat blotting on subculture of the 24
bacteria are shown in Table 4.10. Of these isolates 12/24 reacted positively after
the second subculture; only 4 of these 12 retained the ability to react positively
on third subculture; on fourth subculture 2/4 stained positively; 1 organism
reacted in the assay after a total of 7 subcultures.
4.3.3.2 Anaerobic bacteria
Of the 23 anaerobic bacteria isolated from controls' stools which stained
positively in the immunoblot assay, 9 retained the stain on initial subculture.
These were further subcultured and re-tested (Table 4.11). Of these anaerobic
isolates, 3/9 retained the ability to react positively in the assay after the second
subculture; 1 of these 3 stained positively on third subculture but did not stain
on further subculture and testing.
Table 4.11
Reactivity of anaerobic isolates in the immunoblot assay
following subculture
No. of isolates






Only 3/24 anaerobic bacteria isolated from patients' stools which stained
positively in the immunoblot assay retained the ability to react in the assay on
initial subculture. Of these, 2/3 isolates retained the ability to react in the assay
after a second subculture; 1/2 still stained on a third subculture but not on a
fourth.
When the screening was completed after 5 months, 10 stored isolates from
patients' stools and 10 stored isolates from controls' stools were subcultured
from CMB onto blood agar plates and tested in the immunoassay. Of the 20
isolates only 16 remained viable and of these 5 retained the ability to stain
positively. All the viable bacteria were passaged several times on both blood
agar and MacConkey agar at room temperature and 37°C. Both treatments failed
to induce a positive reaction in those bacteria which were negative on initial re-
testing after storage; the other 5 bacteria continued to display reactivity in the
assay.
4.3.4 Identification of the bacterial component responsible for the positive
reaction in the immunoblot assay
4.3.4.1 Protein staining after PAGE
There were 5 bands corresponding to the molecular weight markers: 1 thick
band with BSA; 3 bands corresponding to the separated OMPG of A. calco. var.
anitratus and several bands with E. coli MS (Plate 4.2).
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Plate 4.2 Polyacrylamide gel electrophoresis of: Lane A - 5 molecular weight
markers from 14,300 to 71,500 kDa; Lane B - Bovine serum albumin, molecular
weight 66,000 kDa; Lane C - separated OMPG of A. calco. var. anitratus; Lane D -
separated OMPG of E. coli MS.
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4.3.4.2 Western blotting
There was no binding of MC27 to the nitrocellulose membrane after transfer of
the separated proteins, but binding of anti-BSA to BSA was identified.
It was important to determine whether intact OMPG complexes i.e., unseparated
by PAGE, bound MC27 and whether this ability was destroyed during the
extraction process. The complexes under test were also boiled in sample buffer
to mimic the conditions of the sample prior to PAGE. The various preparations
were tested in a dot-blot assay.
The reaction of the unboiled samples of the OMPG complexes was the same
regardless of the presence of antibody (Table 4.12). This suggested that protein A-
HRP was binding non-specifically to OMPG complexes. A reaction with BSA
was seen only in the presence of anti-BSA antibody. Boiling in sample buffer,
however, destroyed the reactivity of the OMPG complexes and weakened the
reactivity of BSA and anti-BSA antibody. The possibility that protein A was
binding non-specifically to bacteria or OMPG was investigated using anti-mouse
gammaglobulin-HRP as an enzyme detection system instead of protein A-HRP.
Anti-mouse gammaglobulin-HRP also appeared to bind to whole bacteria and to
the OMPG of E. coli and A. calco. var. anitratus in the absence of MC27.
Table 4.12














OMPG-AC (boiled) - -
OMPG-EC (boiled) - -
BSA (boiled) +/- -
* OMPG from A. calco. var. anitratus
* * OMPG from E. coli MS
or anti-BSA antibody
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4.3.5 Investigation of non-specific binding of protein A-HRP
Various experiments were performed to try to eliminate the apparent non¬
specific binding of protein A-HRP to bacteria.
4.3.5.1 Blocking experiments with protein A
Unconjugated protein A was used to try to block the binding of protein A-HRP
in dot-blot experiments. Colour reaction with BSA was observed where
expected i.e., in those wells in which anti-BSA was present; protein A at either
concentration used (1/250 or 1/500 dilution) did not interfere with this reaction
(Table 4.13). Positive colour reactions were seen in all test conditions with both
bacterial OMPG indicating that there was non-specific binding by protein A-HRP
to the bacterial OMPG which was not blocked by protein A. Positive reaction
was present also in all test conditions with the whole bacterium of E. coli MS
and to a lesser extent with the whole bacterium of A. calco. var. anitratus ; this
reaction was non-specific and not blocked by protein A. Other whole bacteria,
Klebsiella K43 and K30 did not show any reaction in any of the test conditions.
Table 4.13
The effect of protein A as a blocking agent
TEST SCHEME
bacteria/OMPG bacteria/OMPG bacteria/OMPG bacteria/OMPG


















E. coli MS + + + +
OMPG-EC** + + + +
A. calco. var.
anitratus +/- +/- +/- +/-
OMPG-AC*** + + + +
Klebsiella K43 - - - -
Klebsiella K30 - - - -
BSA + + - -
* or anti-BSA antibody
* * E. coli MS OMPG




4.3.5.2 The effect of different concentrations of protein A-HRP
It was possible that at the concentration of protein A-HRP (1/500), it could still
bind to sites on bacteria not blocked by protein A. A range of dilutions of protein
A-HRP (doubling dilutions 1/250-1/4000) were tried in the assay to avoid this
problem.
The colour reactions were equally intense with all dilutions of protein A-HRP
and developed quickly for all bacteria and for the BSA and S. epidermidis
positive controls (Table 4.14). This strongly suggested either that protein A-HRP
was reacting with a substance on the bacteria or that the substrate itself was
reacting with a bacterial enzyme.
Table 4.14
The effect of protein A-HRP concentration in dot-blot assay
Bacteria/OMPG/BSA Bacteria/OMPG/BSA
MC27* HSB
protein A-HRP dilution protein A-HRP dilution
substrate substrate
E. coli MS + +
E.coli MS-OMPG + +
A. calco. var.anitratus + +
K. pneumoniae + +
S. epidermidis + +
BSA + -




4.3.5.3 Detection of a peroxidase enzyme
To investigate this further, the scheme in Table 4.15 was employed. A
concentration of protein A-HRP (1/500) was used and bacteria from 8 patients'
stools were tested.
Table 4.15
Scheme to test for peroxidase in a dot-blot assay
(a) (b) (c)
Test Control Control
STEP 1 bacteria bacteria bacteria
STEP 2 MC27 HSB HSB
STEP 3 protein A-HRP protein A-HRP HSB
STEP 4 substrate substrate substrate
The colour reactions were equally intense for all 3 treatments for each
bacterium. The treatment (c) indicates that the substrate was reacting directly
with the bacteria to produce a colour change. This implies that the bacteria have
a peroxidase enzyme.
4.3.6 Attempts to inactivate peroxidase
Attempts were made to inactivate bacterial peroxidase to see if a colour reaction
then occurred with protein-A-HRP and MC27 which would suggest specific
binding of MC27.
The attempt to inactivate peroxidase by treating the bacteria impregnated in the
NC paper with 0.3% H2O2 in methanol was unsuccessful due to dissolution of
the nitrocellulose by the methanol.
When bacteria were fixed to an ELISA plate and treated with 0.3% H2O2 in
methanol and substrate added, no colour reaction developed in either plate.
Possibilities were that too few bacteria were added, or that the bacteria were
washed off in the washing process, both possibilities being unlikely. More likely
is that the enzyme was inactivated by the high pH (9.6) of the coating buffer.
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Some inhibition of peroxidase activity by paraformaldehyde occurred with some
bacteria (regardless of substrate, either TMB/DONS, diaminobenzidine or amino
ethyl carbazole) but paraformaldehyde did not totally inactivate the enzyme.
4.3.7 Testing for the presence of peroxidase in aerobic bacteria
All the bacteria found to be positive in the initial screening assay were tested
definitively by dot-blot for the presence of peroxidase. TMB/DONS was
employed as substrate; the scheme is outlined in Table 4.16 and the results of
some of the bacteria are shown.
Table 4.16
Scheme to test definitively for the presence of peroxidase
(a) (b) (c) (d) (e)
bacteria bacteria bacteria HSB HSB
MC27* HSB MC27 HSB HSB
protein protein HSB HSB protein
A-HRP A-HRP A-HRP
substrate substrate substrate substrate substrate
K.pneumoniae + + + - -
A. calco. var. + + + - -
anitratus
E. coli MS + + + - -
E. coli + + + - -
C. freundii + + + - -
BSA + - - - -
* or anti-BSA antibody
+ colour reaction
no colour reaction
Of 23 patients' aerobic isolates which had previously stained positively and had
been stored in CMB, 6 showed mixed growth on subculture and were thus
unsuitable for testing; 1 organism failed to grow; 2 isolates showed no staining;
14 showed equal reaction in both the test and the control demonstrating the
presence of a peroxidase enzyme. MC27 and protein A-HRP were superfluous to
the colour reaction.
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For 27 isolates from controls tested, 8 bacteria failed to grow; 5 isolates showed
no staining; 14 showed equal reaction in test and control assays demonstrating
the presence of peroxidase.
4.3.8 Testing for the presence of peroxidase in anaerobic bacteria
Anaerobic bacteria which had been stored at -70 °C were also tested for their
ability to react with substrate (TMB/DONS) in a dot-blot assay (scheme same as
outlined in Table 4.16).
Of 34 anaerobes, 15 showed colour reaction in (a) but no colour in (b). These
bacteria included Bacteroides (10), Lactobacilli (4) and Eubacterium lentae (1).
This suggested that these bacteria do not have a peroxidase enzyme and that the
colour in (a) is due to specific binding of MC27 to bacteria.
There were 16/34 anaerobes that showed equal reaction in (a) and (b) indicating
that these bacteria have catalase. These bacteria included Bacteroides (13),
Lactobacilli (2) and Bifidobacterium (1). The remaining 3/34 samples grew but
there was no colour reaction in (a) or (b).
4.3.9 Flow cytometry to investigate the presence of a HLA-B27 cross-reactive
epitope
Although there was a positive reaction in control dots, the possibility of the
presence of a bacterial HLA-B27 cross-reactive epitope in addition to peroxidase
activity, could not be excluded by the above experiments. To determine
definitively whether or not aerobic bacteria bind MC27 specifically, all
previously isolated organisms which had stained positively on nitrocellulose
were tested for the presence of the epitope by flow cytometry. Controls of S.
epidermidis with anti-staphylococcal antibody and N. meningitidis and Group C
Neisseria capsular polysaccharide antibody were used.
4.3.9.1 Controls for assay system for aerobic bacteria
N. meningitidis reacted with antibody to Group C Neisseria capsular
polysaccharide to produce a value of 44% compared with 4% for Neisseria
without its corresponding antibody. For S. epidermidis, the higher reading of
9% with its corresponding antibody, contrasted with 0.9% without antibody.
19% of the staphylococci were positively fluorescent after immunoanalysis.
121
Although this reading was not as high as expected, it was sufficiently high to
show that the assay was working.
The lower readings of staphylococci compared with Neisseria are probably a
reflection of the age and loss of avidity of the staphylococcal antiserum in
comparison with the meningococcal antiserum. There was no significant
difference in readings between any of the tubes containing Neisseria and MC27
and those containing Neisseria without MC27 indicating the absence of a HLA-
B27 cross-reactive epitope on the surface of the Neisseria.
4.3.9.2 Aerobes
The level of fluorescence in the test and control tubes for each bacterium was
almost identical for all bacteria under investigation. There is no evidence for
specific binding of MC27 to any of the enteric bacteria previously tested. There is
no masking of a HLA-B27 cross-reactive epitope on the bacteria by the colour
observed in the peroxidase/substrate reaction.
4.3.9.3 Anaerobes
The presence of a HLA-B27 cross-reactive epitope on anaerobes (n = 34) was
assessed by the flow cytometry assay.
The staphylococcal control with antibody had a higher reading of 7% compared
with a background reading of 0.7% without antibody. 18% of staphylococci were
positively fluorescent after immunoanalysis.
The readings of all of the test samples showed little difference regardless of the
presence of MC27. There was no evidence for specific binding of MC27 to the
anaerobic bacteria isolated previously.
The above experiment was repeated using a higher concentration of MC27 (1/10)
and a dilute suspension of bacteria (1/10 of a heavy suspension). There was no
significant difference in readings between those tubes with and without MC27.
4.3.10 Testing for peroxidase and a HLA-B27 cross-reactive epitope on bacteria
isolated from fresh faecal samples
Although the experiments were originally performed on bacteria from a fresh
stool sample, all of the above experiments were done on stored bacteria. It is
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possible that if a HLA-B27 cross-reactive epitope had been present initially,
during storage in CMB structural changes could have occurred in the bacteria
which might have obliterated the presence of this epitope. A further collection
of stool samples was obtained from healthy individuals, dilutions and
subcultures made and immunoblot screening performed. Of 10 stool samples, 4
(incubated aerobically) and 2 (incubated anaerobically) showed positively-
staining colonies on immunoassay. The anaerobic subcultures did not grow,
therefore no further investigation could be done. The aerobic bacteria were
subcultured, identified as E. coli and tested for the presence of peroxidase; all
were positive. All 4 isolates were tested by flow cytometry for the presence of a
HLA-B27 cross-reactive epitope; all were negative.
123
4.4 discussion
Much controversy and confusion exists in the literature concerning the
antigenic similarities between HLA-B27 and micro-organisms.
Antisera raised in rabbits to certain enteric bacteria lysed lymphocytes of HLA-
B27-positive patients with AS but not the lymphocytes of HLA-B27-positive or
HLA-B27-negative healthy individuals (Geczy et al., 1983). Further work
(Prendergast et al., 1984) showed that a variety of organisms (Gram-positive as
well as Gram-negative) from rectal swabs of 20 HLA-B27-positive AS patients
were able to absorb the lymphocytotoxic activity of these antisera. Only 1
bacterial sample from 35 HLA-B27-negative controls showed a similar finding;
isolates from 11 HLA-B27-positive healthy controls were unable to do this.
These organisms persisted in the bowel flora of 5 patients for at least 9 months.
The authors suggested that transmission of a plasmid could explain the cross-
reactivity between these diverse bacteria. These findings were supported by a
study on a larger series of 52 AS patients (McGuigan et al., 1986). Enteric
organisms with determinants cross-reactive with HLA-B27-positive
lymphocytes from AS patients were found in 100% of HLA-B27-positive AS
patients but only in 2% of HLA-B27-positive controls.
Antibodies produced against one enteric bacterial species (E. coli, Y.
enterocolitica, K. pneumoniae, S. flexneri or P. maltophilia) have shown cross-
reactivity with the other members of this selection of Enterobacteriaceae (Pease
et al., 1988). No evidence of cross-reactivity was shown, however, between HLA-
B27 and K. pneumoniae by Archer and colleagues (1981) or between HLA-B27
and Y. enterocolitica by Pease et al. (1980). The latter authors suggested that if
bacterial antigens were involved in the pathogenesis of AS, no specific
bacterium was involved. The latter group subsequently used a formalin-treated
preparation of Y. enterocolitica (to avoid destruction of heat-labile antigens) to
prepare antisera in rabbits. They showed cytotoxicity against HLA-B27-positive
lymphocytes from AS patients in some of the pre-immunisation sera as well as
the post-immunisation sera, suggesting a previous encounter with certain
organisms (Macintosh et al., 1982).
In a lymphoproliferative assay, HLA-B27-positive cells from AS patients had a
lower in vitro responsiveness to Klebsiella (isolates 411, 427, 433, 462 and 468)
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compared with cells from HLA-B27-positive and HLA-B27-negative healthy
controls. This could suggest either a cross-reactivity between Klebsiella antigens
and HLA-B27, impaired antigen processing by macrophages or the production of
suppressor cells and/or suppressor factors by lymphocytes of AS patients (Seager
et al., 1979). Antisera to 1/4 strains of Klebsiella (427) produced
lymphocytotoxicity.
In the present study, faecal samples were initially screened for aerobic bacteria
with antigens cross-reactive with MC27 using the technique of van Alphen et al.
(1991). One unusual feature of the procedure is the use of a high salt buffer, an
environment which often interferes with antigen/antibody reactions; but, when
the assay was tested in the current work and a high salt buffer compared with a
low salt buffer, the high salt buffer was found to reduce non-specific background
staining while allowing antigen/antibody interaction to take place.
A significantly higher proportion (75%) of samples from controls were positive
compared with patients (51%). Similarly, on anaerobic culture a higher
proportion of controls' samples were positive on immunoblot (50%) than
patients' (28%). This is probably not be due to intrinsic differences in the flora of
the two populations, but is more likely to reflect the longer period taken for the
patients' specimens to arrive at the laboratory.
The range of aerobic and anaerobic bacteria identified in the immunoblot assay
was diverse but similar in both populations. These results suggested that the
HLA-B27-like epitope was present on a wide range of enteric organisms. E. coli,
the most common aerobe in gut flora, was the most frequently identified aerobe
while Bacteroides and Lactobacilli spp., the most common anaerobes, were the
most frequently identified anaerobes in the assay.
In order to characterise this bacterial epitope, its stability on repeated subculture
of organisms was assessed. Most of the aerobes (whether from patients' or
controls' samples) remained positive in the immunoblot assay for one
subculture. After that there was a low positivity on repeat subculture. Far fewer
anaerobes remained positive on immunoassay on repeat subculture (9/23 from
controls; 3/24 from patients) compared with aerobes (14/25 from controls; 24/43
from patients).
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In order to identify the location of the cross-reactive epitope on the bacteria, the
first step was to determine whether it was present on the outer surface of the
bacterial cell wall. The 2 bacteria which showed the strongest reaction in the
immunoassay were E. coli MS and A. calcoaceticus var. anitratus. The latter
organism is one variant of Acinetobacter calcoaceticus spp which is a frequent
commersal in man. The outer membrane peptidoglycan of the 2 bacteria were
obtained by sonication and separated by polyacrylamide electrophoresis.
Western blotting was performed. The absence of binding of MC27 to the
separated OMPG led to testing the intact OMPG for this ability. The results
suggested non-specific binding of protein A-HRP to the OMPG. A further series
of experiments to investigate this non-specific binding included (unsuccessful)
attempts to block binding with protein A. Different dilutions of protein A-HRP
were used and equally intense reactions were found with the most dilute and
the most concentrated sample of protein A-HRP. A reaction also occurred
between bacteria and substrate alone. This suggested that the colour reaction in
the assay was due to the presence of peroxidase on the bacteria. Further
experiments confirmed this; MC27 and protein A-HRP were superfluous to the
reaction.
Hydrogen peroxide is a strong oxidising agent and is toxic to most living
organisms. Peroxidase enzymes (including catalase) degrade H2O2 and are
present in the majority of aerobes and anaerobes. In this study several aerobic
bacteria were shown to have peroxidase. Some bacteroides and other anaerobes
were also shown to have the enzyme while other strains of bacteroides did not.
It is of interest that the Dutch workers have not had non-specific staining
problems with this assay except with very old bacterial samples and have used
protein A conjugates to detect antibodies to a variety of organisms including H.
influenzae, Neisseria, E. coli and streptococci, all of which have peroxidase (Dr L
van Alphen, personal communication). The reason for this is not clear as the
same procedure was used in this work. There is no detail in their methodology
of steps taken to inactivate bacterial peroxidase.
These results did not refute the possibility that in addition to a peroxidase
enzyme, a HLA-B27-like epitope was also present. This was examined by flow
cytometry. The EPICS allows thousands of cells to be counted and is thus much
less subjective and time-consuming than microscopic assays.
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In this case, it allowed the use of a detection system which did not include an
activity possessed by the bacterium. In all aerobes and anaerobes tested there was
no evidence of such an epitope.
The original experiments were performed on bacteria from a fresh stool sample,
but the subsequent experiments were done on stored bacteria. In the event that a
HLA-B27-like epitope had been present initially, but that during storage changes
occurred which removed the presence of this epitope, a further collection of
stool samples was obtained (from healthy individuals) and bacteria tested by
flow cytometry for such an epitope. None was found.
There is no evidence for cross-reactivity between a mouse monoclonal anti-
HLA-B27 antibody and a range of aerobic and anaerobic enteric bacteria isolated
from patients with spondyloarthropathy (and healthy individuals) as
determined by flow cytometry. This does not exclude the presence of a HLA-
B27-like epitope which might be detected by other monoclonal antibodies to the
HLA-B27 antigen. The majority of previous studies on bacterial antigens that
cross-react with HLA-B27 were carried out with polyclonal sera. It is possible
that in the present study, a polyclonal anti-HLA-B27 antiserum would have had
a greater chance of detecting such determinants on bacterial surfaces cross-
reactive with HLA-B27, but none was available at the time of the study.
The main conclusion is that there is no evidence, as detected by a mouse
monoclonal anti-HLA-B27 antibody, for the presence of a HLA-B27-like epitope
on a range of enteric bacteria isolated from patients with spondyloarthropathy
and from healthy individuals.
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Chapter 5
Humoral Studies in Ankylosing Spondylitis
5.1 Introduction
In some studies of the humoral immune response of patients with AS, total levels of
immunoglobulins, particularly IgA, have been determined. In others, the specific
antibody response to a variety of enterobacteria implicated in the disease
pathogenesis has been measured. These studies have concentrated on the humoral
response to laboratory strains of bacteria, in particular to Klebsiella. Interest has also
been directed at the antibody response in AS to pathogenic bacteria associated with
reactive arthritis such as Shigella, Yersinia and Salmonella. Antibody levels have
sometimes been assessed with reference to disease activity, while other researchers
have chosen to ignore disease activity.
There have been conflicting results for a number of reasons. There have been
technical differences in the method employed to measure antibody levels; radial
immunodiffusion (Kinsella et al., 1975; Cowling et al., 1980b; Calguneri et al., 1981;
Laurent and Panayi, 1983; Franssen et al., 1985; van Bohemen et al., 1986; Collado et
al., 1987; Sanders et al., 1987; Mackiewicz et al., 1989), linear plate method (Veys and
van Laere, 1973), rate nephelometry (Pease et al., 1987) and ELISA (Trull et al., 1983;
Trull et al., 1984) for total antibody levels; radioimmunoassay (Ebringer and
Ghuloom, 1986), radiobinding assay (Ghuloom and Ebringer, 1987), immunoblot
(Shodjai-Moradi et al., 1992) and ELISA (Trull et al., 1983; Trull et al., 1984; Pease et
al., 1987; Cooper et al., 1988; Khalafpour et al., 1988; van Bohemen et al., 1988; Maki-
Ekola et al., 1991) for specific antibody measurement.
Different types of bacterial preparations have been used to measure specific
antibody levels; intact bacteria (Trull et al., 1983; Trull et al., 1984; Ghuloom and
Ebringer, 1987; Cooper et al., 1988; Khalafpour et al., 1988; van Bohemen et al.,
1988), sonicated preparations (Pease et al., 1987); sonicated preparations separated
by PAGE (Shodjai-Moradi et al., 1992) and outer membrane preparations (Maki-
Ikola et al., 1991). These different preparations represent different 'targets' for
antibodies in serum samples to bind to. For example, assays using formalin-killed
bacteria are thought to measure antibodies directed to a multitude of surface
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antigens on the intact organisms; whereas a sonicated preparation consists of
secretory and internal proteins (in addition to surface antigens) due to the
mechanical disruption of the bacterial cell wall. This means that the antibodies
measured to sonicated preparations will have a different specificity from those to
intact bacteria.
In those studies in which correlation between disease activity and antibody levels
has been made, disease activity has been assessed either solely on clinical grounds,
by laboratory criteria (CRP or ESR) or by a combination of the two. Some groups
have even included a raised serum IgA as part of the criteria for assessing disease
activity (Khalafpour et al., 1988; Shodjai-Moradi et al., 1992).
The control populations with which AS patients have been compared have varied
between surveys.
It is difficult, therefore, to make valid comparisons between studies which have
fundemental differences in selection of controls, disease activity assessment and
methodology for antibody measurement.
There have been few longitudinal studies of immunoglobulin levels in ankylosing
spondylitis. In this present survey, most patients (80/112) were seen on 2 visits.
Serum immunoglobulins were measured and correlations made between clinical
disease activity and ESR and CRP as inflammatory markers. As there have been
conflicting reports in the literature concerning the relationship between a raised
serum IgA and the presence of active disease in AS, correlations of these 2
parameters were made.
Invariably, when specific antibody assays have been performed in the past, sera
have been tested against laboratory strains of bacteria which have been cultured for
the purpose of the assay. These bacteria might not indeed have formed part of the
faecal flora of any of the subjects under investigation. Another consideration is that
when bacteria are cultured in vitro surface antigens can alter and may not be the
same as those antigens encountered by the putative host; therefore, serum
antibodies measured to bacteria grown on artificial media may not be very
meaningful.
Measurement of serum antibody levels to autologous gut bacteria from patients
with AS has not previously been determined. It was of interest to examine the
antibody response of AS patients to their own gut bacteria to determine the
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presence of hypo- or hyper- responsiveness; and, to compare this with the antibody
response of healthy individuals to their own gut flora. It was decided to harvest as
many bacteria as possible from faecal samples, to kill them with formalin and to test
the autologous serum samples for antibodies using an ELISA. This type of harvest
would be non-selective for a particular organism and would consist predominantly
of anaerobes which considerably outnumber aerobes in the intestinal flora. The
bacteria would have intact cell walls and sera would be measuring antibodies
predominantly to the surface antigens. An alternative option would have been to
culture each stool specimen, to chose certain colonies, identify, subculture and
formalinise them and use them in an ELISA. The disadvantage of this is that it
would have been impossible to decide which colonies to select as the most
representative of that individual's flora. The temptation would be to select the most
prolific organism on culture, with the proviso that this may not be the most
numerous in vivo, as differential growth occurs in artificial media. Also, it may not
be the most prolific organism which is relevant (if any are) to pathogenesis. For
these reasons, a non-selective bacterial harvest was deemed the most appropriate
for the purposes of the study.
In a separate analysis, serum was collected from a small group of patients on 3
occasions over a 14-month period and tested for antibodies to bacteria harvested
from a single faecal sample.
The objectives of this part of the project were:
1. to measure total serum IgG, IgA and IgM in AS patients and to correlate these
levels with ESR, CRP and disease activity.
2. to investigate the serum humoral immune response to autologous gut bacteria
in AS patients (n = 12) and controls (n = 13).
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5.2 MATERIALS AND METHODS
5.2.1 Measurement of total IgG, IgA and IgM by ELISA
The method described by Zorgani et al. (1992) was used in these studies.
5.2.1.1 Materials
Buffers used are the same as those used in the ELISA for Lewis antigens in section
2.2.5.3.
The main immunoglobulin isotypes were detected with the following:
goat anti-human IgM conjugated with horseradish peroxidase (HRP-anti-IgM)
(Sigma, Poole, Dorset);
rabbit anti-human IgA conjugated with horseradish peroxidase (HRP-anti-IgA)
(Dako, Glostrup, Denmark);
goat anti-human IgG conjugated with horseradish peroxidase (HRP-anti-IgG)
(Sigma, Poole, Dorset).
5.2.1.2 Collection of serum
Approximately 8ml of venous blood was allowed to clot and centrifuged at lOOOg
for 15min. The serum was aliquoted and stored at -20 °C until required.
5.2.1.3 ELISA for measurement of total IgG
Duplicate wells of a microtitre plate were coated (100|il/well) with doubling
dilutions (1/1000 - 1/512000) of standard serum (Behring Diagnostics, Hounslow,
Middlesex) and a dilution of each test serum. Control wells comprising a) serum
but no HRP-anti-IgG and b) HRP-anti-IgG but no serum were incorporated. All
dilutions were made in coating buffer and the plate stored overnight at 4°C. All
subsequent stages were carried out at room temperature. The plate was washed 5
times with washing buffer using a Dynatech plate washer and 100pl blocking buffer
was added to each well to block empty binding sites with BSA. After 30min
incubation, the plate was washed 5 times and 50pl HRP-anti-human IgG diluted in
blocking buffer added per well. After 2hr incubation, the plate was washed 8 times
and 50pl of activated substrate was added to each well. The colour was allowed to
develop for 10-15min and was stopped by adding 50pl sulphuric acid (12.5%).
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Optical density (OD) at 490nm was determined on a Dynatech MR700 ELISA plate
reader and corrected by subtracting the OD of the corresponding blank. Samples
were tested in duplicate and the readings averaged. The mean of the OD ELISA
readings for each dilution of standard serum (containing 1140mg/dl IgG) was
plotted against the IgG concentration at that dilution and a graph drawn. Mean
ELISA readings for each test serum were compared to this graph and the
concentration of IgG determined for the dilution used. From this the concentration
of IgG in each test serum was calculated.
5.2.1.4 ELISA for measurement of total IgA and IgM
A capture method was used to determine total total IgA and IgM. Microtitre wells
were coated with lOOpl of either monoclonal anti-human IgA (1/500 in coating
buffer) (Sigma, Poole, Dorset) or monoclonal anti-IgM (1/500 in coating buffer)
(Sigma, Poole, Dorset) and stored overnight at 4°C. All further stages were carried
out at room temperature. The next day they were washed 5 times and lOOpl
blocking buffer added per well for 30min. The plates were washed 5 times and 50(il
of doubling dilutions of standard serum (1/100 - 1/51200 in blocking buffer) were
added per well to both the IgA and the IgM plates. Test sera (50|xl) diluted in
blocking buffer were added to the IgA plate and to the IgM plate. After 2hr
incubation, the plates were washed 5 times and either HRP-anti-IgA (50pl) diluted
in blocking buffer or HRP-anti-IgM (50pl) diluted in blocking buffer was added per
well. After 2hr incubation, the plates were washed 8 times and the substrate was
added. The plates were then treated as those for the detection of total IgG.
The graph plotting the OD of each standard serum dilution with the concentration
of IgA and IgM was determined from the known concentrations of IgA (250mg/dl)
and IgM (114mg/dl) in standard serum.
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5.2.2 Measurement of specific serum antibodies to autolugous gut bacteria in
AS patients and controls
5.2.2.1 Subjects
Patients
AS patients (12) included 11 (10 male, 1 female; mean age 36 years) with primary AS
and 1 female with AS associated with inflammatory bowel disease (IBD); 9 patients
were secretors and 3 were non-secretors. Details of disease activity, ESR and CRP
are shown in Table 5.1.
Table 5.1
Disease activity, ESR and CRP in patients
Disease activity No. Mean ESR Mean CRP
Inactive 5 15.6 1.4
Probably active 6 15.6 1.6
Active 1 11.0 1.4
Controls
Controls (13) (8 male, 5 female; mean age 36 years) were healthy laboratory staff
with no rheumatic complaints or history of rheumatic disease; 7 were secretors and
6 were non-secretors. ESR and CRP were not determined for controls.
5.2.2.2 Harvesting of bacteria from faeces
A faecal sample was collected from each subject (section 3.2.2). Faeces (5-10g) was
added to 20ml of sterile PBS and mixed thoroughly with a rotary mixer. The
suspension was filtered three times through sterile glass wool to remove particulate
debris. After each passage the glass wool was renewed. The filtrate was
centrifuged at 320g for 7min, the pelleted debris discarded and the supernatant re-
centrifuged at 320g for 7min. This was repeated twice more and the final
supernatant filtered through Whatman No.l filter paper. The resultant filtrate was
examined microscopically (x 40) to check that it was free of significant debris. (If
debris was present, the filtrate was further centrifuged at 320g for 7min and re-
filtered through Whatman No.l paper). The filtrate was centrifuged at 1900g for
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15min to pellet the bacteria. The pellet was washed three times (1900g for 15min) in
20ml sterile PBS. The bacteria were killed by resuspending them in 20ml 0.5%
formalin overnight at 4°C. The bacteria were washed three times (1900g for 15min)
in sterile PBS. The pellet was suspended in 2ml coating buffer and stored at 4°C
until required.
5.2.2.3 Bacterial count
A 1/10 dilution of bacteria extracted from each faecal sample and suspended in
coating buffer was made and the optical density (OD) at 540nm obtained. A sample
from the same bacterial suspension was diluted and stained with 0.1% methyl violet
and counted using a Thoma haemocytometer. From this, the concentration of
bacteria in the neat suspension was calculated. Dilutions of the suspension were
counted and a graph was drawn; the OD and the bacterial concentration were linear
over the range 0.15-0.6. An OD reading of 0.35 was found to represent a bacterial
concentration of 5 x 108/ml. The bacterial concentration of an unknown sample
could therefore be calculated from its optical density.
5.2.2.4 ELISA for measurement of specific antibodies to autologous gut bacteria
An ELISA was used to measure specific antibodies to gut bacteria. In order to
optimise conditions, titration of the bacterial concentration, serum dilution and
concentration of HRP-anti-IgG, HRP-anti-IgA and HRP-anti-IgM was necessary.
Unless otherwise stated, all procedures were carried out at room temperature.
Bacteria suspended in coating buffer (100gl of 2-3 x 108/ml) were added in triplicate
to wells on three different plates which were stored overnight at 4°C. The plates
were washed 5 times, blocking buffer (lOOpl) was added to each well for 30min and
plates were washed again 5 times. For the IgG plate, 50jxl test serum diluted in
blocking buffer was added to each well. For both the IgA and IgM plates, 50gl of
undiluted serum was added to each well. After 2hr incubation, plates were washed
5 times and 50gl of the following (diluted in blocking buffer) were added to the
appropriate wells: HRP-anti-IgG, HRP-anti-IgA or HRP-anti-IgM. After 2hr, plates
were washed 8 times and substrate added.
For each experiment the concentration of specific antibody of each class was
calculated with reference to appropriate graphs of total IgA, IgM and IgG in a
standard serum run in parallel and determined by ELISA.
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5.2.3 Statistical methods
The Kendall correlation coefficient was used to correlate total immunoglobulins in
patients with ESR, CRP, disease activity and secretor status. Mann-Whitney
analysis was used to compare the total and specific immunoglobulins in patients
and controls. The Wilcoxon rank sum test was used to correlate total and specific
immunoglobulins in patients with disease activity and to compare the percentage of




5.3.1 Optimisation of ELISA for measurement of total immunoglobulins
Optimisation of reagents was necessary to ensure that reagent concentration was
not limiting the detection system.
Titration of HRP-anti-IgG for total IgG assay
A range of dilutions of HRP-anti-IgG was tested (Figure 5.1) using serum in excess.
The 1/100 dilution of HRP-anti-IgG produced the highest readings. In the interests
of economy a 1/200 dilution of HRP-anti-IgG was chosen to measure total IgG to




1/16000 1/8000 1/4000 1/2000 1/1000 1/100
Dilution ofHRP-anti-IgG
Figure 5.1 Titration of HRP-anti-IgG for total IgG measurement
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Titration of serum dilution for total IgG assay
Using 1/200 dilution of HRP-anti-IgG, doubling dilutions of test serum (1/100-
1/51200) were tested in an ELISA and compared to dilutions of the standard serum
(1/1000-1/512000) (Figure 5.2). The reading for 1/51200 dilution of test serum
(dilution no.9) corresponded to the middle part of the linear graph for the standard
serum; therefore 1/50000 dilution was chosen to measure total IgG. At this dilution
the majority of samples fall on the linear part of the standard graph.
Dilution of serum
Figure 5.2 Titration of serum dilution for total IgG measurement. The dilutions
represent doubling dilutions from 1/1000-1/512000 for standard serum and 1/100-
1/51200 for test serum samples.
Titration of HRP-anti-IgM for total IgM assay
To determine the optimum concentration of HRP-anti-IgM, the following dilutions
of HRP-anti-IgM were tested in an ELISA assay; 1/1000 and doubling dilutions
1/5000 to 1/40000 (Figure 5.3). Serum was used in excess (1/10) with the capture
monoclonal anti-IgM antibody (1/500). The highest reading was with the 1/1000
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Figure 5.3 Titration of HRP-anti-IgM for total IgM measurement
Titration of serum dilution for total IgM assay
Doubling dilutions (1/20-1/1280) in blocking buffer were made of two control sera
and compared with the same dilutions of standard serum in an ELISA using HRP-
anti-IgM (1/1000) and the capture monoclonal anti-IgM (1/500) (Figure 5.4). The
linear part of the graph of OD plotted against concentration lay between 1/320 and
1/1280 dilutions of the standard serum. For control serum 2, readings for 3
dilutions 1/320, 1/640 and 1/1280 lay on the linear part of the graph, while for
control serum 1, only the value for the 1/1280 dilution fell on the linear part. A
1/1000 dilution of serum was chosen to determine the total IgM.
0.8
0.0
1/1280 1/640 1/320 1/160 1/80 1/40 1/20
Dilution of serum
Figure 5.4 Titration of serum dilution for total IgM measurement
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Titration of HRP-anti-IgA for total IgA assay
Doubling dilutions (1/25-1/3200) of HRP-anti-IgA in blocking buffer were tested in
an ELISA using two control sera in excess (1/50 dilution). The optimal dilution of
HRP-anti-IgA was 1/100 (Figure 5.5).
1/3200 1/1600 1/800 1/400 1/200 1/100 1/50 1/25
Dilution of HRP-IgA
Figure 5.5 Titration of HRP-anti-IgA for total IgA measurement
Titration of serum dilution for total IgA assay
Doubling dilutions (1/40-1/5120) of one control serum were compared with
doubling dilutions (1 /500-1 /64000) of a standard serum in an ELISA using HRP-
anti-IgA (1/100) and monoclonal anti-IgA (1/500). The results are shown in Figure
5.6. The readings for 1/2560 (dilution no.7) and 1/5120 (dilution no.8) of the control
serum corresponded to points on the linear part of the graph of the standard serum.
Therefore, a 1/5000 dilution of serum was used to measure total IgA.
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Dilution of serum
Figure 5.6 Titration of serum dilution for total IgA measurement The dilutions
represent doubling dilutions from 1/500 to 1/64,000 for standard serum and 1/40
to 1/5120 for the test serum.
5.3.2 Total immunoglobulin G, A and M in sera of patients at the 2 visits
Patients were assessed on 2 visits 7 months apart; 112 patients attended on the first
visit and 80 also attended on the second visit. Clinical disease activity was assessed,
and blood samples taken for ESR, CRP and total serum immunoglobulins.
Correlations were made between total serum immunoglobulins, ESR, CRP, disease
activity and secretor status.
The results were analysed in two ways; the results of the total patient group
(patients with primary AS and those with secondary AS ie., AS associated with
other conditions) were compared with the results of the primary AS group to see if
all the spondyloarthropathies, as a group, behaved in the same way as the primary
AS group. (The small numbers of patients in each subgroup of secondary AS
precluded any direct comparison of them with the AS group).
As samples were available for 80 patients seen on 2 occasions, correlations between
changes in variables were made.
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5.3.2.1 Total immunoglobulins in each disease category
The mean immunoglobulin values at both visits for all disease subgroups are shown
in Table 5.2. There was no significant difference in the mean IgG, IgA or IgM
between any of the disease categories at either the first or the second visit.
Table 5.2
Mean serum immunoglobulins (mg/ml) at first and second visits
for patient population
Disease category
AS IBD ReA PSA Total
Visit 1 Number 92 6 8 6 112
IgG 15.96 14.2 15.5 15.9
IgA 6.5 5.62 5.63 6.8
IgM 2.01 2.85 2.27 2.5
Visit 2 Number 63 4 7 6 80
IgG 15.32 14.44 13.6 13.84
IgA 4.83 4.31 6.0 9.21
IgM 2.35 2.71 2.91 3.09
5.3.2.2 Correlations between total immunoglobulins, ESR, CRP, disease activity and
secretor status
a) Total patient group:
There was no correlation between any of the immunoglobulin classes and either
secretor status or disease activity. There was a weak correlation between IgA and
ESR (p < 0.05, r = 0.16) and between IgG and CRP (p < 0.05, r = 0.16). There was no
correlation between IgM and either ESR or CRP.
Comparing the change in IgG, IgA and IgM with changes in disease activity, ESR
and CRP between the 2 visits, the only significant finding was a positive correlation
between the change in IgM levels and the change in CRP (p < 0.05, r = 0.17). The
change in IgM and IgA correlated (p < 0.01, r = 0.23) between the 2 visits, but
neither correlated with changes in IgG.
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b) AS patients:
There was no correlation between total IgG, IgA or IgM and either secretor status,
disease activity or CRP in AS patients. ESR, however, correlated with IgA (p < 0.05,
r = 0.18) and with IgM (p < 0.05, r = 0.15).
The only correlation between the change in serum immunoglobulins between the 2
visits and changes in ESR, CRP and disease activity, was a negative correlation
between the change in IgG and the change in disease activity (p < 0.05, r = -0.2). The
changes in IgM and IgG correlated with each other (p < 0.05, r = 0.19), but neither
correlated with changes in IgA.
5.3.3 Measurement of total immunoglobulin levels and the humoral response
to autologous gut bacteria in AS patients and controls
5.3.3.1 Total serum immunoglobulin G, A andM in AS patients and controls
The ELISA for total serum immunoglobulins was used to measure the total serum
IgG, IgA and IgM in a cohort of patients (n = 12) and controls (n = 13). The values
for the total immunoglobulin levels in patients and controls are shown in Table 5.3.
Table 5.3
Total serum immunoglobulins in patients and controls
Mean total Ig (mg/ml) Patients Controls
No. of subjects 12 13
IgG 17.02 (12.9-21.1)* 14.4 (11.7-17.1)
IgA 4.32 (3.3-5.3) 2.94 (2.0-3.9)
IgM 2.06 (1.5-2.6) 1.93 (1.3-2.5)
* Figures in parentheses represent the 95% confidence interval
There was no significant difference in total immunoglobulin G, A or M levels
between patients and controls and no correlation between immunoglobulins and
disease activity in patients.
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5.3.3.2 Optimisation of ELISA for measurement of specific immunoglobulin
Optimisation of reagents was required to ensure that reagent concentration was not
limiting the detection system.
Titration of bacterial concentration
A range of concentrations of bacteria (106-108 bacteria/ml) were added to wells and
tested in an ELISA (Figure 5.7). The highest reading was for the concentration of 6.6
x 108 bacteria/ml. A concentration of approximately 2 x 108 bacteria/ml was used
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Figure 5.7 Titration of bacterial concentration
Titration of HRP-anti-IgM for specific IgM assay
A microtitre plate was coated overnight with a concentration of 108 bacteria/ml
(100pl/well). Neat serum was added. The following dilutions of HRP-anti-IgM
were tested; 1/1000, 1/2000 and doubling dilutions (1/100-1/6400) (Figure 5.8).




Figure 5.8 Titration of HRP-anti-IgM for specific antibody measurement
Titration of serum dilution for specific IgM assay
A microtitre plate was coated with 1.2 x 10® bacteria/ml (lOOgl/well) and tested
with doubling dilutions of serum (Neat-1/32) and HRP-anti-IgM (1/1000) (Figure
5.9). When the readings were compared with a graph of standard serum, the
highest ELISA reading was for neat serum and this corresponded to the lower end
of the linear part of the graph for the standard serum. Neat serum was therefore
used to measure specific IgM antibodies to gut bacteria.
0.2
i 1 i 1 i 1 i ■ i 1 r
1/32 1/16 1/8 1/4 1/2 1
Dilution of test serum
Figure 5.9 Titration of serum dilution for specific IgM measurement
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Titration of HRP-anti-IgA and serum dilution for specific IgA assay
Doubling dilutions of serum (Neat-1/32) and HRP-anti-IgA (1/25-1/200) were
tested in checkerboard fashion using bacteria at a concentration of 1.2 x 10®/ml.
Comparing the readings obtained with those for standard serum, the optimum
serum dilution was for neat serum (Figure 5.10). There was little difference in
values obtained using 1/100 or 1/200 HRP-anti-IgA. 1/100 was chosen for
convenience as HRP-anti-IgA (1/100) was used to measure total IgA.
Figure 5.10 Titration of serum dilution and HRP-anti-IgA for specific antibody
measurement
Titration of HRP-anti-IgG for specific IgG assay
Using bacteria at a concentration of 1.1 x 10^/ml, and serum in excess (1/2), a range
of dilutions of HRP-anti-IgG were tested (Figure 5.11). The optimum dilution was
1/100, but in order to save reagents without compromising results, 1/200 dilution
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Figure 5.11 Titration of HRP-anti-IgG for specific antibody measurement
Titration of serum dilution for specific IgG assay
Doubling dilutions of serum (neat-1/512) were tested in an ELISA using bacteria at
a concentration of 2.1 x 10®/ml and HRP-anti-IgG (1/200). The optical density
readings plateaued for the neat serum sample down to 1/32 dilution (Figure 5.12).
1 /200 serum dilution was chosen to measure specific IgG antibodies as the reading
lay on the straight part of the graph.
Dilution of serum
Figure 5.12 Titration of serum for specific IgG measurement
146
5.3.3.3 Specific IgG, IgA and IgM antibodies to autologous gut bacteria in AS patients
and controls
The mean values for the specific serum antibodies in patients and controls are
shown in Table 5.4.
Table 5.4
Specific IgG, IgA and IgM antibodies to autologous gut bacteria
in AS patients and controls
Mean specific antibody (pg/ml) Patients Controls
No. of subjects 12 13
IgG 9.72 (6.4-13.1)* 12.57 (7.1-18.1)
IgA 1.85 (0.8-2.9) 2.22 (1.3-3.1)
IgM 1.17 (0.5-1.8) 1.71** (1.3-2,1)
* Figures in parentheses represent the 95% confidence interval
** excluding GS, specific Ig M = 53.4 mg/ml
There was no significant difference in the mean specific IgG or IgA antibodies to
autologous gut bacteria between patients and controls but the mean specific IgM
antibody level was significantly lower in patients than controls (p < 0.05).
Although the absolute levels of specific IgM to autologous gut bacteria were lower
for patients than controls, the percentage of the total antibody that was directed
against enteric bacteria, the specific/total antibody ratio (S/T ratio), was
determined for each subject to see if patients produced a proportionately lower
fraction of their total IgM as specific IgM than did controls. The same ratios were
determined for specific/total IgG and IgA and are shown in Tables 5.5 and 5.6.
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Table 5.5
Percentage of total serum antibody of each class
produced to autologous gut bacteria in patients
Specific/Total antibody %
Patient IgG IgA IgM
GF 0.059 0.272 0.057
P 0.03 0.02 0.103
AD 0.035 0.017 0.039
DB 0.034 0.021 0.048
JR 0.022 0.028 0.046
FB 0.12 0.018 0.081
RM 0.033 0.007 0
PF 0.056 0.022 0.032
JOL 0.074 0.079 0.056
DMCA 0.033 0.024 0.028
JT 0.13 0.033 0.023
DD 0.157 0.106 0.104
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Table 5.6
Percentage of total serum antibody of each class
produced to auologous gut bacteria in controls
Specific/Total antibody %
Control IgG IgA IgM
DB 0.079 0 0.086
DM 0.035 0.018 0.046
VJ 0.008 0.045 0.027
AZ 0.2 0.061 0.103
GS 0.281 0.087 2.19
MK 0.098 2.17 0.09
WM 0.042 0.103 0.22
LC 0.035 0.193 0.107
JV 0.091 0.135 0.10
MA 0.089 0.061 0.245
MB 0.032 0.033 0.068
JS 0.046 0.039 0.115
JC 0.149 0.142 0.101
The S/T ratios for IgM were significantly lower for patients than controls (p < 0.01
with GS included, p < 0.05 without GS included). A high S/T ratio for IgM (2.19%)
was obtained for one control (GS, the author) who had prepared all the faecal
samples (Table 5.6). The specific IgM for GS was very high (53.4pg/ml) compared
with other controls, but the total IgM (2.43mg/ml) was similar to that of the other
controls.
The S/T ratios for IgA were also significantly lower for patients than for controls (p
< 0.05). One of the controls (DB) appeared to be IgA deficient. The total IgA of
another control (MK) was similar to that of the others in the group, but the specific
IgA was very high (38|jg/ml) resulting in a high S/T ratio. The reason for this is not
clear. MK had not had a clinically evident enteric infection in the recent past.
In contrast to the lower S/T ratios for IgM and IgA in patients compared with
controls, there was no significant difference in the S/T ratios for IgG between the
two groups.
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There was no correlation between the total or specific antibody levels of any
immunoglobulin class and the disease activity of the patients.
5.3.3.4 Serial humoral studies in patients with AS
This experiment sought to determine the total IgG, IgA, and IgM in three serum
samples taken at intervals of several months over a 14 month period in a group of
12 AS patients (the same patients as in section 5.2.2.1). Bacteria were harvested
from a faecal specimen produced at the same time as the third serum sample.
Specific IgG, IgA and IgM antibodies to those bacteria were measured in all three
serum samples and the results compared.
Levels of total IgG, IgA, IgM over a 14 month period
a) Total IgG
A complete series of three serum samples was collected for 11/12 AS patients. For
one patients (DD) serum was only available at times 1 and 3. For most patients
there is little variation in the level of IgG with time (Table 5.7). One patient (JD) did
show variation, with a low level of IgG initially which rose considerably in the
second and third samples. There was considerable variation in IgG levels between
patients, from a mean value of all three samples of 6.3mg/ml to 26.1mg/ml. The
mean total IgG of all the samples did not differ significantly at time 1, 2 or 3; 16.7,
17.6 and 18.7mg/ml respectively.
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Table 5.7





Second Third Mean value
GF 8.5 10.15 10.15 9.6
JD 14.2 34.0 30.0 26.1
AD 14.0 17.65 15.15 15.6
DB 18.75 19.25 22.15 20.05
JR 22.15 22.15 23.4 22.4
FB 4.41 4.41 10.15 6.3
RM 15.1 14.6 15.1 14.9
PF 10.03 10.03 10.85 10.3
JOL 23.4 24.6 29.15 25.7
DMCA 17.65 13.3 17.65 16.2
JT 29.15 23.4 23.4 25.3
DD 23.4 — 17.65 20.5
Mean value 16.7 17.6 18.7
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b) Total IgA
Results were complete in 11/12 patients. In one patient (DD) only two serum
samples were available. There was little variation in total serum IgA with time for
all patients (Table 5.8). There was little variation in IgA levels between individuals.
The range in mean values of all three samples for each patient was 2.5mg/ml to
6.45mg/ml. The mean values of total IgA of the serum samples for each time
interval 1,2 and 3 were similar, 4.7,4.6 and 4.1 mg/ml respectively.
Table 5.8
Total IgA in 3 serum samples over 14 months in AS patients
TOTAL IgA (mg/ml)
Patient Serum sample
First Second Third Mean value
GF 5.45 4.35 5.15 5.0
JD 7.25 6.65 5.45 6.45
AD 4.48 4.48 4.35 4.4
DB 2.27 2.7 2.7 2.5
JR 5.15 4.35 3.9 4.5
FB 3.9 3.9 4.35 4.05
RM 2.7 3.9 2.7 3.1
PF 5.15 4.8 4.35 4.8
JOL 3.9 4.35 3.9 4.05
DMCA 5.15 5.45 4.55 5.05
JT 6.65 5.75 4.55 5.65
DD 3.9 — 3.1 3.5
Mean value 4.7 4.6 4.1
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c) Total IgM
Results were complete in 11/12 patients. For one patient (DD) serum was only
available at times 1 and 3. As for IgG and IgA, there was little variation in total
serum IgM with time for any individual patient (Table 5.9). Neither was there any
overall trend in the results. The range in mean values of the three samples for each
patient was 0.71mg/ml to 2.5mg/ml. The mean values of total IgM for each time
interval 1, 2 and 3 are very similar, 1.29,1.34 and 1.4mg/ml respectively.
Table 5.9
Total IgM in 3 serum samples over 14 months in AS patients
TOTAL IgM (mg/ml)
Patient Serum Ssample
First Second Third Mean value
GF 0.87 0.88 1.08 0.94
JD 1.6 1.6 1.7 1.6
AD 1.97 1.88 2.78 2.5
DB 1.21 1.46 1.32 1.33
JR 1.3 1.0 1.21 1.17
FB 1.02 0.93 1.12 1.02
RM 0.65 0.82 0.65 0.71
PF 1.33 1.52 1.33 1.4
JOL 2.15 2.33 1.7 2.1
DMCA 0.87 1.12 1.28 1.1
JT 1.33 1.28 1.28 1.3
DD 1.2 — 1.3 1.25
Mean value 1.29 1.34 1.4
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Specific IgG, IgA and IgM antibodies to autologous gut bacteria harvested from a
single faecal specimen
a) Specific IgG
In 7/12 patients results were complete for all three serum samples (Table 5.10). In 1
patient (DD) only two serum samples were obtained and in 1 patient (DMCA) the
bacterial suspension had lysed, thus rendering the results invalid. In 2 patients
(AD, RM) values were too low to be detected despite repeat testing of the samples
at 1/50 dilution. There is little difference in the level of specific IgG antibodies
between all three serum samples for any one individual. The intra-patient variation
in mean values of all three samples ranged from 6.4jig/ml to 19.0(ig/ml. The mean
values of the serum samples for each time interval 1, 2 and 3 were similiar, 8.8, 8.59
and 9.03gg/ml respectively.
Table 5.10
Specific IgG antibodies in 3 serial serum samples to autologous gut
bacteria from one faecal sample
SPECIFIC IgG (jxg/ml)
Patient Serum sample
First Second Third Mean value
GF 8.56 7.8 7.9 8.1
P 6.4 6.86 6.0 6.4
DB 8.76 10.2 9.32 9.4
JR 11.9 8.3 9.92 10.0
FB 7.8 7.6 6.4 7.3
PF 4.3 5.8 10.2 6.8
JOL 6.2 7.3 6.86 6.78
JT 15.8 23.5 17.72 19.0
DD 10.2 — 7.9 9.05
Mean value 8.88 8.59 9.03
b) Specific IgA
For only 3 patients (JD, AD, RM) were results complete (Table 5.11). In 4 patients
(DB, FB, PF, JT) results were obtained for only two serum samples. In 6 patients
readings were too high to be recorded despite considerable dilution of serum
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samples (1/100). Due to the sparsity of complete results little comment can be
made. There is no obvious trend in the values and no wide variation between
patients.
Table 5.11
Specific IgA antibodies in serum samples to autologous gut bacteria





Second Third Mean value
JD 2.23 2.63 2.5 2.45
AD 0.96 1.15 1.15 1.1
DB 3.12 2.5 too high 2.8
FB 2.1 2.87 too high 2.5
RM 1.7 1.83 0.91 1.5
PF 1.56 1.39 too high 1.5
JT 1.56 1.39 too high 1.5
c) Specific IgM
Results were complete in <Dnly 6 patients (Table 5.12). In 1 patient (AD) only the
first and second samples were available. In 4 patients (JR, JOL, DD, DMCA)
readings were too high (despite considerable dilution of serum samples) and in 1
(RM) too low to be detected. Again there was little intra-patient variation in specific
IgM levels with time in all but one case (GF).
Table 5.12
Specific IgM antibodies in 3 serial serum samples to autologous gut





Second Third Mean value
GF 2.68 1.78 1.08 1.85
JD 1.52 1.38 1.78 1.6
AD 0.72 0.65 too low 0.7
DB 1.97 1.52 1.43 1.6
FB 0.87 0.87 0.65 0.8
PF 1.7 1.74 1.43 1.6
JT 1.33 1.18 1.02 1.2
Mean value 1.54 1.3 1.4
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5.4 Discussion
5.4.1 Total immunoglobulins in patients, disease activity, ESR, CRP and
secretor status
In this part of the study, total serum immunoglobulins were not measured in
controls, therefore no comparisons can be drawn between the levels of serum
immunoglobulins in AS patients and those in healthy individuals. A number of
previous surveys have demonstrated raised serum IgA in AS patients compared
with controls (section 1.7.9.1). In the data presented here, there was no correlation
between serum IgA, G or M and disease activity as assessed clinically, for either
patients with primary AS or with AS in association with other diseases. The lack of
correlation with serum IgA and disease activity in the present study agrees with
others in which disease activity was also assessed on clinical grounds (Laurent and
Panayi, 1983; Pease et al., 1987). The present findings partly agree with Franssen et
al. (1985) who reported no correlation between both total serum IgG and IgM and a
disease activity index. This index was based on the duration of morning stiffness, a
pain score, chest expansion, lumbar flexion measurement and radiological changes.
The index did correlate with serum IgA.
In the present longitudinal study, there was no correlation between the changes in
total serum immunoglobulins and changes in disease activity between 2 visits,
strengthening the observation that total serum immunoglobulin levels in AS
patients bear no relationship to disease activity. This contrasts with the
longitudinal study by Franssen et al. (1985) in which changes in total serum IgA
with time correlated with changes in their index of disease activity. In this latter
study, 38 AS patients were seen 5 times over a 48 week period as part of a clinical
trial comparing two different types of NSAID.
For all patients with spondyloarthropathy and AS patients alone, there was a
significant correlation between serum total IgA and ESR. This agrees with other
workers (Cowling et al., 1980b; Trull et al., 1984; Mackiewicz et al., 1989). As was
previously demonstrated (section 2.3.6), there is a strong correlation between
disease activity and ESR, but not between disease activity and total serum
immunoglobulins of any class. This suggests that the correlation between IgA and
ESR, although it is statistically significant for both the total patient group (p < 0.5, r
= 0.16) and for AS patients (p < 0.5, r = 0.18 ), it is weak (low correlation
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coefficients); so the association between these 2 variables might not have much
relevance. This argument can also apply to the weak correlation between total IgM
and ESR in AS patients.
There was no correlation between serum total IgG, IgA and IgM and CRP in AS
patients. This is in agreement with the data of others for all immunoglobulins and
CRP (Laurent and Panayi, 1983) and with Sanders et al. (1987) for IgA and CRP. In
contrast, Collado et al. (1987) reported a correlation between IgA (but not IgG or
IgM) and CRP in AS; and Trull et al. (1984) also reported a correlation between IgA
and CRP (and IgA and ESR) in AS. In the present study, a weak correlation was
present between total IgG and CRP in the total patient group. As disease activity
strongly correlated with CRP (section 2.3.6) but not with serum total
immunoglobulins, the significance of this weak association between IgG and CRP is
debatable.
Total serum immunoglobulins did not differ significantly between non-secretors
and secretors. This is in agreement with findings (for total IgA and IgG) in females
with recurrent urinary tract infections who had been recently referred to clinic
(Blackwell et al., 1987b), although is in contrast with the lower serum IgA found in
non-secretors who were carriers ofN. meningitidis (Blackwell et al., 1989a).
5.4.2 Total immunoglobulins and antibody response to autologous gut
bacteria
In the experiment to compare total serum immunoglobulins in a small cohort of
patients with AS and age-matched controls, there was no significant difference in
any of the immunoglobulin classes between the 2 groups. The common finding
among several authors of a raised total serum IgA in AS compared with healthy
controls was not confirmed. A criticism of the present experiment would be that the
population under test was small and the standard deviations wide; therefore, one
cannot be certain that in a larger group a difference would not be found.
A novel way of assessing the humoral response to autologous gut bacteria was
devised by harvesting bacteria from faeces and testing the patient's serum for
antibodies to his/her organisms in an ELISA. This approach was not selective for
the antibody response to a particular bacterial species, but investigated the antibody
response to all types of enteric bacteria harvested from faeces, both anaerobic and
aerobic organisms.
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There was no significant difference in the specific IgG or IgA antibody levels
between patients and controls. The only statistically significant result was a lower
specific IgM response in patients to autologous gut bacteria compared with the IgM
response of controls to their own gut bacteria. When the proportion of
specific/total antibody of each class was calculated, it was found that patients
produced proportionately less IgM and IgA to their own gut flora relative to the
total IgM and IgA, than did controls to theirs. There was no difference in the
proportion of the specific IgG/total IgG antibody levels between patients and
controls. It is difficult to explain this result in biological terms. If patients were
mounting a reduced IgM response to their own faecal flora, one would expect a
consequently lower IgG (and IgA) response as B cells sequentially switch
production of immunoglobulin classes as they differentiate. Conversely, if the
patients had been responding over a long period to these organisms, most B cells
would have undergone class-switching away from IgM; IgM levels would,
therefore, be low but IgG and IgA levels should be higher.
There was no correlation between total or specific antibody levels of any class and
disease activity.
Significantly reduced levels of IgM to laboratory strains of K. pneumoniae have been
reported in sera of patients with AS (Cooper et al., 1988, Trull et al., 1983), including
to the K43 strain of Geczy (Cooper et al., 1988). This is the first report of a
significantly lower serum IgM response to autologous bacteria in patients with this
disease compared with controls. The number of individuals in the study was low
and standard deviations high, so the significance of the results is not entirely clear.
If this is indeed a real phenomenon, it may suggest a defect in antigen presentation
in the initiation of an immune response.
The very high specific IgM seen in one of the controls (GS) might be because GS
prepared all the faecal samples. It is likely that GS became sensitised to gut bacteria
from a variety of samples (despite adherence to aseptic technique). The high
specific IgM in this case probably reflects IgM antibodies to shared antigenic
determinants between different enteric bacteria. This is supported by the finding of
a high S/T ratio for IgG in GS, as the plasma cells producing elevated IgM
antibodies to determinants shared by gut bacteria would switch to producing IgG
class.
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5.4.3 Serial humoral studies
The total IgG levels of 3 serum samples from each of 12 patients taken at intervals of
6-7 months showed little intra-patient variation although there was considerable
inter-patient variation. For total IgA and IgM, there was little intra- or inter-patient
variation with time and values fell within the established normal ranges.
For each individual, IgG antibody levels in all 3 serum samples to bacteria
harvested from faeces obtained at the time of the third serum sample, showed little
intra-patient variation. This suggests either that bacterial flora do not alter a great
deal with time, or that there are cross-reacting antibodies present in the first and
second serum samples.
The results for specific IgM antibodies were similar to those for IgG, showing little
intra-patient variation in the levels of antibodies in the 3 samples. Unfortunately,
results were complete for only 6 patients due to lysis of the bacteria stored in
coating buffer. For the IgA assay, results were available for only 3/12 patients for
the same reason. The specific IgA assay was performed last in the series of
experiments. It must be assumed that the longer period of time in coating buffer
caused lysis of bacteria in more of the samples and consequently the results are less
complete. The high ELISA readings obtained would be due to non-specific binding
of reagents to bacterial intracellular proteins released on cell lysis.
The main conclusions are:
1. there is no correlation between total serum IgA, IgG or IgM and clinical
disease activity or secretor status in patients with spondyloarthropathy;
2. there is no correlation between any of the immunoglobulin classes and CRP in
patients with AS;
3. there is a positive correlation between total serum IgA and ESR and IgM and
ESR in AS patients;
4. there is no significant difference in total serum IgA, IgG or IgM between a
small group of AS patients and healthy individuals;
5. AS patients had a significantly lower IgM response to autologous gut bacteria
compared with controls; and, produced proportionately less IgM and IgA to





Detailed discussion of the results has been given at the end of each chapter. The
objective of this chapter is to assess the general conclusions of this study with
reference to the major hypotheses proposed for explaining the pathogenesis of
AS and proposals for further research.
6.1 OriginalObjectives
This work set out to investigate the previously reported association of non-
secretion of ABO blood group antigens with AS and reactive arthritis
(Shinebaum et al., 1987b); to compare the acute phase response and clinical
disease assessments in secretors and non-secretors; to correlate clinical disease
activity with ESR and CRP in the total patient population; to compare the faecal
flora in patients with spondyloarthropathy with that of healthy individuals; to
determine the prevalence of bacteria expressing molecules with structural
similaries with the HLA-B27 antigen; and, to compare the humoral responses of
patients and controls to their own faecal flora.
6.2 Secretor Status
The previous observation that non-secretion of ABO blood group substances
was associated with AS was of considerable interest as non-secretion is a
susceptibility factor for infection of mucosal surfaces; and, for many years
infection has been postulated to be involved in the pathogenesis of AS.
Mechanisms suggested to explain this association included the possibility that
the Lewis3 antigen of non-secretors acted as a receptor for arthritogenic bacteria
promoting colonisation of mucosal surfaces. It has been demonstrated here that
there is no increased prevalence of non-secretors in a large population of AS
patients compared with healthy individuals. Investigation of the patients who
had been typed 5 years ago and also in the present study has revealed that some
patients were originally mistyped as non-secretors when they were in fact
secretors. The most likely explanation is that enzymatic degradation of blood
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group antigens in saliva samples occurred in the initial study, probably because
the samples were not promptly processed. This highlights the need for speedy
processing of saliva samples prior to secretor status determination. Since the
proportion of non-secretors in the AS population was the same as that in the
healthy control population, further experiments to investigate the putative role
of Lewis3 as a receptor for arthritogenic bacteria (such as binding studies of
bacteria to buccal epithelial cells of secretors and non-secretors) were not
performed.
More recent studies have suggested that secretors have variable amounts of
Lewis3 on their epithelial cells (Blackwell et al., 1992; Saadi et al., in press).
There is evidence that Le3 is a receptor for some strains of S. aureus -producing
pyrogenic toxin (Saadi et al., in press). The hypothesis that Le3 might be a
receptor for some arthritogenic bacteria cannot be eliminated.
There is no evidence from this study that non-secretors with AS experience
more active disease than secretors as assessed clinically, or that they display a
more intense acute phase response as determined by ESR and CRP. This
contrasts with the report of elevated ESR and (especially) CRP levels in non-
secretors compared with secretors with urinary tract infections (Lomberg et al.,
1989); but, it is not clear whether the non-secretors in that study were more
heavily infected than the secretors. In the present work, ESR and CRP did
correlate with clinically-assessed disease activity in patients irrespective of
secretor status. This confirms the findings of some surveys (Cowling et al.,
1980a) which have shown a positive correlation between ESR and CRP and
disease activity, but disagrees with others (Laurent and Panayi, 1983; Sheehan et
al., 1986) all of which have assessed disease activity in a similar way to that
employed here.
6.3 Role of Faecal Flora
AS and reactive arthritis have several features in common (HLA-B27, enthesitis,
sacroiliitis, peripheral arthritis, uveitis) which have been a major influence in
development of the link between Klebsiella and AS. Reactive arthritis follows
clinically-proven infections by gut bacteria which has not been demonstrated for
AS.
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The present studies of faecal flora showed that there was no major difference in
the range of bacteria identified from the stools of healthy individuals and AS
patients. This agrees with the findings of Ferraz et al. (1990) in Brazil who also
performed a semi-quantitative analysis of stool specimens from AS patients and
healthy controls and found both a similar variety of bacteria and bacterial
counts/gram of faeces for both populations. Apart from the Brazilian centre, no
other group has examined the faecal flora in such a way; by making dilutions of
the stool sample a minimum growth of 500 organisms/gram of faeces would be
detected.
In some surveys only the prevalence of Klebsiella was sought (Eastmond et al.,
1980; Warren and Brewerton, 1980; van Kregten et al., 1991); in others stools
were examined for Enterobacter and Yersinia (Ebringer et al., 1977; Ebringer et
al., 1978; Hunter et al., 1981); and only one other survey has examined for a
wider range of organisms and found scanty numbers of Citrobacter, Proteus,
Alkaligenes and no isolation of Salmonella, Shigella or Yersinia (Kuberski et
al., 1983).
Klebsiella is the single species which has excited the most interest as a potential
trigger of flare-ups of the disease. This followed the original observation of
increased isolation of Klebsiella in active AS (Ebringer et al., 1977; Ebringer et
al., 1978). These workers concluded that a positive Klebsiella culture in a
patient with inactive disease was a harbinger of active disease developing 2-3
months later (Ebringer et al., 1978). The validity of this conclusion remains
controversial. Criticisms of this report were that controls attended on only 1
occasion whereas patients attended on 2-3 occasions; patients with active disease
attended more often than those with inactive disease and had more samples
taken; therefore, they were more likely to have at least 1 sample positive
(Brewerton and Warren, 1978). Kuberski et al. (1983) also found an increased
isolation rate of Klebsiella in active AS.
In the present survey, there was no increase in the isolation of Klebsiella from
the faecal samples of patients compared with controls. This agrees with many
studies (Warren and Brewerton, 1979; Eastmond et al., 1980; Warren and
Brewerton, 1980; Hunter et al., 1981; Brewerton, 1983; van Kregten et al., 1991)
but disagrees with the results of Ebringer et al. (1977) and (1978) and Kuberski et
al. (1983). In the data presented here, in those patients from whom Klebsiella
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was isolated, there was no relationship between its presence and disease activity.
Although studies vary with regard to Klebsiella isolation in active disease, there
is agreement in the literature that AS patients with inactive disease do not have
increased carriage of Klebsiella and indeed many normal individuals carry
faecal Klebsiella.
The lower Klebsiella isolation rate in patients (8.5%) compared with controls
(19.4%) in the present work might be partly due to delays in sample arrival, as
patients' samples were delivered by post whereas controls' samples were
delivered in person. The isolation rate of faecal Klebsiella from controls in the
present survey was 19.4% and has varied worldwide from 13% in Arizona
(Kuberski, 1983) to 60% in the Netherlands (van Kregten et al., 1991). Differences
between studies are probably due to a combination of factors: different types of
controls; different faecal sampling methods; different culture methods; and
geographical variations in the prevalence of Klebsiella .
6.4 Cross-Tolerance Hypothesis
Ebringer's cross-tolerance hypothesis (Ebringer, 1983) was based on studies of
faecal flora in AS patients and on a number of pieces of evidence of antigenic
similarity between HLA-B27-positive lymphocytes and K. pneumoniae and
other Gram-negative enterobacteria. Antibodies to HLA-B27 cross-reacted with
K. pneumoniae (Avakian et al., 1980; Ebringer et al., 1976). Rabbit antisera to
Klebsiella showed cytotoxicity to B27-positive lymphocytes (Welsh et al., 1980)
although this was not confirmed by Beaulieu et al. (1983). Cross-reactivity has
also been demonstrated by Chen et al. (1987) who found that a membrane
protein of Y. pseudotuberculosis reacted with an anti-HLA-B27 monoclonal
antibody (Ye-2). Zhang et al. (1988) reported that the 35kDa bacterial outer
membrane protein reactive with several anti-HLA-B27 monoclonal antibodies
was the outer membrane protein A (OmpA) common to many Gram-negative
enterobacteria. Although such reports of serological cross-reactivity exist,
antibodies to HLA-B27 are not found in the sera of patients with a recent Gram-
negative enteric infection (Cavender and Ziff, 1986; Kapasi et al., 1988).
The cross-tolerance hypothesis suggests that a humoral response is directed to
antigenic determinants on enteric bacteria and some of these antibodies cross-
react with HLA-B27 molecules on the surface of cells in the vicinity of sacroiliac
163
joints. Complement-mediated inflammatory reaction occurs leading to tissue
damage. This does not explain the selectivity of tissue damage in
spondylarthropathies as most of the cells in the body bear MHC class I antigens
(Daar et al., 1984).
If inflammation in AS is initiated by cross-reactions between bacterial antigens
and HLA-B27, then one might expect the tissue distribution and relative density
of these cross-reacting epitopes to play a role in tissue localisation and the extent
of inflammation. Although MHC class I antigens can be detected on most
nucleated cells (Daar et al., 1984), the relative tissue density of the antigens is
little known. The major sites affected in AS are ligamentous, articular and
synovial structures within the axial skeleton, sacroiliac joints and tendon
insertions. Husby et al. (1989) reasoned that if the series of events postulated by
the molecular mimicry theory contributed to the pathogenesis of AS, these
cross-reacting epitopes should be concentrated at these sites. Synovial tissues
from HLA-B27-positive AS patients were examined by an immunoperoxidase
technique using antisera to synthetic peptides representing antigens shared
between HLA-B27.1 and K. pneumoniae nitrogen reductase. Positive staining
was localised with either antiserum to the synovial lining cells, endothelium of
small and medium vessels and to a lesser extent within some inflammatory
cells. The control synovial tissues from HLA-B27-negative patients with
rheumatoid arthritis, juvenile chronic arthritis or osteoarthritis did not show
any significant staining. Examination of skin biopsies from 2 HLA-B27-positive
normal individuals showed staining in epidermal cell membranes but this was
much less pronounced than in synovial tissues from AS patients. It is not clear,
however, whether the epitope was the native HLA-B27 molecule or a bound
peptide. It is not clear whether the prominent expression of HLA-B27 antigen in
synovial tissue is primarily related to pathogenesis of HLA-B27-related
arthropathy or whether it represents a secondary phenomenon related to the
inflammatory process.
The reason for uveal involvement in some patients with spondyloarthropathy
is not clear. MHC class I antigens are not normally expressed on uveal cells in
vivo although they are present throughout the blood vessel endothelium of the
uveal tract (Abi-Hanna and Wakefield, 1988). These antigens are expressed on
tissue-cultured uveal cells and interferon-a and interferon-y can enhance the in
vitro expression of MHC class I antigens. Several tissues which normally lack
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HLA antigens are found to express these in disease states. Skeletal muscle is
normally devoid of HLA antigens but expresses class I antigens in Duchenne
muscular dystrophy. It might be that induction of HLA antigens on uveal cells
is a prerequisite for the initiation of an autoimmune response in the eye.
In the present work, a search was made for faecal bacteria bearing epitopes which
show antigenic similarity to HLA-B27. A monoclonal anti-HLA-B27 antibody
was used as a probe to identify HLA-B27-like antigens on enteric bacteria.
Although initial immunoblotting experiments detected positively-staining
colonies, it became apparent that the detection system was identifying organisms
bearing a peroxidase enzyme; the monoclonal antibody was superfluous to the
reaction. Flow cytometry using fluorescein-labelled anti-mouse
immunoglobulin is a sensitive method of detecting mouse antibodies bound to
bacteria. How cytometry experiments on those strains that were positive in the
initial screening step did not reveal any evidence of HLA-B27-like antigens on
any of the faecal flora (either anaerobic or aerobic organisms). No evidence was
found therefore to support the cross-tolerance theory.
Much attention has been focussed on the hexameric amino acid sequence which
is shared by HLA-B27.1 (B*2705 subtype) and the nitrogen reductase enzyme of
K. pneumoniae. It has been calculated that the probability of two proteins
sharing a 6 amino acid sequence is 1 in 64 x 10^ (Schwimmbeck et al., 1987). The
protagonists of the molecular mimicry theory have proposed that this remote
probability must have some biological significance. It was suggested that this
hexameric sequence provides an epitope that would induce an immune
response against the same 6 amino acids in B*2705 in vivo. Sera from 7/24
(29%) AS patients and 18/34 (53%) Reiter's syndrome patients had antibodies to
a synthetic peptide containing the amino acid sequence in amounts above those
seen in normal individuals. A significant overlap, however, was found
between patients and controls for borderline values. Ewing et al. (1990)
produced similar results but the overlap between patients and controls was
large. In contrast, some groups have failed to detect such antibodies (de Vries et
al., 1990; Tsuchiya et al., 1989) and there is no evidence for cytotoxicity directed
against HLA-B27-positive lymphocytes (Kono et al., 1984; Cavender and Ziff,
1988). Although antibodies in the sera of some patients react with synthetic
peptides, there is no evidence that they react with the intact HLA-B27 molecule.
In the intact HLA-B27 molecule the homologous sequence is coiled inside an
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alpha helix structure in contrast to the linear conformation of the hexamer in a
synthetic peptide.
The cross-reactivity described by Ebringer appears to involve a protein in the
outer membrane of Klebsiella, not the sequence in the nitrogen reductase
enzyme which is homologous with HLA-B27; therefore, Ebringer's work is not
supported by the serological findings mentioned above.
If cross-reactivity with intact HLA-B27 proteins cannot be firmly established, it
would suggest that the molecular mimicry between HLA-B27 and Klebsiella has
no pathogenetic relevance whatsoever. Molecular mimicry alone cannot
explain the disease. Much effort has been concentrated on the homology of K.
pneumoniae nitrogen reductase and HLA-B27.1 while it would appear that little
attention has focussed on the fact that the enzyme is found in only a small
proportion of faecal strains, is expressed only in anaerobic conditions and in
protein-free mediums and, therefore, not in the human host. The Klebsiella
strains that carry the particular enzyme are predominantly soil bacteria (Brill,
1980).
It is likely that the important regions of HLA-B27 are those that make it different
from the other HLA-B antigens and are conserved between subtypes (Benjamin
and Parham, 1990). This is suggested by the observation that there is no selective
association of AS with a particular subtype (Breur-Vriesendorp et al., 1987) or
different subtype distribution in patients compared with normals (Grumet et al.,
1981). The hexameric sequence is part of the antigen binding groove and is
situated in the hypervariable region of the alpha 1 domain of B*2705. Amino
acid substitution here markedly alters T cell recognition suggesting that some
peptide binding capabilities are also modified in the different HLA-B27 subtypes
(Lopez de Castro, 1990; Calvo et al., 1990). It is likely that it is those amino acid
sequences in the peptide groove that are both unique to HLA-B27 and common
to all its subtypes that are important, not directly, but because they help specify
the nature of the peptides that can bind in the antigen binding groove of all
HLA-B27 variants.
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6.5 Humoral Immune Response
Antibodies to Klebsiella and other enterobacteria have been found to be
elevated in AS by some researchers but other groups have not confirmed these
observations (reviewed in section 1.7.8).
In the present study, AS patients were shown to mount a lower IgM response to
their own faecal flora than healthy individuals did to theirs. Also,
proportionately less of the total IgM and IgA was directed to autologous gut
bacteria in patients than in controls. As there was no significant difference in
the total immunoglobulins between patients and controls, it suggests, that if this
is indeed a real phenomenon there may be a defect in antigen presentation in
AS patients. One might expect that a low IgM response to an antigen would
result in a low IgG titre to that antigen as B cells sequentially switch in
immunoglobulin classes as they differentiate, but this was not observed. Low
IgM responses to Klebsiella K43 have been previously noted but not explained
(Cooper et al., 1988). Few hard conclusions can be drawn from the present
findings in view of the small numbers of subjects studied. If a larger group was
examined the results might be different. There is no convincing evidence from
any source that AS is a humorally-mediated disease.
There was no significant difference in total serum IgA between patients and
controls. This confirms other reports, but disagrees with some groups who have
found elevated serum IgA which in some cases has been related to disease
activity. There is evidence to suggest that raised IgA in AS might be an
epiphenomenon. NSAIDs increase intestinal permeability (Bjarnason et al.,
1986) causing blood and protein loss (Bjarnason et al., 1987). Increased intestinal
permeability in AS patients has been demonstrated using ^Chromium-labelled
EDTA (Wendling et al., 1990). A comprehensive ileocolonoscopic study
revealed inflammatory lesions of the gut in high frequency in both ReA (65%)
and in AS (57%) patients especially those with peripheral arthritis and also those
not on NSAIDs (Mielants et al., 1988). Disturbed gut permeability (from
whatever cause) could result in increased absorption of enteric bacterial antigens
and a polyclonal increase in IgA. This could also explain the raised IgA
antibodies to Klebsiella (Trull et al., 1983) and Yersinia (Wagener et al., 1985)
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which have been found in AS. The raised IgA could be part of the immune
response to a subclinical infection in the ileum in the presence of chronic ileitis.
6.6 FutureWork
While examples of molecular mimicry are common in nature (Oldstone, 1989),
there is little evidence that such antigenic similarity contributes to disease. One
notable exception is rheumatic fever in which anti-streptococcal antibodies
cross-react with an identical sequence in cardiac structures as is present in the M
protein of group A streptococci (Bronze et al., 1988). Cross-reactivity between
HLA-B27-positive lymphocytes and K. pneumoniae and other Gram-negative
enterobacteria has been demonstrated by different laboratories, but many other
groups have failed to confirm these findings. In the current work, there was no
evidence for the presence of a HLA-B27-like epitope on enteric bacteria from the
faeces of either AS patients or healthy controls.
It is intuitively unlikely that an individual would mount an immune response
to their own MHC class I antigens. If cross-tolerance is involved, then cross-
reactivity is more likely to decrease the response to Klebsiella, perhaps thereby
allowing undue persistence of the organism and disease than inducing anti-self
MHC class I reactivity. In addition, cross-reactivity does not explain the
distribution of disease. Future research into the pathogenesis of AS should be
directed away from further investigating cross-reactivity between HLA-B27 and
enterobacteria.
The majority of evidence (including the present work) suggests that Klebsiella
carriage is not increased in active AS. In the instances that such an observation
has been made, it is more likely to be an epiphenomenon than having any
biological significance. Further studies of faecal flora are unlikely to advance
our understanding of this disease.
The most exciting recent developments in AS have been the discovery by X ray
crystallography that peptides bound to HLA-B27 appear to be nonamers and are
in a largely extended conformation (Madden et al., 1991). A series of these
peptides have been identified as self peptides derived from proteins which are in
abundance in the cell such as histones, ribosomal proteins and members of the
90K heat shock proteins (Jardetzky et al., 1991). It would be of interest to
determine if there is any difference in the range of peptides bound to the HLA -
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B27 molecule in healthy and diseased HLA-B27-positive individuals. One could
speculate that peptides which form part of a self protein derived from articular
tissue/enthesis might be identified in the antigen binding groove of the HLA-
B27 molecule.
As there is no convincing evidence that AS is a humorally-mediated disease,
further studies into T cell function and antigen presentation may improve our
understanding of the disease process.
There is considerable evidence that non-secretion of ABO substances is a
susceptibility factor for certain mucosal infections and autoimmune diseases
with a proposed infective aetiology (Blackwell, 1989). The only other rheumatic
disease examined so far which is associated with non-secretion is psoriatic
peripheral arthropathy (but not psoriatic spondyloarthropathy or uncomplicated
psoriasis (Shinebaum et al., 1987a)). Non-secretion is not associated with
rheumatoid arthritis. It might be that the Lewis3 antigen on the cells of non-
secretors acts as a receptor for micro-organisms triggering psoriatic arthropathy
and further research could be directed towards this.
In summary, further research into the nature of the peptides bound by the HLA-
B27 molecule, and into antigen presentation and T cell immunity in AS may
elucidate the pathogenesis of this fascinatng disease.
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